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Abstract 
X-linked severe combined immunodeficiency, caused by mutations in the common γ-
chain, is characterized by absence of T and NK cells which leads to life-threatening 
infections. The disease can only be cured by bone marrow transplantation or gene 
therapy. Even after successful replacement of the T-cell compartment, patients display 
a persistent susceptibility to severe cutaneous human papillomavirus (HPV) infections. 
We hypothesized that persistent HPV susceptibility is due to residual γ-chain deficiency 
in keratinocytes.  
The role of γ-chain in skin is unknown. In this thesis, we confirmed the expression of γ-
chain in keratinocytes by reverse transcription PCR (RT-PCR) and flow cytometry and 
demonstrated that it is functional, mediating an increase in STAT5 and AKT 
phosphorylation in response to IL-2 and IL-15 stimulation. We then generated a γ-chain 
knock-down cell line which showed reduced levels of phopho-AKT after stimulation with 
IL-15 compared to control cells showing impaired signaling.    
Using HPV pseudovirions, an increase of 50% in infectivity in knock-down cells 
compared to control cells was observed indicating an increase in initial infection. In an 
organotypic raft model using keratinocytes transfected with HPV18, we observed 
increased suprabasal DNA synthesis in knock-down cells indicating dysregulation of 
keratinocyte proliferation even though expression of HPV life cycle markers was 
unchanged. 
Moreover, an increase in chemokine secretion after IL-15 stimulation was only 
observed in control but not in γ-chain deficient cells. These secreted levels of 
chemoattractants were able to induce migration of neutrophils, dendritic cells and 
CD4+ T cells. Using supernatants collected from keratinocytes transfected with HPV18 
as chemoattractant, we saw altered migration towards supernatant from HPV18 
positive γ-chain deficient cells compared to that of HPV18 positive control 
keratinocytes.  
Together the results presented here suggest that γ-chain deficiency in keratinocytes 
leads to an increased susceptibility to HPV infection, altered regulation of infection and 
impaired immune cell recruitment.  
 
  
3 
 
Acknowledgements  
Three years and a tiny bit after I started working on this project, this thesis is finally 
done and now it is time to thank the following people without whom I would have never 
been able to do this project: 
Number 1 has to be my amazing primary supervisor Siobhan Burns who has helped 
me so much during the whole PhD, who was always there to give advice and to listen 
when experiments were not working and to find a way to help me. Even though it was 
not always easy with working in two different places and everyone being busy, we 
always managed to find a way to make things work. Thank you so much! 
A another huge thank you goes to my secondary supervisor Wei Li Di who taught me 
everything I needed to know about keratinocytes and who was also always there to 
listen to my experimental issues and gave me tips on how to solve my problems.  
A big thank you also goes to Adrian Thrasher who was always supportive of and 
interested in my project and gave me interesting ideas for further experiments. 
Paul Lambert and his lab members (especially Amy Liem, Aayushi Uberoi, Denis Lee 
and Kathleen Makielski) at the University of Madison-Wisconsin also deserve a big 
thank you for welcoming me so nicely, for teaching me so many things, for helping me 
all the time and for making my time in Madison so enjoyable and productive. Without 
them I would know significantly less about HPVs.  
Further thanks go to Daniela Linzner who taught me how to isolate cells from blood, 
how to do neutrophil migration experiments and for making it so entertaining.  
Thank you also to all the lovely healthy blood donors from the unit without whose cells I 
would not have been able to do so many experiments. Especially to Roland, Kathryn, 
Yusuf and Dave that gave me blood on multiple occasions. 
Of course a big thank you to all the lovely people in MIU/MCI who had to deal with me 
and my occasional mood swings during this project and who helped to keep me sane, 
especially Miguel, Jo, Albert, Pili, Neelam and Marlene.  
The very last but definitely not least thank you goes to my parents without whom I 
would not be who I am today, who are always supportive and who are the best parents 
anyone could ever wish for.   
4 
 
TABLE OF CONTENTS  
 
Declaration           1 
Abstract          2 
Acknowledgements         3 
Table of Contents         4 
List of Figures          10 
List of Tables          12 
List of Abbreviations         13 
 
 
 
1. INTRODUCTION 16 
1.1 The skin 17 
1.1.1 Skin anatomy and skin cells 17 
1.1.2 The differentiation programme of keratinocytes 19 
1.1.3 The antigen-presenting cells of the skin 21 
1.1.4 The immunological functions of keratinocytes 23 
1.2 The human papilloma virus family 25 
1.2.1 Viral structure and genome 27 
1.2.2 Papillomavirus life cycle 31 
1.2.3 Mechanisms of HPV immune evasion 34 
1.2.4 Regression, Persistence and Latency of HPV infections 37 
1.2.5 The mouse papilloma virus 39 
1.3 The common γ-chain and its cytokines 42 
1.3.1 The γ-chain and its co-receptor 42 
1.3.2 Signalling via the common γ-chain 44 
1.3.3 The effects of γ-chain cytokines 47 
1.4 Severe combined immunodeficiency (SCID) and other primary 
immunodeficiencies associated with γ-chain cytokines 49 
1.5 HPV infections in SCID patients 52 
1.6 Hypothesis and Aim 57 
5 
 
2. MATERIALS AND METHODS 58 
2.1 Materials 59 
2.1.1 General Supplies 59 
2.1.2 Buffers and solutions 59 
2.1.2.1 Commercial buffers 59 
2.1.2.2 Buffers prepared in house 59 
2.1.3 Antibodies 63 
2.1.3.1 Antibodies for flow cytometry (FC) 63 
2.1.3.2 Antibodies for Western Blot 65 
2.1.3.3 Antibodies for Immunofluorescence 66 
2.1.4 Enzymes 68 
2.1.5 Cytokines 68 
2.1.6 Primers 69 
2.1.7 Probes and Standards 70 
2.1.8 Tissue Culture 71 
2.1.9 Cell lines 76 
2.1.9.1 HEK 293T/17 76 
2.1.9.2 293FT 76 
2.1.9.3 ED-7R 76 
2.1.9.4 NIKS 76 
2.1.9.5 3T3 77 
2.1.10 shRNA vectors 78 
2.1.11 Others reagents 78 
2.2 Methods 80 
2.2.1 Cell and tissue culture 80 
2.2.1.1 Culturing of cells 80 
2.2.1.2 Passaging cells 80 
2.2.1.3 Isolation of primary keratinocytes 80 
2.2.1.4 Lentiviral preparation 81 
2.2.1.5 Titration of lentiviral particles by FC 81 
2.2.1.6 Lentiviral transduction of the NIKS cell line 81 
2.2.1.7 Puromycin selection of NIKS cells 82 
2.2.1.8 Proliferation Assay using BrdU incorporation and FC 82 
2.2.1.9 Proliferation Assay using BrdU incorporation and a platereader 83 
2.2.1.10 Production of HPV Virus-Like-Particles (VLP) 83 
2.2.1.11 Infectivity assay 84 
2.2.1.12 Transfection of NIKS with HPV18wt vector 85 
2.2.1.13 Making organotypic rafts 85 
2.2.1.14 Isolating peripheral blood mononuclear cells (PBMCs) from whole blood 86 
2.2.1.15 Isolation of CD14+ cells and differentiation to DCs 86 
6 
 
2.2.1.16 Isolation of CD4+ and CD8+ T cells 86 
2.2.1.17 Isolation of neutrophils 87 
2.2.1.18 Migration experiments using neutrophils 87 
2.2.1.19 Migration experiments using DCs 87 
2.2.1.20 Migration experiments using CD4+ and CD8+ T cells 88 
2.2.2 Protein Biology 89 
2.2.2.1 Cell lysis and sample preparation for Immunoblotting 89 
2.2.2.2 SDS-PAGE and Immunoblotting 89 
2.2.2.3 Surface Staining for FC 89 
2.2.2.4 Intracellular Staining for FC 90 
2.2.2.5 Analysis of JAK/STAT signalling by FC 90 
2.2.2.6 Sample preparation for analysis of pAKT by immunoblotting 90 
2.2.2.7 Cytokine Array 91 
2.2.2.8 Luminex assay 91 
2.2.3 Molecular Biology 92 
2.2.3.1 Isolation of RNA 92 
2.2.3.2 Reverse transcription 92 
2.2.3.3 Polymerase chain reaction (PCR) 92 
2.2.3.4 Quantitative PCR (qPCR) 93 
2.2.3.5 Agarose gels 93 
2.2.3.6 Plasmid DNA preparation 93 
2.2.3.7 Preparation of HPV18wt re-circularised plasmid 93 
2.2.3.8 Isolating extrachromosomal DNA (HIRT-DNA) 94 
2.2.3.9 Southern Blot 95 
2.2.4 Staining of paraffin embedded sections 96 
2.2.4.1 Haematoxylin and Eosin staining 96 
2.2.4.2 Immunofluorescent staining of paraffin embedded slides 96 
2.2.4.3 Making the probe for fluorescence in situ hybridisation (FISH) 96 
2.2.4.4 FISH 97 
2.2.5 Animal experiments 98 
2.2.5.1 Infection with MmuPV1 particles 98 
2.2.5.2 Grafting of ear skin onto the back of WT animals 98 
2.2.6 Data analysis and statistics 99 
3. THE COMMON -CHAIN IS EXPRESSED AND FUNCTIONAL IN 
KERATINOCYTES 100 
3.1 Introduction 101 
3.2 The γ-chain is expressed in keratinocytes 102 
3.3 Multiple γ-chain co-receptors are expressed in keratinocytes 104 
7 
 
3.4 Stimulation with γ-chain cytokines induces phosphorylation of STAT5 in 
keratinocytes 107 
3.5 Stimulation with γ-chain cytokines induces phosphorylation of AKT in 
keratinocytes 109 
3.6 Generation of a common γ-chain knock-down cell line: Screening of shRNAs 
using the ED-7R cell line 110 
3.7 Generation of a common γ-chain keratinocyte knock-down cell line 111 
3.8 Signalling mediated by γ-chain is defective in knock-down keratinocyte cell line
 114 
3.9 Discussion 116 
4. INFECTIVITY WITH PSEUDO- AND QUASIVIRIONS IS INCREASED IN -
CHAIN DEFICIENT CELLS 118 
4.1 Introduction 119 
4.2 Preparation of HPV18 wt plasmid 122 
4.3 Making HPV quasivirions 124 
4.4 Infectivity using pseudovirions is increased in γ-chain deficient keratinocytes 127 
4.5 Proliferation is not changed between different NIKS cell lines 131 
4.6 Infectivity using quasivirions is increased in γ-chain deficient keratinocytes 133 
4.7 Discussion 136 
5. CONTROL OF HPV IS ALTERED IN KERATINOCYTES LACKING 
FUNCTIONAL -CHAIN 139 
5.1 Introduction 140 
5.2 γ-chain deficiency in keratinocytes does not influence keratinocyte proliferation 
and differentiation in organotypic raft cultures 142 
5.3 HPV genomes are maintained over multiple passages in scr control and KD NIKS
 145 
5.4 HPV does not affect the proliferation in γ-chain deficient keratinocytes cultured as 
a monolayer 147 
8 
 
5.5 Presence of HPV18 affects the differentiation and proliferation of rafts made with 
γ-chain deficient keratinocytes 148 
5.6 γ-chain deficiency in keratinocytes does not affect HPV18 life cycle in organotypic 
rafts 153 
5.7 Discussion 155 
6. CHEMOKINE SECRETION IN -CHAIN DEFICIENT KERATINOCYTES IS 
ALTERED AND REDUCES IMMUNE CELL RECRUITMENT 157 
6.1 Introduction 158 
6.2 Cytokine and chemokine secretion is not changed after infection with HPV 
quasivirions 159 
6.3 Cytokine array shows cytokines and chemokines differentially secreted after IL-7 
and IL-15 stimulation 162 
6.4 IL-8, Mip-3α and Gro-α are induced following stimulation with IL-15 166 
6.5 Levels of IL-8, Gro-α and Mip-3α secreted by keratinocytes are able to attract 
neutrophils 169 
6.6 Dendritic cell migration is stimulated by IL-8, Mip-3α and Gro-α 172 
6.7 IL-8, Mip-3α and Gro-α are able to attract CD4+ T cells 174 
6.8 Gro-α secretion is increased in HPV18 positive control cells but not in γ-chain 
deficient cells 176 
6.9 Higher Gro-α concentrations attract less CD4+ T cells 178 
6.10 HPV18 presence in control but not in γ-chain deficient cells leads to increased 
attraction of CD4+ T cells 180 
6.11 HPV18 presence only in γ-chain deficient but not in control cells leads to 
increased attraction of CD8+ T cells 182 
6.12 Discussion 184 
7. FINAL DISCUSSION 188 
7.1 The absence of the common γ-chain affects HPV infection at multiple stages 189 
7.2 Potential treatment options of X-SCID 193 
9 
 
7.3 Future experiments 195 
7.4 Relevance of this project to patients 197 
8. APPENDIX – USING MMUPV1 IN -CHAIN DEFICIENT MICE TO STUDY 
INFECTION 198 
8.1 Introduction 199 
8.2 MmuPV1 infection can successfully be established in γ-chain KO mice 200 
8.3 Skin grafting model for studying HPV infection in X-SCID skin 201 
8.4 No lesions develop using the initial skin graft model for MmuPV1 infection studies
 202 
8.5 Discussion 203 
9. REFERENCES 205 
  
10 
 
List of Figures 
 
Figure 1: Skin anatomy and cells 18 
Figure 2: Map of the circular HPV18 reference genome 28 
Figure 3: Effect of HPV16 E6 and E7 on cycle progression 30 
Figure 4: Life cycle of high-risk HPVs 33 
Figure 5: Receptors for γ-chain cytokines 43 
Figure 6: Signalling via the common γ-chain 46 
Figure 8: Expression of γ-chain mRNA and protein in keratinocytes 103 
Figure 9: Expression of γ-chain co-receptors mRNA 105 
Figure 10: Expression of γ-chain co-receptors 106 
Figure 11: Phosphorylation of STAT5 NIKS cells after stimulation with γ-chain 
cytokines 108 
Figure 12: Phosphorylation of AKT after stimulation with γ-chain cytokines 109 
Figure 13: Knock-down of γ-chain in ED-7R + γc cells 110 
Figure 14: Knock-down of γ-chain protein using shRNA3 112 
Figure 15: Knock-down of γ-chain mRNA 113 
Figure 16: pAKT levels in γ-chain knock-down and control cells after IL-15 stimulation
 115 
Figure 17: Reconstruction of HPV18wt plasmid 123 
Figure 18: Identifying HPV18 quasivirions containing fractions 125 
Figure 19: Titering HPV18 quasivirions 126 
Figure 20: Levels of infectivity in NIKS cell lines 48 h post pseudovirion infection 127 
Figure 21: Levels of infectivity in NIKS cultured in different media 129 
Figure 22: Infectivity with pseudovirions after stimulation with γ-chain cytokines 130 
Figure 23: Proliferation of NIKS cell lines 132 
Figure 24: Validation of E1^4 qPCR assay 134 
Figure 25: Infectivity in NIKS cell lines using HPV18 quasivirions 135 
Figure 26: H&E staining of HPV negative rafts 143 
Figure 27: Keratin-10, Keratin-14, Loricrin and BrdU staining in HPV negative rafts 144 
Figure 28: Maintenance of HPV18 genomes in transfected NIKS cells 146 
Figure 29: DNA synthesis in HPV18 positive NIKS cell lines infected with HPV18 147 
Figure 30: H&E staining and Keratin-14 and Loricrin staining of HPV18 positive rafts
 150 
Figure 31: Keratin-10 and BrdU staining of HPV18 positive rafts 151 
Figure 32: Quantification of BrdU positive cells in HPV18 positive rafts 152 
11 
 
Figure 33: Expression of HPV markers E4 and MCM7 and fluorescent-in-situ 
hybridisation (FISH) for HPV18 genome expression in matured rafts 154 
Figure 34: Secreted cytokines and chemokines after infection with HPV18 quasivirions
 159 
Figure 35: Secretion of cytokines in untransduced NIKS after IL-7 and IL-15 stimulation
 163 
Figure 36: Secretion of IP-10, IL-1α and RANTES after different stimulations 167 
Figure 37: Secretion of Gro-α, IL-8 and Mip-3α after IL-7 and IL-15 stimulation 168 
Figure 38: Neutrophil migration towards different chemoattractants 170 
Figure 39: Neutrophil migration towards different chemoattractants 171 
Figure 40: Dendritic cell migration towards Gro-α, IL-8 and Mip-3α 173 
Figure 41: CD4+ T cell migration towards different cytokines 175 
Figure 42: Secretion of Gro-α, IL-8 and Mip-3α in HPV18 positive NIKS 177 
Figure 43: Migration of CD4+ T cells towards different concentrations of Gro-α 179 
Figure 44: CD4+ T cell migration towards supernatants from HPV positive and negative 
NIKS 181 
Figure 45: CD8+ T cell migration towards supernatants from HPV positive and negative 
NIKS 183 
Figure 46: Model for the effect of γ-chain deficiency on HPV infection 191 
Figure 47: Successful skin transplant on a mouse 201 
 
  
12 
 
List of Tables  
 
Table 1: Characteristics of immune cells in HPV regression vs. persistence 38 
Table 2: Commercial buffers used 59 
Table 3: Isotype controls for FC 63 
Table 4: Antibodies for specific immunogens for FC 64 
Table 5: Primary antibodies for Western Blot 65 
Table 6: Secondary antibodies for Western Blot 66 
Table 7: Primary antibodies for Immunofluorescence 67 
Table 8: Secondary antibodies for Immunofluorescence 67 
Table 9: Enzymes 68 
Table 10: Cytokines 69 
Table 11: Primers 70 
Table 12: Tissue culture reagents 75 
Table 13: shRNA vectors 78 
Table 14: Other reagents 79 
Table 15: Chemokine and cytokine secretion after quasivirion infection 160 
Table 16: Quantification of the cytokine array after IL-7 and IL-15 stimulation 164 
Table 17: Formation of wart lesions in mice 200 
 
  
13 
 
List of abbreviations  
 
ADA   adenosine deaminase 
BMT   bone marrow transplantation 
BPV   bovine papilloma virus  
CD   Cluster of differentiation 
cDC   conventional dendritic cell   
CDK   cyclin-dependent kinases 
CLL   chronic lymphocytic leukaemia 
COPV   canine oral papilloma virus  
CRPV   cottontail rabbit papilloma virus  
DC   dendritic cell 
dDC   dermal dendritic cell  
DNA   deoxyribonucleic acid 
dsDNA   double-stranded DNA viruses 
E6-AP   E6-associated protein 
EBV   Epstein-Barr-virus 
ECM   extracellular matrix 
EDC   epidermal differentiation complex 
ELISA    Enzyme-linked immunosorbent assay 
ERK   extracellular signal regulated kinase  
EV   Epidermodysplasia Verruciformis 
FC   Flow cytometry  
FDA    Food and Drug Administration 
fMLP   N-Formylmethionyl-leucyl-phenylalanine 
GAG   glycosaminoglycan 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GFP   green fluorescent protein  
GM-CSF  Granulocyte-macrophage-colony-stimulating-factor 
Gro   Growth-regulated-protein 
GSK   GlaxoSmithKline 
GT   gene therapy  
GVHD   graft-versus-host-disease 
FISH   fluorescent-in-situ-hybridisation  
HLA   human leukocyte antigen 
HPKC   human primary keratinocytes 
HPV   human papilloma virus 
HSCT   haematopoietic stem cell transplantation 
14 
 
HSPG   heparin sulphate proteoglycans 
HSV   herpes simplex virus  
ICAM   intracellular adhesion molecule  
IFN   interferon 
Ig   immunoglobulin 
IL   interleukin 
IP-10   interferon-γ- inducible protein 10 
JAK   Janus-kinase 
K%   keratin-% 
KD   knock-down   
LC   Langerhans cell 
LCR   long control region 
LFA   Lymphocyte-function-associated-antigen 
LMP   low molecular protein 
M&M   Materials and Methods 
MAPK    RAS-mitogen-activated protein kinase 
MCP-1   monocyte-chemoattractant-protein-1 
McPV   Mastomys coucha papilloma virus  
MHC   Major-histocompatibility-complex 
Mig   Monokine-induced-by-gamma-interferon 
Mip   Macrophage-inflammatory-protein 
MmuPV  Mus musculus papilloma virus  
MFD   match family donor 
MSD   Match-sibling donor 
NK    natural killer  
ORF   open-reading frame 
pAKT   phosphorylated Akt  
PBMCs   peripheral blood mononuclear cells 
PCR   polymerase chain reaction  
pDC   plasmatocytoid dendritic cell 
PI3K   phophoinositide 3-kinase 
pRB   retinoblastoma protein 
PRR   pattern-recognition receptors 
PV   papilloma virus  
RANTES  Regulated-on-activation,-normal-T-cells-expressed-and-secreted 
RLU   relative light units  
RNA   Ribonucleic acid 
ROPV   rabbit oral PV 
RT-PCR  reverse transcription PCR 
15 
 
SCID   Severe combined immunodeficiency 
scr   scrambled  
SH   Scr-homology 
SCC   squamous cell carcinoma 
STAT   Signal-Transducers-and-Activators-of-Transcription 
TAP   transporters of antigenic protein 
TCGF   T cell growth factor 
TG   Transglutaminases 
Th   T helper cell  
TLR   Toll-like receptor 
TNF    Tumor-necrosis-factor 
TSLP   thymic stromal lymphopoietin 
URR   upstream regulatory region 
UV    ultraviolet 
Vge   viral-genome equivalents  
VLP   virus-like particle  
WHIM   Warts, Hypogammaglobulinemia, Infections and Myelokathexis 
WHO   World Health Organization 
wt   wild-type  
XCR   XC-chemokine receptor 
X-SCID  X-linked severe combined immunodeficiency 
 
  
16 
 
1. Introduction  
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1.1 The skin 
 
1.1.1 Skin anatomy and skin cells 
 
The skin is the external cover of the body and one of its largest organs accounting for 
15 – 20% of its mass. It has many essential functions as a barrier to the outside world. 
It is important to withstand chemical and physical traumas of everyday activities, e.g. 
as a mechanical barrier, permeability barrier and UV protection. It protects the host 
from harmful pathogens in the surrounding environment as an immune organ and 
against dehydration by retaining body fluids. It is also involved in sensation and 
homeostasis (e.g. thermoregulation) as well as excretion and endocrine functions (e.g. 
secretion of hormones, cytokines and growth factors).  
The skin is made up of two distinct layers: the epidermis and the dermis which are 
separated by the basement membrane. The epidermis is further subdivided into 
multiple layers: the basal layer (stratum basale), spinous layer (stratum spinosum), 
granular layer (stratum granulosum) and the stratum corneum. Certain areas of the 
skin such as palms and soles (the so-called “thick” skin) also include a stratum lucidum 
(“clear layer”) which is also considered to be part of the stratum corneum (reviewed in 
(1-3) and compare with Figure 1). 
The epidermis mainly consists of keratinocytes (~85%) but it also contains 
melanocytes (~5%), Langerhans cells (2-5%) and Merkel cells (6-10%) (3). It is not fully 
clear, yet, what the role of Merkel cells is. They are proposed to be important for 
somatosensation. As such they form slowly adapting touch receptors. They have also 
been considered to have endocrine functions and chemosensitive functions (4). 
Melanocytes are specialised cells that produce the pigment melanin which helps 
protect the body from UV radiation. The rate of melanin production determines the skin 
tone. They are mainly confined to the basal layer (5). Langerhans cells are specialised 
antigen-presenting cells of the epidermis and they are most prominent in the stratum 
spinosum (6). 
The dermis is made up of connective tissue matrix and specialised immune cells such 
as dermal dendritic cells (dDCs) and T cells as well as mast cells and macrophages. It 
also contains fibroblasts, hair follicles, various glands as well as lymphatic and blood 
vessels (reviewed in (7)). 
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Figure 1: Skin anatomy and cells 
The skin is made up of two distinct layers, the epidermis and the dermis which are separated by 
the basement membrane. The epidermis is further subdivided into four (“thin” epidermis) or five 
(“thick” epidermis, shown here) layers. It mainly consists of keratinocytes but Langerhans cells, 
melanocytes and Merkel cells are also present. The dermis consists of connective tissue matrix 
and contains immune cells such as dendritic cell (DC) subsets, e.g. dermal DCs, and different T 
cells subsets. Other cell types – which are not shown here – such as mast cells, macrophages 
and fibroblasts are also found in the dermis. Adapted from Nestle et. al., 2009, (7).  
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1.1.2 The differentiation programme of keratinocytes 
 
One of the most important functions of the skin is its role as a protective barrier. The 
efficiency of the barrier formation depends on the correct execution of the 
differentiation programme of the keratinocytes in the epidermis.  
In the epidermis only the basal layer contains stem cells or amplifying cells; 
incorporation of nucleotide analogues such as BrdU usually cannot be observed in any 
other layer. When keratinocytes start to leave this layer and move upwards, they lose 
their proliferative capabilities and begin terminal differentiation. As cells pass from the 
basal to granular layers, they increase in size, however, their nuclear size stays the 
same (8, 9).  
The family of the 54 keratins accounts for some of the most important proteins inside 
keratinocytes. They constitute around 15-25% of the protein in basal cells but this 
number increases to more than 85% in the fully differentiated squamous cells 
(reviewed in (10)). During the course of terminal differentiation, there are changes in 
synthesis and therefore expression of different keratins. Inner layers (e.g. basal and 
spinous layers) only synthesize smaller keratins, whereas the outer layers of the 
epidermis express both large and small ones. In the stratum corneum there is no 
synthesis of keratins (9). Inside cells, keratins span the cytoplasm and anchor to the 
cytoplasmic plaques of desmosomes and hemi-desmosomes. That means that keratins 
are important for integrity and mechanical stability of single cells as well as epithelial 
tissues. They also provide attachment to the basement membrane (11).  
There are two different groups of keratins: acidic type I keratins and basic type II 
keratins with heterodimers forming between a member of each group. Basal cells 
express the type II keratin keratin-5 (K5) and type I keratin K14. When the cells enter 
the suprabasal layers and become post-mitotic, expression of K5 and K14 ceases 
while type II K1 and type I K10 are induced. Their expression is an early indicator that a 
cell has undergone commitment for terminal differentiation. Filaments formed of K1 and 
K10 self-aggregate more than K5 and K14 filaments and they are less easily 
solubilised (9, 10, 12, 13). The epidermis also expresses other keratins such as K20 
which is a marker for Merkel cells. A wide range of keratins (at least 26) is specifically 
expressed in hair-follicles and hair fibres (reviewed in (11, 14)).  
During differentiation, a gene cluster named “epidermal differentiation complex” (EDC) 
is expressed. It encodes for the proteins involucrin, loricrin and filaggrin (15). Loricrin is 
a major component of the cornified envelope. It is highly insoluble and it is made during 
the later stages of terminal differentiation (16). Involucrin is synthesized when the cells 
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leave the basal layer and crosslinked by the enzyme transglutaminase (TG) in the later 
stages of differentiation (17, 18). Filaggrin is the main component of the keratohyalin 
granules which are the defining characteristic of the stratum granulosum. It enables the 
aggregation of keratin filaments into dense macrofibrils in the stratum corneum. It is 
also important for maintaining epidermal hydration as it is degraded to free amino acids 
in the upper stratum corneum (19-21).  
In addition to changes and crosslinking of the protein filaments to form the cornified 
envelope, the organelles and the intracellular content of keratinocytes are replaced by 
a compact proteinaceous cytoskeleton and the resulting corneocytes are linked to a 
multicellular structure which is biologically dead. The process of cornification is a 
special type of cell death different from apoptosis and necrosis. Various anti-apoptotic 
and anti-necrotic mechanisms are employed by keratinocytes to avoid untimely death. 
What the intermediate stages of organelle breakdown look like is largely unknown 
(reviewed in (15)).  
The skin continuously self-renews over the course of an individual’s life and therefore, 
there must be different stem cell populations within the skin. The potential for long-term 
self-renewal differentiates a stem cell from a progenitor cell as the latter can only self-
renew short-time. There are different stem cell populations in the skin. The hair follicle 
and melanocyte stem cells reside in the bulge of the hair follicle. In follicular epidermis, 
these hair follicle stem cells can also be mobilised to repair damaged epidermis 
(reviewed in (22) and (23)). In interfollicular epidermis, the basal epidermal layer is 
made up of self-renewing stem cells and progenitors which express K5 and K14. The 
progenitor cells receive pro-proliferative signals from the dermal fibroblast to give rise 
to the terminally differentiated cells that form the suprabasal layers and are eventually 
shed from the surface (24, 25). 
The process from leaving the basal cell layer to desquamation and shedding from the 
skin surface takes around 2 – 4 weeks. This takes place throughout life and therefore, 
the cells of the adult epidermis are replaced every few weeks (14).  
  
21 
 
1.1.3 The antigen-presenting cells of the skin 
 
The skin is not only a physical barrier to the outside world but it is also an important 
immune organ providing protection from pathogens in the surroundings. It is also home 
to around 1012 bacteria per m2 which act a barrier against colonialization with 
pathogenic bacteria. In addition, there is continuous trafficking of immune cells 
between the skin, the draining lymph nodes and the periphery. The immune system of 
the skin is mainly formed of different DC population in dermis and epidermis, tissue 
resident T cells and keratinocytes (26).  
The skin DC population can be divided into two main groups: LCs which are resident in 
the suprabasal layers of the epidermis and dermal DCs (dDCs) which are found just 
below the dermal-epidermal junction in the dermis (7).  
LCs are characterised by the presence of Birkbeck granules which are intra- 
cytoplasmic organelles. The expression of langerin in mice and CD1a in humans has 
been used to differentiate them from other cell types. They are derived from yolk-sac 
derived myeloid precursors and fetal liver derived monocytes. They acquire a mature 
morphology directly after birth and undergo extensive proliferation between day 2 and 7 
after birth (27, 28). Afterwards, they self-renew in the skin under steady state 
conditions throughout life and are not replaced by bone marrow derived precursors 
cells (29). 
LCs are radio-resistant and they have close interactions with the keratinocytes that 
surround them via E-cadherin. When LCs mature they downregulate E-cadherin to 
dissociate from keratinocytes and to be able to migrate across the basement 
membrane (30). LCs have the ability to take up antigens, migrate to local draining 
lymph nodes and prime naïve T cells, especially CD8+ T cells. In addition, they are 
able to secrete chemokines and cytokines (31). It has mostly been suggested that LCs 
have immunosuppressive or tolerance-inducing functions, e.g. antigen-specific contact 
hypersensitivity responses are enhanced in the absence of LCs and they protect mice 
from allergic contact dermatitis by inducing tolerance, deletion of allergen-specific T 
cells and activation of Tregs  (32, 33). They might also have functional plasticity 
inducing activation of T cells depending on the signal they detect (34).  
There are different types of dermal DCs in the dermis including plasmacytoid DCs 
(pDCs), conventional DCs (cDCs) and monocyte-derived DCs. Of these three types, 
pDCs are only found in the dermis during inflammation (34). dDCs and monocyte-
derived DCs are found in the healthy dermis and in contrast to LCs, have short life-
span and are replaced by bone-marrow derived precursors in around 7 days. cDCs 
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originate from a subpopulation called pre-cDCs and monocyte-derived DCs are derived 
from blood LYC6hi monocytes (35-37).  
cDCs can transport cutaneous antigens to the T cell zones of the draining lymph nodes 
and present to and activate naïve T cells, leading to clonal expansion and acquisition of 
T cell effector functions. Monocyte-derived DCs are very similar to cDCs. They are also 
able to present antigens to naïve T cells, however, they have poor migratory ability and 
are therefore more suited to activate skin-tropic T cells (reviewed in (34)). Overall, 
dDCs have higher migratory abilities than LCs and they arrive earlier in the draining 
lymph nodes than LCs and both groups colonise distinct areas (30).  
In conclusion, the presence of different types of antigen-presenting cells in the skin is 
probably due to functional specialisation of the different cell types. They continuously 
patrol both epidermis and dermis to detect incoming pathogens and to be able to 
activate T cell immune responses. However, important immune modulatory functions 
are provided not only by the skin-resident DCs and LCs, but also the keratinocytes.  
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1.1.4 The immunological functions of keratinocytes  
 
Keratinocytes are often considered to be the first immune sentinel that is encountered 
by pathogens when they enter the skin. They as such play an important role in immune 
responses as they express various pattern-recognition receptors (PRRs), have the 
ability to secrete immune modulatory molecules and can present antigens. 
Various studies have shown that keratinocytes express many different Toll-like 
receptors such as TLR-1, 2, 4, 5 and 6 on their cell surface and TLR-3 and TLR-9 in 
their endosomes. TLR expression can be regulated by mycobacteria, viruses or other 
pathogen related products. Their activation leads to activation of the nuclear factor B 
and interferon regulatory factor pathways resulting in secretion of type I interferons 
(IFN) and tumour necrosis factor (TNF) α. The expression of other surface PRR such 
as the C-type lectin dectin-1 is inducible on keratinocytes. Keratinocytes also express 
cytosolic PRRs such as NOD-like receptors and the RIG-like helicase receptors such 
as RIG-I, MDA-5 and protein kinase R, which are important for detection of intracellular 
pathogens such as viruses (26, 38-42). As keratinocytes express a variety of PRRs, 
they can screen and recognise pathogens when they enter the skin. PRR ligation 
activates innate immune responses resulting in secretion of chemotactic and 
proinflammatory molecules and thereby activation of other immune cells (43).  
One consequence of keratinocyte stimulation by pathogens or wounding of the skin 
barrier is the secretion of a wide range of chemokines which can attract various 
professional immune cells such as DCs, LCs and T cells. These chemokines include 
Interferon-γ-inducible protein 10 (IP-10) / CXCL-10, Monokine-induced-by-gamma-
interferon (Mig) / CXCL-9 and Regulated-on-activation,-normal-T-cells-expressed-and-
secreted (RANTES) / CCL5 which can attract T cells, Macrophage-inflammatory-
protein 3α (Mip-3α) / CCL20 which attracts LCs and DCs, and Interleukin (IL) 8 and 
Growth-regulated-protein α (Gro-α) to attract neutrophils. Apart from chemokines, 
inflammatory and immunological mediators such as TNF-α, IFN-γ and Granulocyte-
macrophage-colony-stimulating-factor (GM-CSF) are also released (44-46). TNF-α is a 
cytokine of the acute phase reaction, it induces apoptosis and inflammation and can 
inhibit viral replication and tumourigenesis (47). IFN-γ has antiviral, immunoregulatory 
and anti-tumour properties, e.g. it promotes NK cell activity, promotes differentiation of 
CD4+ T cells to Th1 cells and increases antigen presentation of macrophages (48). 
GM-CSF is leukocyte growth factor as it stimulates the production of granulocytes and 
monocytes from stem cells (49). As a consequence of the secretion of these various 
cytokines and chemokines neutrophils, macrophages and T lymphocytes are recruited 
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and infiltrate the affected tissue leading to an orchestrated immune response against 
pathogens or induction of wound repair (26). 
While keratinocytes clearly have role in recruiting professional immune cells, they can 
also act as antigen-presenting cells. Keratinocytes express various molecules that are 
necessary for antigen-presentation to T cells. They constitutively express major-
histocompatibility-complex (MHC) class I and they can be stimulated by IFN-γ to 
express MHC class II (50, 51). They also express low levels of the co-stimulatory 
molecule CD86 (51). However, the other co-stimulatory molecule, CD80 cannot be 
detected on keratinocytes unless stimulated with allergens or irritants (52). 
Keratinocytes also express Intracellular-adhesion-molecule (ICAM) 1 which is a 
component of the immune synapse required for intercellular interactions (53). 
Initial studies of the antigen-presenting potential of keratinocytes showed induction of 
tolerance or anergy but did not show activation of T cells (reviewed in (43) and in (7)). 
Keratinocytes are therefore considered to be non-professional antigen-presenting cells 
and can only re-activate T cells that have been primed by professional antigen-
presenting cells (51). However, in an in vivo model, LCs and dDCs cells were 
dispensable for the induction of keratinocyte-directed CD8+ T cell responses 
suggesting that keratinocytes might be able to prime naïve T cells as the two 
professional antigen-presenting cell subsets were absent (54). In any case, activation 
of T cells by keratinocytes is not as efficient as activation by DCs.  
In conclusion, keratinocytes provide not only a physical protection from the outside 
world but they are also important to mount an immune response against pathogens. 
They are able to not only sense them but also recruit immune cells by secretion of 
chemokines. Keratinocytes also act as antigen-presenting cells. However, many 
aspects about the interaction between keratinocytes and the immune system remain 
unknown and require further study.    
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1.2 The human papilloma virus family 
 
Papilloma viruses (PV) are a family of small, non-enveloped, double-stranded DNA 
viruses with a circular genome of approximately 8 kb. More than 170 human papilloma 
virus (HPV) genotypes have been identified of which many have been found in clinical 
lesions. In addition, over 60 animal PVs have been sequenced, infecting e.g. cow (Bos 
Taurus, bovine PVs, 13 types), dog (Canis familirias, canine PVs, 15 types), horse 
(Equus caballus, 7 types), dolphin (Tursiops truncates, 7 types), mouse (the newly 
discovered MmuPV1), different bird and different turtle species and a variety of other 
species (Papillomavirus Episteme (PaVE), http://pave.niaid.nih.gov/) and it is 
hypothesized that PVs are ubiquitously present in all present day amniotes (55). In fact, 
they are so widely expressed that porcine PVs can be found in ground pork purchased 
from supermarkets (56). 
Different HPVs are associated with disease manifestations ranging from causing 
benign epithelial proliferation such as warts to different forms of cancer (55, 57). In fact, 
HPVs are associated with causing nearly all cervical cancers and HPVs can also be 
causative for cancers of the head and neck, penis, vagina, vulva and anus. Cervical 
cancer is one of the most common cancers with an estimated 530,000 new cases in 
2012 and one of the cancers leading to most deaths in women, with 270,000 deaths in 
2012, most of them (85%) in developing countries 
(http://www.who.int/mediacentre/factsheets/fs380/en/). 
PVs are divided into 29 different genera based on DNA sequence analysis of the L1 
protein which is well conserved and can be aligned for the known PVs. HPVs have 
been divided into five groups while other mammalian PVs occupy 20 genera, avian 
three and reptile PVs one. Most PV types in one genus have less than 60% of L1 
sequence identity with PVs from other genera. These groups are associated with 
different life cycle characteristics, target tissue and pathogenicity (58, 59). 
Supergroup A or α-papillomaviruses contains mucosal and cutaneous HPV types, 
including the high-risk mucosal HPV types whose DNA are found in nearly all cases of 
cervical cancers. They initially cause mucosal lesions that can progress to high-grade 
neoplasia and cancer in some individuals. HPV16 and HPV18 are the two high-risk 
viruses which are found in more than 70% of all cervical cancers. HPV31, HPV33, 
HPV45 and HPV58 account for a further 15% of cervical cancer cases with no HPV 
type identified in just 5% of affected individuals. In total, 12 HPV types have been 
defined by the World Health Organization (WHO) as being cancer-causing (the six 
mentioned before above along with 35, 39, 51, 52, 56 and 59) (55, 60, 61).  Moreover, 
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HPVs are also the causative agent in 90% of anal cancer cases, 40% of vaginal, vulvar 
and penile cancers as well as 35% of oropharyngeal and 25% of oral cavity cancers. 
Again, HPV16 and HPV18 are the main HPV types found in these HPV positive 
cancers ranging from 60% for penile cancers to more than 90% for anal, oropharyngeal 
and oral cavity cancers (62). The α-PV group also contains the low-risk mucosal types 
that cause benign lesions such as genital warts. HPV6 and 11 are causative in 90% of 
cases but they are generally not considered to cause cancer (60). In addition, low-risk 
cutaneous HPV types such as HPV2 and HPV57 which cause common warts and 
HPV3 and HPV10 causative of flat warts are also part of supergroup A (55, 63). 
The second major group are the β-papilloma viruses or the supergroup B. It includes 
high-risk and low-risk cutaneous types and is typically associated with inapparent or 
latent infections in the general population (55). However, immunocompromised 
individuals and Epidermodysplasia Verruciformis (EV) patients are more susceptible to 
infections with these viruses where they can proliferate and form open infections (64). 
Persistent infections with β-types are associated with development of squamous cell 
carcinoma (SCC) of the skin especially in immunosuppressed individuals and EV 
patients but the link has also been shown in immunocompetent people (65). HPV types 
such as HPV5, HPV14 and HPV36 are members of this group (58).  
The third group are the γ-papillomaviruses which cause benign lesions in the general 
population and the resulting warts resemble those caused by α-PVs but their DNA is 
only very rarely detected in skin cancers. HPV4 belongs to this group (55, 58).  
Mu- and Nu-papillomaviruses make up the final two HPV groups. They usually cause 
benign cutaneous infections in the general population. Mu-PV lesions are usually found 
at palmar and plantar epithelial sites and they are not associated with cancer. So far, 
the two members of this group are HPV1 and HPV63. Even though it is mostly found in 
benign infections, Nu-PV DNA is occasionally found in skin cancers and its only 
member is HPV41 (55, 58).  
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1.2.1 Viral structure and genome 
 
HPVs belong to the Virus Group I after the Baltimore classification which describes 
double-stranded DNA viruses (dsDNA virus). They contain a circular, double-stranded 
relatively small genome of 8 kb (66). The genome can be divided in three main parts: 
the non-coding upstream regulatory region (URR) which is also known as long control 
region (LCR) and the “early” and the “late” region (see Figure 2).  
The URR contains the viral origin of replication, sequences required for genome 
maintenance and transcriptional enhancers and promoters. This region is highly 
conserved between different PVs (67, 68).  
The late region contains the genes for L1 and L2 which code for the structural HPV 
proteins (the major and minor capsid proteins). They are expressed in the late stages 
of the viral life cycle. L1 is the major capsid protein; the capsid contains 360 copies of 
L1 organised into 72 pentamers called capsomeres (69). Up to 72 copies of L2 are 
contained within the capsid mostly hidden inside the virus lumen (70). Together they 
form a so-called T = 7 icosahedral capsid of approximately 55 – 60 nm which 
surrounds the viral DNA which is organised in chromatin form (69).  
In contrast to the late region, the early region codes for the non-structural proteins. It 
contains six to seven open-reading frames (ORFs). It generally codes for the early 
genes E1, E2, E4, E5, E6 and E7 but some PVs contain an extra ORF for a small E8 
protein. The early genes are important for replication, immune evasion and enhancing 
proliferation of the infected keratinocytes (63). 
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Figure 2: Map of the circular HPV18 reference genome 
HPV18 was chosen as a typical example of a high-risk α-type HPV genome. The early region of 
the HPV18 genome encodes for six ORFs E1, E2, E4, E5, E6 and E7 (shown in green) and the 
late region encodes the two capsid proteins L1 and L2 (shown in blue). Also shown are the 
spliced variants for E1^4 (orange), E8^2 (red) and E6 (purple). The upstream regulatory region 
(URR) is shown in yellow, taken from PaVE (http://pave.niaid.nih.gov/). 
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HPV replication is dependent on the cellular DNA synthesis machinery as the virus 
itself does not encode any polymerases. PVs are able to re-programme the cell’s DNA 
replication machinery to serve for their own replication. The early proteins E6 and E7 
are importantly involved in these processes. E6 and E7 of high-risk HPV types are 
oncogenes that can interfere with the cell cycle control. These processes are best 
studied in HPV16 (71).  
HPV E7 shares functional and structural similarities with oncogenes from other small 
DNA viruses such as the polyomavirus SV40 large tumour antigen and adenovirus 
E1A. They all contain a LXCXE motif which is the canonical binding site for 
retinoblastoma protein Rb (pRB). HPV E7 can bind pRB and its related pocket proteins 
p107 and p130 and lead to their degradation (72, 73). This leads to the aberrant 
expression of the transcription factor E2F and as result E2F-mediated activation of 
cyclin A and E and therefore activation of the cell cycle (74, 75). In addition, HPV E7 
prevents p21Cip1-and p27Kip1-mediated inhibition of cyclin-dependent kinases (CDK) 
such as CDK2 and induces S phase entry by bypassing the G0/G1 arrest (76, 77). 
These effects are important for carcinogenic progression and are pronounced in high-
risk HPV types such HPV16 but markedly reduced in non-oncogenic types such as 
HPV6 (76). 
The E7-induced activation of E2F also leads to stabilisation of p53 via activation of 
p14ARF. Stabilisation of p53 would normally induce cell cycle arrest or apoptosis (71). 
Here however, HPV E6 protein plays its role in cellular transformation as it induces 
ubiquitination-dependent degradation of p53 through interaction with the cellular protein 
E6-associated protein (E6-AP) (78, 79).  
Together these abilities of high-risk HPV E6 and E7 are sufficient to override the G1/S 
checkpoint which allows viral DNA replication in non-dividing cells. This can also lead 
to deregulation of growth control and the development of cancer. 
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Figure 3: Effect of HPV16 E6 and E7 on cycle progression 
HPV16 E6 and E7 can affect cell cycle progression. HPV16 E6 binds and degrades p53 and 
HPV16 E7 degrades pRb and the other pocket proteins, p107 and p130. As a result, E2F-
mediated activation of cyclin A and E leads to cycle progression without passing through the 
appropriate cell cycle checkpoints (adapted from (71)). 
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1.2.2 Papillomavirus life cycle  
 
HPVs are very successful pathogens. They usually induce chronic infections that rarely 
kill the host but shed large amounts of infectious virions. Moreover, the virus is very 
effective at evading the host’s immune system which it manages by employing different 
mechanisms. One of the main reasons for its success is the exclusively intraepithelial 
nature of its life cycle. Infection and growth are dependent on complete keratinocyte 
differentiation and there is no evidence that viral genes are expressed in any other cell 
type than keratinocytes (reviewed in (80)).  
Even though there are different HPV genera showing different pathogenicity and 
tropism, general principles of the life cycle are the same for all types (81). The virus life 
cycle begins by infection of the basal layer cells of the epidermis or the mucosal 
epithelium as a consequence of abrasion, wounding or microtrauma which exposes 
areas of the extracellular matrix (ECM), e.g. the basement membrane. It is generally 
thought that infection begins in epithelial stem cells (82, 83). For cutaneous HPV types 
it is thought that they enter via hair follicles infecting stem cells in this location and 
forming reservoirs which can be reactivated. HPV DNA has been found in plucked hair 
from both immunosuppressed individuals as well as healthy controls (84). 
In order to enter the cell, PVs initially bind to cell surface receptors and to the ECM via 
the glycosaminoglycan (GAG) chains of heparin sulphate proteoglycans (HSPG). 
Different PV types (e.g. cutaneous vs. mucosal) recognise different forms of HSPGs 
(85, 86). For certain HPV types binding to the ECM can also occur via laminin 332 but 
this interaction is not conserved, e.g. α9 types such as HPV16 use laminin 332 but α7 
members such as HPV18 do not (87). These pre-entry requirements might explain site 
preferences of HPV types.  
After binding to the ECM, the PV particle changes conformation (88). These changes 
include exposure of the L2 protein which is usually found inside the virus lumen and its 
cleavage at the N-terminus by furin at sequence conserved amongst PVs. This 
cleavage is essential for successful infection (89).  
The virus is then taken up into the cell and it is thought that a secondary receptor may 
trigger this uptake. However, no receptor has been identified so far and it has been 
suggested that in fact PVs do not bind to just one but multiple molecules (90). In 
addition, it is thought that the binding to the secondary receptor happens via L1 through 
a binding site that is only exposed after furin cleavage of L2 (82). After binding, PVs are 
taken up by endocytosis. It was initially thought that the endocytosis was clathrin- or 
caveolin-mediated, however, for HPV16 pseudovirions it was shown the process is 
clathrin-, caveolin-, flotillin-, cholesterol- and dynamin-independent but rather 
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dependent on actin dynamics. It is suggested that PV particles are taken up by a novel, 
ligand-activated pathway (91, 92).  
After endocytosis, PVs are transported to endosomes where the virus is uncoated. The 
PV genome is then transported by the L2 protein into the nucleus via a currently 
unknown mechanism and the L1 protein is degraded in the lysosome (68, 90, 93). 
Inside the nucleus, transcription is initiated and the viral proteins are made.  
Once the virus has entered the nucleus it is replicated in three different stages: 
establishment, maintenance and amplification (68). 
Establishment is the replication process during which HPVs establishes itself as a 
multi-copy extrachromosomal replicon (= nuclear plasmid) in basal cells. The viral 
proteins E1 and E2 are required for this process (94, 95). After initial establishment, the 
infected cell undergoes cell division. During this process, the HPV genome is replicated 
and partitioned to daughter cells. In this maintenance phase, HPV is replicated at a 
constant copy number between 50 – 200 copies per cell. HPV E2 is important for the 
attachment of the genome to host cell chromatin and therefore necessary for 
maintenance (96). Depending on the HPV type, the expression of E6 and E7 proteins 
are also important for maintenance. For example, HPV16 and HPV31 E6 are essential 
for maintenance, while HPV18 is maintained without the presence of HPV18 E6 albeit 
at lower levels (97). 
The final stage of replication is called amplification, vegetative replication or productive 
phase of the replication. It is restricted to the differentiated layers of the skin. At this 
stage, the viral genome is amplified to a high copy number and each cell can contain 
many thousands of virus copies (98).  
After the viral genome is successfully amplified, it is packaged into the capsid. The late 
proteins L1 and L2 are expressed and the icosahedral capsid is assembled in the 
nucleus. The virus matures in the superficial, dying keratinocytes which involves 
formation of disulphide bonds between the L1 monomers (99, 100). The virions are 
shed from dying cells and released into the surroundings in a passive manner.  
The viral life cycle dictates where certain viral components can be detected: viral DNA 
and E4 are detected in the suprabasal layers, whereas E6 and E7 are expressed 
throughout the epithelium. L1 and L2 proteins are only expressed in the superficial 
layer of the epithelium (compare with Figure 4 and (55, 101).   
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Figure 4: Life cycle of high-risk HPVs 
HPVs enter via a micro-wound and infect basal cells of the epithelium. The genome is 
maintained at low copy number there. As cells divide the genomes are distributed between the 
daughter cells which will undergo their normal life cycle and move up inside the layers. Different 
virus proteins are expressed in different layers of the skin. Viral genomes are amplified in 
suprabasal layers where normally no DNA synthesis occurs. Virions are formed in the upper 
layers and shed from there. Adapted from Doorbar et.al. 2012 (55). 
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1.2.3 Mechanisms of HPV immune evasion   
As previously mentioned, HPVs are very successful pathogens. They have developed 
multiple strategies to evade the immune system. 
One of the strategies employed by HPVs is to keep a “low profile” as it is exclusively 
intra-epithelial. Viral particles are only formed and shed from external and differentiated 
cells that are destined to die, thereby reducing the exposure to the host immune 
system. The life cycle is non-lytic and does not induce any inflammatory signals to 
activate an immune response. The E proteins which are present in lower layers of the 
epidermis are expressed at low levels and mainly in the cell nuclei. In addition, the 
highly immunogenic L1 and L2 proteins are only expressed in the outer layers and 
therefore “hidden” from the immune system meaning that presentation of viral peptides 
to the immune cells is very limited. There is also no blood-borne or viremic phase of the 
infection leaving HPV essentially invisible to the immune system as most of the life 
cycle takes place in relative distance to the immune cells of the dermis. In addition, 
even though LCs can detect presence of the virus, HPV has developed multiple 
strategies to avoid their recruitment (80, 102, 103). 
HPV is not only “hidden” from the immune system but its proteins directly affect the 
activation of the innate immune system. As already described keratinocytes express a 
range of TLRs that can detect viral DNA and RNA whose activation lead to production 
of type I interferons and to Th1-type cytotoxic responses via activation of interferon 
regulatory factor (IRF) and nuclear factor of κ-light chain enhancer of activated B cells 
(NFκB) pathways. Type I interferons (e.g. IFN-α, -β and –λ) have antiviral, 
antiproliferative and immunostimulatory properties, e.g. stimulation of DCs. In addition 
keratinocytes are able to secrete chemokines and cytokines to recruit and activate 
other immune cells (7, 44-46, 104, 105).   
High risk HPVs are able to influence innate immune signalling, e.g. interferon and IRF 
signalling as well as the NFκB and inflammasome pathways. They can also affect the 
adaptive immune response by changing MHC surface expression and peptide 
presentation. In addition, HPV alters the normal growth and apoptosis programmes of 
keratinocytes after infection ((106) and reviewed in (107)).  
In particular, IFN-inducible genes and TLRs are downregulated or their activation 
inhibited. HPV16 and to a lesser extent HPV18 are able to downregulate the 
expression of TLR9 (108). HPV16, 18 and 31 inhibit the expression of antiviral genes 
such as IFIT1 and MX1, IFN signalling components such as STAT1, pathogen 
recognition receptors such as TLR3, RIG-I and MDA5 as well as the proapoptotic 
genes TRAIL and XAF1. This correlates with a reduction in the induction of IFN-β and 
the different IFN-λs after stimulation (109).   
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In addition, the high-risk HPV oncoproteins can also inhibit the production and the 
effects of different type I interferons, especially those of HPV16 and 18. HPV16 and 18 
E7 interact with IRF-1 thereby inhibiting IRF-1 mediated activation of IFN-β. E7 is also 
able to induce recruitment of histone deacetylases to the IFN-β promoter interfering 
with IRF-1’s trans-activating functions (110, 111). 
HPV16 E6 protein (but not HPV18 E6) can bind to IRF-3 inhibiting its trans-activation 
function and thereby inhibiting IFN-β transcription and its secretion after viral infection 
(112). High-risk HPV E2 reduces the expression of STING which is activated by DNA 
sensors of the cell usually activating IRF-3 signalling also reducing IFN-β transcription 
and both E2 and E6 reduce the expression of the type I interferon IFN-κ (113, 114).  
High-risk HPVs also interfere with signalling downstream of interferon receptors. 
Binding of HPV18 E6 occurs to Tyk2 which inhibits phosphorylation of Tyk2 resulting in 
reduced phosphorylation of STAT-1 and STAT2 impairing JAK-STAT signalling after 
IFN-α/β stimulation ((112) and reviewed in (80, 115)). HPV16, 18 and 31 E6 are further 
able to reduce the transcription and translation of STAT1. IFN-α/β mediated signalling 
is also inhibited by HPV E7 via binding to IRF-9 which prevents its translocation to the 
nucleus and therefore formation of the ISGF-3 transcription complex. As a 
consequence IFN-inducible genes are not transcribed (116). 
Another important signalling pathway other than the IFN pathways that is activated 
after stimulation of PRRs is the NFκB signalling pathway leading to production of 
immune modulatory cytokines. High-risk HPVs also have various effects on the NFκB 
signalling pathway. After activation of both the canonical and non-canonical NFκB 
pathways by PRRs and CD40 or TNFR2 and CD40, respectively, NFκB1 and 2 
translocate to the nucleus where they bind to DNA and initiate gene transcription. High-
risk HPVs impair NFκB translocation into the nucleus and its function there at multiple 
stages of the signalling pathway by, e.g. sequestering NFκB family members in the 
cytoplasm or reducing their transcriptional activity as well as using endogenous 
proteins to prevent ubiquitination and therefore degradation of IκBα, an inhibitor of the 
NFκB pathway. E7 is also able to block NFκB DNA binding activity (106, 107, 117-119). 
This leads to decreased production of pro-inflammatory cytokine and recruitment of 
immune cells (120).    
Another effect of HPV is the global downregulation of cytokine responses in 
keratinocytes. Activation of NOD-like receptors leads to activation of pro-inflammatory 
signalling pathways, e.g. the inflammasome. This is essential for the activation of 
tissue-resident immune cells such as LCs and recruitment of effector T cells (121). 
HPV E6 as previously described binds to E6-AP and p53 leading to degradation of pro-
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IL1β in the proteasome and therefore a significantly reduced IL-1β secretion but cannot 
completely abolish it (122, 123).  
Via interfering with the NFκB and IFN pathway, high-risk HPVs inhibit induction of 
chemokines, e.g. secretion of Mip-3α and IL-8 after stimulation with TLR9 ligands is 
inhibited by expression of HPV16, 18 and 31, as are basal levels of these cytokines 
(108, 109, 124). Reduced expression of Mip-3α leads to a reduction in LC migration 
(125) and IL-8 is important for attraction of T cells and neutrophils (126). This might 
explain the reduced numbers of LCs found in lesions infected with high-risk mucosal 
types such as α7 and α9 and low-risk cutaneous types such as γ and Nu (127).   
HPVs do not only affect the chemoattraction of immune cells but also proteins 
important for antigen presentation. HPV E7 proteins are able to down-regulate the 
expression of MHC class I molecules by repressing the promoter activity of the heavy 
chain. Some of the E7 proteins are also able to repress the expression of low 
molecular protein (LMP) 2 and TAP-1 which are important for the transport of MHC 
molecules to the cell surface (128). E7 as described above interferes with IRF-1 
signalling and thereby reducing IFN-γ mediated upregulation of MHC class I molecules 
via the JAK1/STAT1/IRF-1 pathway and E5 is able to retain MHC class I in the Golgi 
and therefore hampering its transport to the cell surface. E5 also blocks peptide-
loading of MHC class II and reduces MHC II surface expression after IFN-γ stimulation 
(129-131). 
In summary, HPVs employ a wide range of strategies to successfully evade the 
immune system and induce infection by a) “hiding” from the immune system, b) 
interfering with pathways that would induce an anti-viral state inside keratinocytes, c) 
reducing the production of cytokines and chemokines for recruitment of immune cells 
and d) inhibiting parts of the antigen machinery (also reviewed in (115) and (107)). 
However, all these mechanisms have only been studied in detail using high-risk 
mucosal HPV types and not all are not found in low-risk HPV types.  
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1.2.4 Regression, Persistence and Latency of HPV infections 
 
Virus infection of a host with a virus can have multiple outcomes. An acute infection 
can develop which is associated with open symptoms and signs of disease. It is often 
followed by recovery or complete elimination of the virus. However, it can also result in 
chronic infection or latent infection. During a chronic infection the host is still infectious 
but there are usually no overt signs of disease. A latent infection is associated with no 
clinical signs of disease and no production or release of infectious particles. The 
disease can, however, be reactivated leading to synthesis of new virions. A typical 
example of a latent infection is the infection with herpes simplex virus 1 (HSV-1) (132).  
Most HPV infections spontaneously regress and eventually get cleared by the immune 
system. However, in certain cases they persist and this persistence can enable the 
formation of cancer. It is not yet fully understood which immune cells are important for 
regression and control of HPV infection. Regression of HPV-induced lesions is usually 
associated with infiltration of T lymphocytes. Most studies describe a mixed lymphocyte 
population consisting of both CD4+ and CD8+ cells, e.g. in animal studies using canine 
oral PV (COPV), rabbit oral PV (ROPV) and bovine PV (BPV) 4 (133-135) with initially 
an influx of mainly CD4+ T cells. This correlation between regression and a high 
CD4:CD8 cell ratio has also been described in humans (136). 
In contrast, in cottontail rabbit PV (CRPV)-induced papillomas regression was 
associated with an influx of CD8+ T cells and only few CD4+ cells but viral DNA 
persisted for months after clearance of the overt infection (137). It is, therefore, 
possible that different PV infections are cleared in different ways.  
Following initial clearance, viruses can enter a latent state. For HPVs this is suggested 
as often overt papillomatosis can be seen in immunosuppressed patients such as 
people on immunosuppressive treatment following a transplant or in the context of HIV 
infection (138, 139). This correlation is seen for a variety of HPV types such as the 
high-risk mucosal types but also for certain β- and γ-HPV types (140). 
It is thought that HPVs persists in the form of viral genomes in the basal layers 
(suggested to be epithelial stem cells) with little or no expression of viral genes. For 
ROPV it has been shown that viral copy number decreases from 50 copies per cell 
during active infection to less than one copy per cell in latency. During this time no 
evidence of productive infection can be found (141). In animal models, viral DNA is 
found in cells months after immune regression and in sites adjacent to the regressed 
papillomas. Reactivation of the virus can again lead to wart formation (142).     
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Table 1: Characteristics of immune cells in HPV regression vs. persistence  
Adapted from Hibma, 2012 (143) 
Regression Persistence 
Increased TLR expression Reduced TLR expression 
TNF-α production by infiltrating 
mononuclear cells 
Chronic inflammation in the epidermis 
CD4 and CD8 infiltrate Impaired natural killer (NK) cell function 
and IFN pathways 
High CD4:CD8 ratio Low CD4:CD8 ratio with few or no CD4 
cells present at site 
Infiltration of antigen-presenting cells Reduced number of antigen-presenting 
cells and impaired antigen presentation  
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1.2.5 The mouse papilloma virus  
 
For many decades papilloma virus research was limited to using tissue culture 
methods as well as transgenic mice that were modified to express viral oncogenes of 
BPVs or HPVs such as E6 and E7 of HPV16. Lacking a PV that infected the laboratory 
strain mice (Mus muculus) naturally significantly limited the research as the full power 
of mouse genetics and available knock-out and knock-in strains could not be used to 
study PV infections. Available animal models for PV infection studies included dogs 
using COPV, rabbits using CRPV and cows using BPV 1, 2 and 4 (133, 144, 145). 
In 2011, the Sundberg group identified a novel mouse papilloma virus (initially called 
MusPV, later renamed to MmuPV1). Papillomatosis occurred in a closed colony of 
NMRI-Foxn1nu/Foxn1nu mice at the Advanced Centre for Treatment Research and 
Education in Cancer (ACTREC) in Khargar, Navi Mumbai, India. Papillomas mainly 
appeared around the mouth and nose and in low numbers in other haired skin sites but 
they were limited to cutaneous surfaces. Histological analysis showed a phenotype 
similar to koilocytes which are found in many productive PV infections. Sequencing 
analysis identified a virus with 65% genomic and 83% L1 amino acid similarity to the 
Mastomys coucha (Southern multimammate mouse) PV, McPV2. Using cell-free 
suspensions from these papillomas, they could be transferred onto other 
immunocompetent laboratory mice (S/RV/Cri-ba/ba) (146). Following the discovery of 
this novel PV, another variant of it was discovered a year later (147).   
The complete MmuPV1 sequence is 7510 nt and it is classified as a member of the π-
genus as it has around 60% similarity with rodent PVs from this genus which includes 
McPV2. It has seven ORFs coding for the early proteins E1, E2, E4, E6 and E7 and L1 
and L2. No E5 ORF has been identified. A binding site for pRb has been found on E6 
and not on E7 like in other PVs. In addition, it has multiple binding sites for other 
transcription factors such as AP1 and GATA1, a p53 (TRP53) binding site and a C-
terminal PDZ binding domain in E7 usually found in E6 (147, 148).  
Even though the initial study showed development of papillomas in immunocompetent 
S/RV/Cri-ba/ba mice, in other studies immunocompetent hosts such as wild type 
FVB/NCr, C57BL/6J or BALB/c mice did not develop papillomas when scarified and 
inoculated with MmuPV1 and no MmuPV1 DNA could be detected in swabs taken from 
these animals 1 months post-inoculation (149-151). Lesions can be induced in some 
immunocompetent strains when they are treated with immunosuppressive drugs such 
as ciclosporin A which inhibits T cell activation and cytokine production. However, 
different strains show different susceptibilities with FVB/NCr and SENCAR being highly 
susceptible, BALB/c intermediately susceptible and C57BL/6J mice being relatively 
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resistant to lesion formation after MmuPV1 infection. In addition, all lesions that 
develop regress once the ciclosporin A treatment is stopped indicating that their 
formation is due to the induced immunosuppression. If ciclosporin A treatment was 
started a few months after inoculation no lesion formation was observed showing that 
the initial infection was effectively cleared (151). 
Lesions develop in immunocompromised animals when scarified sites are inoculated 
with either live virus isolated from other lesions, MmuPV1 DNA encapsidated into L1/L2 
capsids of either MmuPV1 or HPV16, or naked MmuPV1 DNA. In some cases, they 
appear as early as 2 to 3 weeks after application of the virus or viral DNA. Secondary 
infections have also been observed that developed after around 3 to 4 months and they 
show broadened tissue tropism being present at tail, face, back, urethra, anus and 
vagina. This indicates that infectious virions are shed from the surface of lesions (150, 
152).  
Interestingly, different skin sites on the body of the mice show different susceptibility to 
lesion formation after MmuPV1 infection. Whereas at muzzle, tail and ear effective 
lesion formation can be observed, the skin of the back is relatively resistant even 
though all three sites are permissive for transduction with MmuPV1. The formation of 
papillomas is related to the amount of E1^4 transcript copies and therefore viral 
transcription found in the inoculated site (150). This seems to indicate that there are 
region-specific factors that are responsible for the resistance to papilloma formation in 
the back.  
MmuPV1 can also be used to assess the immune response following infection with a 
PV. Both CD4+ and CD8+ T cells infiltrate MmuPV1 infected tissue (more than 10-fold 
increase compared to mock infected sites) with CD4+ T cells being present in the 
epithelium and the underlying dermis whereas CD8+ T cells are mainly present in the 
epithelium only (151). 
CD3+ T cell depletion before infection from immunocompetent hosts such as SENCAR 
and C57BL/6 leads to efficient formation of papillomas. Whether single depletion of 
CD4+ and CD8+ T cells is sufficient to induce papilloma formation depends on the 
background strain: in highly susceptible SENCAR mice single depletion is sufficient 
whereas in C57BL/6 mice both CD4+ and CD8+ T cells need to be depleted (151).  
C57BL/6 knock-outs for either CD4+ or CD8+ T cells alone do not develop papillomas 
after MmuPV1 infection. However, in CD4+ T cell single knock-outs the levels of E1^4 
transcripts peak at 2 weeks post-infection which does not happen in wild type or CD8+ 
T cells knock-outs indicating that CD4+ T cells are responsible for early viral gene 
expression control. CD1d-deficient mice lacking NKT cells or B-cell deficient mice 
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strains do not form lesions suggesting that these cells do not play a critical role in 
MmuPV1 control (151, 153). 
Overall, it is clear from the initial MmuPV1 studies that T cell immunity is essential for 
the control of PV infections. However, different mouse strains show different 
susceptibility to MmuPV1 infection which needs to be taken in consideration when 
working with this system (151, 153). 
Most of the initial studies were done on scarified skin and proved cutaneous tropism of 
MmuPV1. At the beginning of 2015, Cladel et al. also confirmed its mucosal tropism. 
The vaginal canal and cervix of Foxn1nu/Foxn1nu are susceptible to MmuPV1 infection 
as well as cutaneous and mucosal tissues of the anal canal (154). Therefore, MmuPV1 
can potentially also be employed to further the research done on the cancer-inducing 
properties of PVs on mucosal surfaces. 
In fact, malignant potential of MmuPV1 at cutaneous sites has already been shown as 
not only papillomas but also trichoblastomas (benign neoplasm of follicular germinative 
cells) were identified in some animals (153) and pre-malignant lesions were found in 
others (152).   
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1.3 The common γ-chain and its cytokines  
 
1.3.1 The γ-chain and its co-receptor 
 
The common γ-chain, also known as IL-2Rγ or CD132, is a cytokine receptor subunit 
which is encoded by the IL2RG gene located on the long (q) arm of the X chromosome. 
The gene consists of eight exons and seven introns and spans only 4.2 kb. It shows 
many genetic features characteristic for a member of the cytokine receptor superfamily, 
e.g. two pairs of conserved cysteines in exon 2 and 3 and a WSXWS motif in exon 5. 
Exon 6 encodes the transmembrane domain and the entire cytoplasmic domain is 
encoded in exons 7 and 8 (155).  
The common γ-chain was originally detected as co-precipitate of IL-2Rβ. It was also 
bound to IL-2 and identified to be a part of the high-affinity IL-2 receptor together with 
the β-chain and IL-2Rα – these three chains forming a heterotrimer (156). It was 
subsequently identified that the amount of γ-chain co-precipitated with IL-2Rβ was 
proportional to numbers of IL-2 binding sites and that it is essential for the transduction 
of intracellular signals as a complex formed of IL-2Rα and IL-2Rβ can bind IL-2 with 
high affinity but does not activate downstream signals (157, 158).  
The subunits of the IL-2 receptor have different binding affinities for IL-2. IL-2Rα alone 
has low binding affinity (Kd ≈ 10 nM) and is not involved in signal transduction. IL-2Rβ 
alone has a very low affinity (Kd ≈ 100 nM) whereas γ-chain cannot bind IL-2 on its 
own. A complex formed of IL-2Rβ and γ-chain has an intermediate affinity (Kd ≈ 100 
pM) and it is the receptor which is usually found on macrophages, NK cells and resting 
T cells. The heterotrimer with IL-2Rα forms a high affinity receptor (Kd ≈ 10 pM) and is 
found on activated T cells. The IL-2Rβ and the γ-chain are sufficient and necessary for 
IL-2 signal transduction, which does not depend on IL-2Rα (159, 160).  
It was subsequently identified that the common γ-chain is part of a number of different 
cytokine receptors including those for the interleukins (IL) IL-2, IL-4, IL-7, IL-9, IL-15 
and IL-21 (161-166). The majority of these receptors are heterodimers (IL-4, IL-7, IL-9 
and IL-21), which are formed of a specific α-chain and the common γ-chain. The IL-
15R, however, like IL-2R forms a heterotrimer formed of a private α-chain (IL-15Rα), 
the β-chain shared with IL-2R (IL-2Rβ) and the common γ-chain (163, 167). For all 
these receptors the γ-chain is essential for signalling processes.  
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Figure 5: Receptors for γ-chain cytokines 
The common γ-chain is part of the receptors for six different cytokines. Four of these receptors 
– for IL-4, IL-7, IL-9 and IL-21 – are heterodimers formed of a specific α-chain and the γ-chain. 
The two other receptors – for IL-2 and IL-15 – are formed of their private α-chains (IL-2Rα and 
IL-15Rα), a shared β-chain (IL-2Rβ) and the γ-chain. These receptor chains hetero-dimerise or 
hetero-trimerise when the respective cytokines bind and activate downstream signals. Adapted 
from Rochman et al, 2009 (168).  
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1.3.2 Signalling via the common γ-chain 
 
The receptors of the common γ-chain family lack intrinsic tyrosine kinase activity and 
therefore transmit signals via the Janus-kinase (JAK) and Signal-Transducers-and-
Activators-of-Transcription (STAT) pathway: the carboxyl-terminal region of the γ-chain 
is associated with the N-terminal region of JAK3; the cytoplasmic part of the α-chains 
(except IL-2Rα and IL-15Rα) and IL-2Rβ are bound to JAK1 (169, 170). When the 
respective cytokines bind to their receptors, the receptor chains hetero-dimerise or 
hetero-trimerise, which leads to catalytic activation of the receptor-associated JAKs. In 
addition, JAK1 and JAK3 trans-activate each other. JAK1 is essential for further 
downstream signalling even though it is not directly associated with γ-chain, e.g. cells 
from JAK1 knock-out mice do not show any responses to γ-chain cytokines (171). The 
trans-activation of JAK1 and JAK3 creates interaction sites for proteins with 
phosphotyrosine-binding Scr-homology 2 (SH2) domains. STATs contain these motifs 
and are then recruited to the cell membrane and are phosphorylated by the JAKs on 
conserved tyrosine residues. Phosphorylated STATs dimerise and acquire high-affinity 
DNA-binding activity. They translocate into the cell nucleus and function there as 
nuclear transcription factors and activate downstream targets. IL-2, IL-7, IL-9 and IL-15 
mainly signal via STAT5A and STAT5B, IL-4 via STAT6 and IL-21 via STAT3 (cytokine 
signalling and the JAK-STAT pathway are reviewed in (172, 173)).  
In addition to the JAK/STAT pathway, common γ-chain cytokines also activate other 
pathways such as the phophoinositide 3-kinase (PI3K/Akt) pathway, e.g. binding of IL-2 
to its receptor leads to activation of PI3K which results in phosphorylation of Akt. 
Activated Akt translocates to the cytosol and the cell nucleus where it activates its 
targets resulting, e.g. in a block of apoptosis and induction of cell cycle progression. 
These distinct outcomes differ from the results of the activation of STAT proteins (174-
176). Different RAS-mitogen-activated protein kinase (MAPK) pathways are activated 
by common γ-chain cytokines as well (177). The combination of these different 
pathways leads to the specific effects of the different cytokines.  
However, there is one receptor in the γ-chain family that exists in two forms, one of 
which does not rely on the common γ-chain for its signalling function – the receptor for 
IL-4. One of its forms is made up of the IL-4Rα and the common γ-chain and the other 
one of IL-4Rα and IL-13R. In certain cells, e.g. colon cancer cell lines, IL-4 does not 
signal via the common γ-chain but instead via its complex with IL-13Rα. In this case, 
different downstream molecules are activated namely JAK1, JAK2 and Tyk2 whereas 
no changes in phosphorylation of JAK3 are observed (178, 179).  
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Moreover, the receptor for IL-15 is the only receptor from the γ-chain family that is 
known to be able to trans-present and this accounts for most IL-15 signalling. The IL-
15Rα and IL-15 form high-affinity interactions and so the receptor can present the 
cytokine in cis or trans to the β/γ-complex. Cis-presentation means that the quaternary 
complex made of IL-15 and the three receptor chains is assembled on the surface of 
the same cell, whereas trans-presentation happens between two different cells. This 
allows cytokine signalling through cell contact rather than usual soluble messenger 
mechanisms and presentation of IL-15 to cells that only express the β/γ-complex but 
not IL-15Rα, e.g. the presentation by monocytes to CD8+ T cells upon cell-cell 
interaction (180, 181).  
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Figure 6: Signalling via the common γ-chain 
When the respective cytokine binds to its receptor – here shown for IL-2 – and the single 
receptor chains dimerise or trimerise, JAK3 (bound to the γ-chain) and JAK1 (bound to the α-
chains of the heterodimers or IL-2Rβ of the heterotrimers) are activated and phosphorylate each 
other. This leads to activation of different downstream pathways such as the STAT pathway, the 
MAPK pathway via ERK1/2 and the PI3K/Akt pathway. This activation and translocation of 
transcription factors to the nucleus leads to the activation and transcription of target genes. 
Activating phosphorylations are shown in red, inhibitory phosphorylation in blue.  
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1.3.3 The effects of γ-chain cytokines 
 
The common γ-chain cytokines can induce various effects on different cell types but 
their effects have only been thoroughly examined in cells of the immune system, such 
as T, B and NK cells.  
IL-2 was initially identified by Morgan et al. in 1976 as a glycoprotein present in 
conditioned media from phytohemagglutinin stimulated lymphocytes that induced a 
selective growth advantage of the T lymphocyte fraction of bone marrow cells (182). It 
was initially also known as ‘T cell growth factor’ (TCGF) and its cDNA was cloned in 
1983 (183). IL-2 was subsequently shown to also increase the cytolytic activity and 
IFN-γ production of NK cells (184), to enhance proliferation of NK and activated B cells 
(184, 185) and to be important for the differentiation of Th cells (186, 187). Even 
though IL-2 has various effects in vitro, in in vivo systems it is implied to be more 
important for immune tolerance as it is involved in the development of regulatory T cells 
(188-190).  
IL-2 deficient mice present with generalised autoimmune diseases and show symptoms 
such as inflammatory bowel disease or haemolytic anaemia (191, 192). IL-2Rα 
deficient mice have normal T and B cell development at young age but later on present 
with enlargement of secondary lymphoid organs, lymphoproliferative disorder, 
haemolytic anaemia and inflammatory bowel disease (191). This data shows the 
importance of IL-2 for immune tolerance.   
IL-4 is involved in the development and function of Th2 cells, it is a T cell growth factor 
and it is involved in class switching of immunoglobulins especially for IgE and IgG1 and 
it is therefore involved in allergic reactions (193). IL-4 is also a survival factor for 
dendritic cells and is used in vitro in combination with GM-CSF to induce DCs from 
human CD14+ monocytes (194).  
IL-4 deficient mice show normal T and B cell development but IgG1 and IgE serum 
levels are greatly reduced. In addition, IgE secretion cannot be induced in these 
animals and IgG1 levels remain low even after T cell activation. Their ability to secrete 
Th2 derived cytokines is reduced as well. (195, 196). IL-4Rα knock-out mice are very 
similar to IL-4 knock-out mice (197).  
IL-7 was identified in the late 1980s as a novel haematopoietic growth factor (198). It is 
involved in stimulating the proliferation of pre-B cells, thymocytes and mature T cells 
(199). It is constitutively expressed by epithelial and stromal cells in the primary 
lymphoid organs – bone marrow and thymus – as well as the T cell zones in the 
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secondary lymphoid organs (200, 201). The IL-7Rα is mainly expressed on naïve and 
memory T cells but not on activated T cells (202).  
IL-7 deficient mice are highly lymphopenic in both blood and lymphoid organs, and 
splenic T and B cellularity as well as thymic cellularity are reduced (203). This shows 
that IL-7 is important in mice for the development of both B and T cells. In addition, IL-
7Rα deficient mice have reduced thymic and peripheral lymphoid cellularity (204). 
IL-9 was identified in 1988 as a murine Th cell-derived T cell growth factor and it was 
initially called P40 (205, 206). The human homologue was identified two years later 
(207). IL-9 is correlated with activation of B cells, mast cells and eosinophils (208). It 
enhances the production of IgE and IgG in presence of IL-4, but has no effect on IgM 
production (209).  
IL-9 deficient mice do not display changes in T cell development or differentiation or 
antigen-driven antibody responses. They show differences in specific Th2 responses to 
lung challenges with allergens underlining IL-9’s importance in allergic reactions (210).  
IL-15 was identified in 1994 as a cytokine that was able to induce T cell proliferation 
and that was similar in its activities to IL-2 and used components of the IL-2 receptor 
(211). IL-15 signalling is essential for NK cell development and survival as well as the 
long-term survival of CD8+ memory T cells (212, 213).  
IL-15Rα deficient mice are lymphopenic due to reduced proliferation and decreased 
homing of lymphocytes to peripheral lymph nodes. IL-15 is important for the 
development of NK cells as IL-15Rα deficient mice are deficient in this cell type. They 
also lack NKT cells and CD8+ T cells (214). Similarly, IL-15 knock-out mice have a 
greatly reduced NK cell and CD8+ memory T cell pools (215).  
IL-21 is the member of the γ-chain cytokine family that was found the latest (in 2000) 
and it is closely related to IL-2 and IL-15 (216). IL-21 is able to induce proliferation of B 
cells, differentiation of plasmablasts and antibody secretion (217). IL-21 is not only 
important for the regulation of B cell development, but it is also involved in the 
proliferation and maturation of NK and T cells. (218, 219).  
The roles of γ-chain cytokines are also reviewed in (168). The role of the common γ-
chain cytokines in other cell types has not been widely examined and is therefore 
largely unknown. For keratinocytes, it has been shown that they express IL-7, IL-15 
and IL-21 and that these cytokines have pro-proliferative effects on keratinocytes (220-
222). In addition, they express IL-9R and IL-9 signalling can induce secretion of 
cytokines such as IL-8 (223).  
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1.4 Severe combined immunodeficiency (SCID) and other 
primary immunodeficiencies associated with γ-chain 
cytokines 
 
Severe combined immunodeficiency (SCID) is a group of primary immunodeficiencies 
which are characterised by the absence of a functional adaptive immune system mainly 
due to lack of T cells. The immunodeficiencies are relatively similar in all cases of SCID 
regardless of the underlying genotype. The prevalence of SCID is 1 in 100,000 live 
births even though it is higher in certain ethnic groups. Patients suffer from severe 
opportunistic infections such as pneumocystis, adenoviruses, EBV and Candida 
albicans. Due to the absence of a functional adaptive immune system, children need to 
live in an enclosed sterile environment. The risk of mortality within the first years of life 
due to recurrent infections is very high if patients are not treated (224, 225). 
The proportions of different types of SCID vary between different cohorts. For example, 
the numbers of autosomal recessive forms are higher in countries with higher 
consanguinity. The most widely cited study about percentages for SCID cases is from a 
single-centre study in the United States where data from 170 SCID patients was 
analysed in a retrospective study. There, the majority of genes responsible for SCID 
regulated cytokine signalling and antigen receptor recombination, processes which are 
important for the development of lymphocytes and their metabolism. The SCID types 
associated with defective cytokine signalling are: a) X-linked SCID (X-SCID), the most 
common type of SCID is caused by mutations in the common γ-chain, characterised by 
an absence of T and NK cells and B cells are present but dysfunctional. It accounted 
for 46% of cases. b) Mutations in JAK3, which signals downstream of the common γ-
chain, accounted for 7% of SCID cases and patients are phenotypically identical to X-
SCID boys. c) Mutations in IL-7Rα are the third group of SCID cases with an 
involvement of cytokine signalling and were present in 10% of patients. In these 
patients only T cells are absent (225). 
The second most common (17%) SCID type is due to defective metabolism: ADA SCID 
is caused by mutations in adenosine deaminase (ADA) which leads to cellular 
accumulation of adenosine and its derivates resulting in lymphocyte apoptosis and an 
absence of T, B and NK cells. The other types of SCID are due to problems in antigen 
receptor recombination and are characterised by an absence of T and B cells, but NK 
cells are present. They are caused by mutations in T- and B-cell receptor arrangement 
associated ARTEMIS (1.2%) and RAG (2.9%) genes. For a small percentage of 
patients the underlying mutations remain unknown (225). 
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In a London cohort of 117 patients, the numbers differed from the ones presented in 
the US study: the percentages for X-SCID (17%), ADA-SCID (19%) and RAG-
deficiency (15%) were nearly identical with 17% of patients not having been diagnosed 
at the time of transplant (226).  
The only curative treatment available for all types of SCID is bone marrow 
transplantation (BMT). Its outcome varies depending on the type of transplant, the type 
of underlying SCID, preceding comorbidity and the age at transplant. Match sibling 
donors (MSD) and match family donors (MFD) usually show a high survival rate. 
Nowadays, there is over 85% overall survival for MSD or MFD but only around 55% for 
haploidentical donors. Moreover, generally, B- SCID types are associated with lower 
survival rates than B+ SCID types (226, 227).  
Moreover, it is important to consider whether conditioning regimes should be used prior 
to transplantation as they are associated with short- and long-term toxicity. For SCID 
an unconditioned transplant can be performed due to the lack of significant host 
adaptive immunity reducing the risk of rejection. Studies have shown that T-B+ forms 
of SCID (such as X-SCID, JAK3 and IL-7Rα deficiency) and ADA-deficiency show 
excellent outcomes after unconditioned, matched transplants. However, it has also 
been described that for certain types of SCID, e.g. T-B-NK+ SCID, the survival is 
higher after unconditioned transplants, but the immune reconstitution is lower and 
further treatment is more often needed. In general, for X-SCID, unconditioned BMT is 
performed when there is a MSD or MFD available, otherwise patients will undergo 
conditioning (226, 227).  
As unmatched or haploidentical transplants are still associated with a high mortality 
rate, gene therapy (GT) has been developed in the past decades for patients who lack 
an optimal donor. SCID forms are ideal diseases for GT due to their monogenetic 
nature, the fact that BMT has been successful at curing the disease and that the 
genetic correction of the cells gives them a positive selective advantage over non-
corrected cells. GT has been successfully developed for X-SCID showing good 
engraftment and reconstitution of the immune system (228). However, in early GT trials 
5 patients developed T-cell leukaemia due to insertional mutagenesis (229). New 
clinical trials using self-inactivating vectors have shown promising results, however, it is 
too early to make a final statement about their safety (230). GT for X-SCID is 
performed without any conditioning and adds the significant advantage that autologous 
cells are utilised thereby removing the risk of graft-versus-host-disease (GVHD).  
There are three forms of SCID associated with the γ-chain pathway (X-SCID, JAK3 and 
IL-7Rα deficiency) as described. In addition, there are also other immunodeficiencies 
associated with this pathway which are even rarer. IL-2RA or CD25 deficiency in 
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humans is a primary immunodeficiency showing decreased numbers of peripheral T 
cells with abnormal proliferation but B cell development is normal. Absence of CD25 
interferes with thymocyte differentiation and apoptosis resulting in elevated numbers of 
auto-reactive cells (231). In a few cases, the disease manifests with chronic infections 
and severe autoimmunity and a similar phenotype as IPEX syndrome caused by 
mutations in FOXP3 (232). This shows that IL-2 is important for T cell development and 
immune regulation.   
In 2013, two kindreds with loss-of-function mutations in the IL-21R were identified with 
two affected individuals each. A lack of phosphorylation of STAT1, STAT3 and STAT5 
after IL-21 stimulation was observed in these patients. Impaired IL-21 signalling in 
these patients led to reduced class-switching and proliferation of B cells, defective 
cytotoxicity in NK cells and reduced cytokine secretion in T cells highlighting the role of 
IL-21 for immune cell development (233).  
Very recently, a family with a mutation in the IL-7 gene was identified. Patients 
presented with severe CD4+ T cell lymphopenia in their adult age. This is in contrast to 
IL-7Rα patients which present with SCID early on. It was hypothesized that the milder 
phenotype in IL-7 deficient patients results from substitution of some of the effects of 
IL-7 by thymic stromal lymphopoietin (TSLP). IL-7Rα is part of the receptor for TSLP 
which is the potential reason for the more severe phenotype of IL-7Rα deficiency 
compared to IL-7 deficiency in humans (234).  
Mutations of IL-4 or IL-4Rα, IL-9R or IL-9, IL-15Rα nor IL-15 have not been identified in 
human patients so far. 
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1.5 HPV infections in SCID patients  
 
BMT is a curative treatment for all forms of SCID and GT is available for some types of 
SCID. However, there is evidence that even after otherwise successful BMT and GT, a 
persistent selective immunodeficiency remains, which leads to a high susceptibility of 
patients to HPV infections. 
In a single-centre cohort at Hôpital Necker in Paris, 90 SCID patients were examined 
several years after BMT. Among them, 22 patients had mutations in γ-chain, 16 had 
mutations in JAK3 and the other patients had different mutations in other genes. In this 
cohort, 23 out of 90 patients presented with HPV infections. 9 of these patients had 
severe HPV infection with persistence of more than 30 lesions for more than 2 years. 
Of these nine severely infected patients, 3 were γ-chain- and 6 JAK3-deficient. The 
median disease onset was 7 years and ranged from 4 to 15 years after BMT. Fourteen 
patients in this cohort had mild HPV infections (less than 20 lesions over 2-year period) 
with 8 having γ-chain deficiency and 2 of them JAK3 mutations. The third group of 
patients that developed mild HPV infections had mutations in IL-7Rα indicating the 
potential importance of the γ-chain cytokine IL-7 in this pathology. The median onset of 
disease in this group was 10 years and ranged from 5 to 19 years. In this cohort 50% 
(11/22) of patients with mutations in γ-chain and 50% (8/16) of patients with JAK3-
deficiency and 33% (2/6) of patients with IL-7Rα mutations developed HPV infections 
of the skin compared to no HPV infections in other SCID types. The HPV types were 
mainly from the β1 (e.g. HPV5, HPV14 and HPV36) and α4 (e.g. HPV2 and HPV57) 
HPV classes even though members of other genera were also isolated. Multiple 
individuals were affected by more than one HPV type (235, 236).  
In another cohort study in London, 9 SCID patients developed severe HPV infections 
with 7 of those patients having mutations in γ-chain and 2 having JAK3 mutations. A 
total of 14 patients with either mutations in JAK3 or γ-chain were alive at the time of the 
study and therefore 64% (9/14) of patients with γ-chain or JAK3 mutations developed 
HPV infections (237). Again, patients with other forms of SCID did not present with 
severe HPV infections. In this cohort, HPVs also mainly from β1 (e.g. HPV5, HPV14, 
HPV21, HPV24 and HPV36) and α4 (HPV2, HPV27 and HPV57) families were isolated 
from lesions as well as members of the γ1 (HPV4) and μ2 (HPV63) classes (personal 
communication, C. Harwood). In addition, a female patient with JAK3 deficiency 
presented with severe cervical dysplasia associated with HPV16 and 18 in early 
adulthood (237). 
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In both studies, patients with other forms of SCID such as ADA and RAG1/2 
deficiencies did not develop HPV infections and therefore, there seems to be a distinct 
defect in γ-chain and JAK3 deficient patients that is not cured with BMT. Moreover, 
both studies could not demonstrate any significant differences in transplant specific or 
immunological parameters such as CD4+ T cell counts, NK cell counts or NK cell 
cytotoxicity in patients that presented with HPV infections and those without. The 
occurring HPV infections were difficult to treat and the usual therapy options such as 
the use of TLR agonists had hardly any effect. However, in a few cases the disease 
spontaneously regressed without any further treatment ((236, 237) and personal 
communication S. Burns).  
However, recently, a paper published by Kamili et al. argued that poor NK cell 
engraftment is the reason for the observed HPV susceptibility of X-SCID patients. They 
performed a retrospective study of 65 SCID patients treated between 1981 and 2012 in 
their centre. Six patients developed severe cutaneous HPV infections defined as 2 or 
more locations and resistant to more than 3 forms of treatment. Four patients with 
chronic HPV infections were followed up for more than 10 years and they had good 
engraftment with normal T cell function and three of them had normal B cell function. 
They all had X-SCID and did not receive conditioning prior to transplant and the mean 
disease onset was 7.4 year post-BMT. In these four patients the NK cell count 
remained low post-transplant and did not change significantly from pre-transplant 
numbers whereas HPV negative patients showed good NK cell restoration. When only 
X-SCID and JAK3 patients’ NK cell numbers were compared, there was a significant 
difference between HPV positive and negative patients. In addition, NK cell cytotoxicity 
was reduced in HPV patients.  
However, this study had a few limitations such as that there was no data was available 
for 5 patients of which 2 had evidence of HPV disease. Moreover, all SCID cases 
without HPV disease received myeloablative conditioning in contrast to the HPV 
positive cases indicating that the engraftment of immune cells including antigen-
presenting cells in the skin might have been different between the two groups. In 
addition, the mean follow-up in the HPV negative group was only 6.5 years post-BMT, 
a time point at which in the majority of patients no indication of HPV disease has been 
detected in other studies. This might also explain why their numbers of HPV positive 
cases was lower (19%) than in other studies (50% and 64%) (238). This study, 
however, shows again the link between mutations in γ-chain- and JAK3-deficiency and 
HPV infections of the skin.  
Further indication for a link between JAK3 and γ-chain mutations and HPV infections 
comes from individuals suffering from milder immunodeficiency forms. Members of a 
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family with a mutation in γ-chain that only led to decreased numbers and not absence 
of T cells, presented with bacterial infection of the respiratory tract, herpes simplex 
infections and chronic HPV infections located at the hands. In the oldest member of 
this kindred the chronic papillomatosis progressed to fatal squamous cell carcinoma 
(SCC) (239). In a family with a mutation in JAK3 associated with persistence of 
circulating T cells, one of the siblings presented with recurrent cutaneous warts at 
9 years of age that spontaneously regressed when she was 14 (240).  
Interestingly, this susceptibility to infections with papilloma viruses in γ-chain deficient 
individuals has also seen observed in other species.  
Canine X-SCID is a naturally occurring disease and it has been identified in Cardigan 
Welsh Corgis and Basset Hounds (241, 242). Its clinical and immunological 
phenotypes are virtually identical to the human disease and it arises due to naturally 
occurring mutations of γ-chain. At the University of Pennsylvania, Philadelphia, an X-
SCID dog colony was established which harbours a 4-bp deletion in exon 1 resulting in 
a frame shift with a premature stop codon. The colony was established using a single 
female carrier (243). X-SCID dogs present with a failure to thrive and a small, 
dysplastic thymus. Recurrent or chronic infections start from 8 weeks of age and the 
affected dogs do not usually survive past 3 to 4 months of age. New born dogs present 
with normal or elevated levels of B cells and significantly reduced or absent T cells 
which is identical to the presentation of the majority of human X-SCID patients (242, 
244, 245). X-SCID dogs have been used for BMT and GT studies and they achieve full 
immunologic reconstitution and engraftment of donor B and T cells without cytoablative 
therapy. Typically, the T cell compartment is exclusively of donor origin whereas the B 
cell compartment shows mixed chimerism after BMT studies (246).  
In a study using X-SCID dogs, 71% of dogs developed severe chronic cutaneous 
papilloma virus infections at 8 to 15 months post-BMT, whereas papillomas were not 
present in healthy male dogs or female carriers. All dogs that developed the disease 
showed a normally reconstituted immune function after transplant with normal levels of 
naïve T cells, normal IgG levels and a normal response to immunization. Moreover, the 
papillomas were unusual in their location on feet, especially affecting footpads. Canine 
papillomas usually spontaneously regress within 6 to 8 weeks but were persistent in 
the X-SCID dogs suggesting that the development of papillomas in SCID dogs is 
similar to the disease affecting SCID patients. In addition, studies have also shown that 
a high percentage (67%) of dogs with papillomas developed invasive SCC 3½ years 
after transplantation, with 75% of these dogs developing metastatic disease. A 3 ½ 
year dog is equivalent to a 30-year old human based upon aging studies (247).  
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As already indicated earlier in this chapter, not only JAK3- and γ-chain-deficiency are 
associated with severe cutaneous HPV infections, but also individuals with mutations in 
IL-7Rα present with HPV infection albeit with a milder form (235). In addition, patients 
of the kindred with the IL-7 mutation presented with verrucous skin lesions in their 
twenties due to infection with α2-type HPV3. One patient suffered from recurrent SCC 
since early adulthood on sun-exposed areas (234). This suggests that IL-7 signalling is 
important for the protection from HPV infections. However, as disease phenotypes for 
both IL-7 and IL-7Rα deficiency were milder than for patients with X-SCID or JAK3 
deficiency, another γ-chain cytokine is likely to play a role in the protection from HPV 
infections. 
Whether IL-21 signalling is important cannot be deduced from the study of the IL-21R-
deficient kindreds. For one family, patients were still young when they were identified 
and described (8 and 13 years) and unfortunately, all patients from the other kindred 
died due to infections or therapy-associated complications (233). 
All described studies indicate that the susceptibility for HPV infections may be linked to 
the common γ-chain pathway and to cells, which are not or only insufficiently replaced 
by BMT. In experiments using parabiotic mice, Merad et al. presented data showing 
that certain skin-resident immune cells such as LCs are not replaced by BMT (29). In 
parabiotic mice that shared a single blood circulation, complete mixing of granulocytes, 
T and B cells was observed after 10 days, whereas mixing of LCs was not observed 
even after 6 months. Similarly, dermal DCs (dDC) remained to > 80% of host origin. In 
lethally irradiated mice, that were transplanted with unfractioned bone marrow, >90 % 
of donor engraftment in the blood was achieved after 8 weeks, whereas less than 3 % 
of LCs in the skin were of donor origin but only 25% of dDCs remained of host origin 
(29, 248). This shows that whereas LCs are radio-resistant only a small subset of dDCs 
are radio-resistant and proliferative. Human LCs are able to survive conditioning 
therapy in significant numbers, e.g. in the lowest intensity non-myeloablative 
transplantation 100% of LCs and 75% of dDCs remain of host origin despite complete 
donor-derived leukocyte chimerism (249). In a double human hand allograft, results 
showed that 4.5 years after transplantation, the LCs in the allograft remained of donor 
origin (250), indicating as well that LCs self-renew in the skin under steady state 
conditions. 
These studies indicate that due to the conditioning protocol used for transplanting X-
SCID patients, it is very likely that myeloid cells such dDC and LCs are not replaced 
and γ-chain and JAK3 mutations in those cells could lead to the susceptibility to HPV 
infections.  
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In a γ-chain deficient mouse model, it has been shown by our group that the common 
γ-chain was required for effective antigen-induced CD4+ T cell activation by DCs (251, 
252). In this mouse model, the optimal CD4+ T cell activation by DCs was shown to be 
dependent on trans-presentation of IL-15, which requires the expression of the 
common γ-chain. Therefore, absence of the common γ-chain leads to functional 
defects in DCs. It is, however, unknown if these defects are responsible for the 
susceptibility to HPV infections. As proposed by Kamili et al., limited NK cell 
reconstitution might explain the disease seen in X-SCID and JAK3-deficient patients, 
however, this correlation has not been observed in other studies where there was no 
difference between HPV negative and positive patients in their NK cell levels.  
A different possibility is that the susceptibility is due to a defect in keratinocytes as they 
cannot be replaced by BMT or GT and HPV infections are limited to these cells. 
Moreover, keratinocytes have multiple immune functions which are altered by HPV in a 
normal infection making them a likely target for the increased susceptibility.  
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1.6 Hypothesis and Aim 
 
As keratinocytes are not replaced by BMT or GT and HPV infection is limited to these 
cells, we hypothesise that common γ-chain deficiency in keratinocytes could result in 
persistent HPV susceptibility in treated SCID patients due to influences on the anti-
HPV immunity by one or more of the following mechanisms: 
- The lack of the γ-chain could influence initial infectivity of keratinocytes with 
HPV particles leaving patients more permissive to HPV infections. 
- The γ-chain could have an impact on the interferon response of keratinocytes, 
which would lead to a decrease in the direct effects on the virus and dampen 
the first line of the immune response. 
- The absence of the γ-chain might lead to the virus having a greater influence on 
the keratinocyte differentiation programme leading to increased 
hyperproliferation or increased copy number in the patients’ cells.  
- The secretion of cytokines and chemokines from γ-chain deficient keratinocytes 
might be reduced decreasing the chemoattraction of professional immune cells. 
- The direct cell-cell interaction of keratinocytes with immune cells might be 
altered in γ-chain deficient cells similar to the effects seen in γ-chain deficient 
dendritic cells. 
We, therefore, aimed to analyse the expression of the common γ-chain and its co-
receptors in keratinocytes as well as signalling pathways via γ-chain in the skin. As X-
SCID skin samples are in short supply, we generated a common γ-chain knock-down 
cell line to analyse the effect of the common γ-chain on: 
- Keratinocyte infectivity of HPV virus-like particles  
- Secretion of cytokines and chemokines from keratinocytes after stimulation with 
γ-chain cytokines and the effect of these chemokines on immune cell migration 
- HPV life cycle in skin raft cultures  
From these experiments, we wished to determine whether keratinocyte defects result in 
increased HPV susceptibility or whether it is more likely that DCs and LCs play a role. 
This will be important for the design of future therapies for HPV in SCID patients and 
refinement of BMT/GT protocols. 
Moreover, we will generate information about the γ-chain signalling pathway in 
keratinocytes, which has not been – to our knowledge – studied before.  
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2. Materials and Methods 
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2.1 Materials 
2.1.1 General Supplies 
Chemicals were, if not stated otherwise, purchased from Fluka Analytical, Sigma-
Aldrich Corporation and VWR International.  
 
2.1.2 Buffers and solutions  
2.1.2.1 Commercial buffers 
 
Buffer Company + Catalogue 
Number 
Usage 
CEP hybridization 
buffer 
Abbott Molecular 
07J36-011 
Fluorescent in situ 
hybridisation 
Perm Buffer III BD Phosflow 
558050 
Intracellular staining for  flow 
cytometry (FC) 
Lyse/Fix buffer BD Phosflow 
558049 
Intracellular staining for  FC 
NuPAGE® MOPS 
SDS Running Buffer 
(20X) 
LifeTechnologies  
NP000102 
SDS-PAGE  
NuPAGE® Transfer 
Buffer (20X) 
LifeTechnologies 
NP00061 
Immunoblotting 
Table 2: Commercial buffers used 
 
2.1.2.2 Buffers prepared in house 
2.1.2.2.1 Protein analysis and immunoblot 
 
Blocking solution   5% (w/v) BSA in TBS-T 
 
Cell lysis buffer:   130 mM NaCl 
     20 mM Tris 
     1% (v/v) IGEPAL 
     1 mM EDTA 
     10 mM NaF 
Add fresh on the day of use: 1x Protease Inhibitor Cocktail (Roche)  
 
Coomassie stain   50% (v/v) methanol 
     10% (v/v) glacial acetic acid 
     0.25 g/l brilliant blue 
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Destain solution   50% (v/v) methanol 
     10% (v/v) glacial acetic acid 
 
5x SDS Page Loading Buffer  10% (w/v) SDS 
     30% (v/v) Glycerol 
     0.001 % (w/v) Bromphenol blue 
     In 0.5 M Tris/HCl, pH 0.5 
     Add 100 mM DTT fresh on the day of use  
 
TBS-T     150 mM NaCl 
     10 mM Tris/HCl, pH = 7.0 
     0.1% (v/v) Tween-20  
 
 
2.1.2.2.2 Fluorescent in situ hybridisation 
 
10 x NT buffer    0.5 M Tris-HCl pH 8.0 
     50 mM MgCl2 
     0.5 mg/ml BSA 
 
Denaturation solution   70% (v/v) formamide 
     10% (v/v) 20x SSC, pH 5.3 
 
FISH wash    4x SSC 
     0.05% (v/v) triton X-100 
 
FISH detection solution  1% (v/v) streptavidin-Cy3 (Sigma) 
     in STM solution 
 
Pre-hybridisation solution  2x SSC 
     0.5 % NP-40 
     Adjust pH to 7.0 
 
STM solution    5% (w/v) non-fat dried milk 
     0.05% (v/v) Tween-20  
     4x SSC 
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2.1.2.2.3 HIRT DNA preparation and Southern Blot 
 
HIRT DNA lysis buffer  1.25 M NaCl 
     10 mM EDTA pH 7.4 
     20 mM Tris HCl pH 7.4 
     0.75% (w/v) SDS 
     add Proteinase K to 100 μg/ml on the day of use 
 
HIRT DNA resuspension buffer  150 mM NaCl 
     10 mM EDTA pH 7.4 
     20 mM Tris HCl pH 7.4 
 
Depurination buffer   0.24 N HCl 
 
Denaturation buffer   0.5 N NaOH 
     1.5 M NaCl 
 
Neutralisation buffer   0.5 M Tris pH 7.4 
     1.5 M NaCl 
 
Church Hybridisation buffer  0.25 M Na2HPO4, pH 7.2 
     1 % (w/v) BSA 
     7 % (w/v) SDS 
     50 µM EDTA pH 8.0  
 
Church Wash buffer   1% (w/v) SDS 
     0.02 M Na2HPO4, pH 7.2 
     1 µM EDTA pH 8.0  
 
2.1.2.2.4 Others  
 
6x Agarose loading dye  0.25% (v/v) bromophenol blue 
0.25% (v/v) xylene cyanol 
50% (v/v) glycerol 
 
20x SSC     3 M NaCl 
     0.4 M monosodium citrate 
     adjust pH to 7.0 
62 
 
 
Alcoholic HCl     1 % HCl 
70 % ethanol  
 
HindIII ladder    20% (v/v) λ DNA-HindIII Digest 
1x Agarose loading dye 
in TE 
 
LB Medium    20 g LB Broth in 1 L water 
     Autoclave before use 
 
TAE solution    40 mM Tris 
     20 mM acetic acid 
     1 mM EDTA  
 
TE buffer    10 mM TrisCl 
     1 mM EDTA 
     adjust pH to 7.4 or 8.0 
 
Virus lysis buffer    0.5 % (w/v) SDS 
     25 mM EDTA 
     1 mg/ml Proteinase K  
63 
 
2.1.3 Antibodies 
2.1.3.1  Antibodies for flow cytometry (FC) 
2.1.3.1.1  Isotype controls  
Species + Isotype Clone Company + Catalogue 
Number 
Dilution Conjugation 
Mouse, IgG1, κ MOPC-21 BioLegend 
400111 
1 μl per test PE 
Mouse, IgG2a, κ MOPC-173 BioLegend 
400213 
2.5 μl per test PE 
Mouse, IgG2b, κ MPC-11 BioLegend 
400313 
2.5 μl per test PE 
Rat, IgG2b, κ RTK4530 BioLegend 
400612 
5 μl per test APC 
Table 3: Isotype controls for FC 
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2.1.3.1.2 Antibodies for specific immunogens  
Immunogen  Species + Isotype Clone Company + Catalogue Number Dilution Conjugation 
Human Stat5 (pY694) Mouse, IgG1, k  47 BD Pharmingen 
612599 
5 μl per test Alexa Fluor 647 
Human CD25 
(IL-2Rα) 
Mouse, IgG1, k BC96 BioLegend 
302605 
2.5 μl per test PE 
Human CD124 (IL-4Rα)  Mouse, IgG2a, k G077F6 BioLegend 
355003 
2.5 μl per test PE 
Human CD129 (IL-9R) Mouse, IgG2b, k AH9R7 BioLegend 
310403 
2.5 μl per test PE 
Human CD215 (IL-15Rα) Mouse, IgG2b, k JM7A4 BioLegend 
330207 
10 μl per test PE 
Human CD360 
(IL-21R) 
Mouse, IgG1, k 2G1-K12 BioLegend 
347805 
10 μl per test PE  
Human CD132 (γ-chain) Rat, IgG2b, k TUGh4 BioLegend 
338608 
5 μl per test APC  
Table 4: Antibodies for specific immunogens for FC 
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2.1.3.2 Antibodies for Western Blot 
2.1.3.2.1 Primary Antibodies  
Immunogen Species + Clonality  Company + Catalogue 
Number 
Dilution Size of protein (kDa) 
p-Akt (Ser473) rabbit, monoclonal Cell Signaling 
#4060 
1:2000 60 
Akt (pan) (C67E7) rabbit, monoclonal Cell Signaling 
#4691 
1:1000 60 
GAPDH (6C5) mouse, monoclonal Santa Cruz Biotechnology 
Sc-32233 
1:1000 37 
IL-2RB (C-20) rabbit, polyclonal Santa Cruz Biotechnology 
Sc-671 
1:200 70-75 
IL-7R (H-215) rabbit, polyclonal Santa Cruz Biotechnology 
Sc-25475 
1:200 76 
Table 5: Primary antibodies for Western Blot 
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2.1.3.2.2 Secondary Antibodies  
Antibody Company + Catalogue Number  Dilution 
Anti-mouse IgG, HRP-linked whole antibody 
(from sheep) 
GE Healthcare Life Sciences  
NA931  
1:3000  
Anti-rabbit IgG, HRP-linked whole antibody 
(from donkey) 
GE Healthcare Life Sciences 
NA934 
1:1000  
Table 6: Secondary antibodies for Western Blot 
 
 
2.1.3.3 Antibodies for Immunofluorescence  
2.1.3.3.1 Primary antibodies 
Immunogen Species + Clonality Company + Catalogue Number Dilution 
BrdU Mouse, monoclonal Calbiochem 
NA61 
1:100 
E4 Rabbit Provided by Dr. John Doorbar 
Department of Pathology 
University of Cambridge 
Tennis Court Road 
Cambridge, CB2 1QP  
1:100 
Keratin-10 Rabbit, polyclonal Covance 
PRB-159P 
1:1,000 
Keratin-14 Rabbit, polyclonal Covance 
PRB-155P 
1:1,000 
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Loricrin Rabbit, polyclonal Covance 
PRB-145P 
1:500 
MCM7 Mouse, monoclonal  NeoMarkers 
MS-862-P 
1:200 
Streptavidin, Cy3 
conjugated 
Mouse, monoclonal Sigma 
S6402-1ml 
1:100 
Table 7: Primary antibodies for Immunofluorescence 
 
2.1.3.3.2 Secondary antibodies 
Antibody Company + Catalogue 
Number 
Dilution Conjugation 
Anti-mouse IgG (H+L) 
from donkey 
Invitrogen 
A31571 
1:500 Alexa-647 
Anti-rabbit IgG (H+L) from 
donkey 
Invitrogen 
A21206 
1:500 Alexa-488 
Table 8: Secondary antibodies for Immunofluorescence 
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2.1.4 Enzymes 
Enzyme Company + Catalogue Number 
E.coli polymerase I New England Biolabs 
M0209S 
DNase I Roche  
04716728001 
HindIII New England Biolabs 
R0104S 
NcoI New England Biolabs 
R0193S 
PlasmidSafe (ExoV) Epicentre 
E3105K 
Proteinase K Roche 
03 115 879 001 
RNase A Roche 
10 109 142 001 
T4 ligase New England Biolabs 
M0202M 
T4 PNK  New England Biolabs 
M0201S 
XmnI New England Biolabs 
R0194S 
Table 9: Enzymes  
 
2.1.5 Cytokines 
 
Cytokine Company + Catalogue number 
Fractalkine (CX3CL1) PeproTech 
300-31 
GM-CSF PeproTech 
300-03 
Gro-α/CXCL1 PeproTech 
300-11 
IFN-β PeproTech 
300-02BC 
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IFN-γ PeproTech 
300-02 
IL-2 PeproTech 
200-02 
IL-4 PeproTech 
200-04 
IL-7 PeproTech 
200-07 
IL-8/CXCL8 PeproTech 
200-08 
IL-9 PeproTech 
200-09 
IL-15 PeproTech 
200-15 
IL-21 PeproTech 
200-21 
Mip-3α/CCL20 PeproTech 
300-29A 
Table 10: Cytokines 
 
2.1.6 Primers 
 
All primers were purchased from Life Technologies. 
Name Forward primer Reverse primer Product 
length 
E1^4 TGTGCATCCCAGCAGTAAG GGTGCTGGAATACGGTGA 116 
γ-chain ACAGGCCACACAGATGCTAA CTATGCTGGTTGCATGGGG
A 
645 
IL-2Rα I CATTTCGTGGTGGGGCAGAT CCGTGTCCTGTGATGTGAC
T 
557 
IL-2Rα II AATGCAAAGTCCAATGCAGC
C 
TGTATCCCTGGACGCACTG
A 
146 
IL-2Rβ TATGAGTTTCAGGTGCGGGT
C 
GAGCCACGGAATGGTGTCC 123 
IL-4R AATGGGGTGGCTTTGCTCTG GCTCATGTAGTCGGAGACG
C 
121 
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IL-7Rα CTCTGTCGCTCTGTTGGTCAT ATCTGGCAGTCCAGGAAAC
T 
171 
IL-9R ATGTGGTAGAGGAGGAGCGT CGACAGCTTGAACAGGAGG
T 
182 
IL-15Rα GTCTCTCCTGGCATGCTACC GCTGGTTTCCCCGAGTTTC
A 
159 
IL-21R CCCGGTCATCTTTCAGACCC TGCACCCACCCATTTCTTGA 226 
GAPDH CCCATCACCATCTTCCAGGA CCAGTGAGCTTCCCGTTCA
GC 
473 
Table 11: Primers 
 
2.1.7 Probes and Standards 
 
E1^4: Probe: [DFAM]AACAATGGCTGATCCAGAAGTACCAGTGACGACA[DTAM]  
 
E1^4 Standard: 
ccg tgg tgt gca tcc cag cag taa gca aca atg gct gat cca gaa gta cca gtg acg aca cgg tat 
ccg cta ctc agc ttg tta aac agc tac agc aca ccc cct cac cgt att cca gca ccg tgt ccg t  
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2.1.8 Tissue Culture 
All media and supplements were purchased from Gibco® (Life Technologies) if not 
stated otherwise.   
 
E-medium (keratinocyte growth medium) 
44.5% (v/v) DMEM/F-12, GlutaMAX™ (31331-028) 
 44.5% (v/v) DMEM, high glucose, pyruvate (41966-029) 
 10% (v/v) Fetal Calf Serum (FCS) 
 1% (v/v) Penicillin-Streptomycin (P/S; 10,000 U/mL; 15140-122) 
0.4 μg/ml hydrocortisone 
10-10 M choleratoxin 
1.8 x 10-4 M adenine 
5 μg/ml insulin  
10ng/ml EGF 
 
1:3 medium 
50% (v/v) DMEM/F-12, GlutaMAX™ (31331-028) 
 50% (v/v) DMEM, high glucose, pyruvate (41966-029) 
 
DMEM + FCS 
89% (v/v) DMEM, high glucose, GlutaMAX™ (61965-026) 
10% (v/v) FCS 
1% (v/) P/S 
 
RPMI 
89% (v/v) RPMI 1640 Medium, GlutaMAX™ (61870-010) 
10% (v/v) FCS 
1% (v/) P/S 
 
Optimem (31985-070) 
 
KSFM (10744-019) 
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Keratinocyte plating medium  
 48.75 % F-12 (21765-029) 
 48.75 % DMEM/F-12, GlutaMAX™ (31331-028) 
 0.5 % FCS  
 1 % P/S 
0.4 μg/ml hydrocortisone 
10-10 M choleratoxin 
1.8 x 10-4 M adenine 
5 μg/ml insulin  
10ng/ml EGF 
 
Cornification medium 
Keratinocyte plating medium 
Add FCS to 5% FCS  
10 μM C8:0 
 
EF-1-F medium 
 94 % F-12 (21765-029) 
 5 % FCS 
 1 % P/S 
 
293FT medium 
89 % DMEM (11965-092) 
10 % FCS 
1x sodium pyruvate (11360-070) 
1x MEM Non-Essential Amino Acids (11140-035) 
1 % P/S 
500 µg/ml G418 
 
10x DME salts 
53.7 mM KCl 
10 mM NaH2PO4 
2.5 uM Fe(NO3)3 * 9 H2O 
1.1 M NaCl 
0.25 M Dextrose 
0.4 mM g Phenol Red  
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Calcium-free DMEM 
 1x DME salts 
1x Glycine 
1x MEM Amino Acids Solution (11130-036) 
1x MEM Non-Essential Amino Acids (11140-035) 
1x MEM Vitamin Solution (11120-037) 
1.45 mM MgSO4  
4 mM sodium bicarbonate 
Adjust pH to 7.2 
1x glutamine 
 
Low Ca2+ medium 
 70.5% Calcium-free DMEM 
 23.5% F-12 medium 
 5% Chelex-treated FCS 
 1% P/S 
0.4 μg/ml hydrocortisone 
10-10 M choleratoxin 
1.8 x 10-4 M adenine 
5 μg/ml insulin  
10ng/ml EGF 
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Reagent Company + Catalogue Number 
μ-Slide Chemotaxis 3D 
Collagen IV coated  
Ibidi 
80322 
Accutase Solution Sigma-Aldrich 
A6964 
Blasticidin Gibco 
A11139-03  
BrdU Reagent Sigma-Aldrich 
B5002 
CD4+ T Cell Isolation Kit Miltenyi Biotec 
130-096-534 
CD8+ T Cell Isolation Kit Miltenyi Biotec 
130-096-496 
CD14 MicroBeads, human Miltenyi Biotec 
130-050-201 
CyQuant NF Cell Proliferation Assay Kit LifeTechnologies 
C35007 
CellTiter-Glo® Promega 
G7570 
Chelex-100 Resin Biorad 
142-2842 
C8:0 Santa Cruz 
Sc-202397A 
Collagen I 
Cell Matrix type I-P 
Wako Chemicals  
634-00663 
Deep Well Plate 
6-Well-Plate 
Corning 
355467 
Dunn Chamber 
 
Hawksley, Medical & Laboratory Equipment 
DCC100 
Fibrinogen  Sigma-Aldrich 
#F3506 
fMLP Sigma-Aldrich 
#F3879 
FuGENE® HD Promega 
E2311 
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Luciferase Assay System Promega 
E1500 
Mitomycin C Sigma-Aldrich 
M0503 
MS Columns  Miltenyi Biotec 
130-042-201 
Neutrophil Isolation Kit, MACSexpress Miltenyi Biotec 
130-604-434 
OptiPrep™ Density Gradient Medium Sigma-Aldrich 
D1556-250ML 
Polyethylenimine (PEI) Sigma-Aldrich 
872-7  
Puromycin  LifeTechnologies 
A1113803 
Transwell, 0.4 μm polyester membrane, 
24 mm insert, 6 well plate 
Costar 
3450  
Transwell, 5.0 μm polycarbonate 
membrane, 6.5mm insert, 24 well plate 
Costar  
3421 
Table 12: Tissue culture reagents  
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2.1.9 Cell lines 
 
All cell lines were routinely tested for mycoplasma contamination before they were 
used for experiments.  
 
2.1.9.1 HEK 293T/17 
HEK 293T/17 (ATCC®, catalogue: CRL-11268™) are a variant of the 293 cell line. The 
293 cell line was established from primary embryonal human kidney cells which were 
transformed using sheared human adenovirus type 5 DNA which leads to expression of 
adenoviral E1A in these cells. 293T is a derivate of the 293 cell line into which the gene 
for SV40 T-antigen was inserted (293tsA1609neo). These cells were cloned and the 
clones tested for their capability of producing high titres of infectious virus. This cell line 
was purchased from ATCC. 
 
2.1.9.2 293FT  
293FT cells (Invitrogen, catalogue: R700-07) are another variant of the 293 cell line. 
The 293-FT cell line was derived from the 293F cell line (Invitrogen) – a fast-growing 
variant of the 293 cell line – by stably transfecting it with SV40 large T antigen from the 
pCMVSPORT6Tag.neo plasmid. This cell line was used for the production of papilloma 
virus stocks and it expresses a neomycin resistance gene. It was purchased from 
Invitrogen. 
 
2.1.9.3 ED-7R 
ED-7R cells are a subline of a human T cell line derived from the peripheral blood of a 
patient with adult T cell leukaemia. They express IL-2Rα, IL-2Rβ but they lack the γ-
chain (253). For some experiments, a genetically modified ED-7R line (ED-7R + γc) 
was used which expresses the wild-type γ-chain (254).  
 
2.1.9.4 NIKS 
Normal Immortalised KeratinocyteS (NIKS) are a spontaneously immortalised 
keratinocyte cell line derived from neonatal human foreskin. It is negative for HPV16 
and HPV31 as well as HIV provirus sequences. The cell line is not tumorigenic in 
athymic nude mice. It is morphologically the same as normal human keratinocytes and 
it has keratinocyte cell-type specific growth requirements, e.g. dependence on EGF. 
They contain 47 chromosomes due to an extra copy of the long arm of chromosome 8. 
The cell line is able to form fully stratified squamous epithelium in organotypic cultures 
(255). This cell line was kindly provided by Dr. John Doorbar, Department of Pathology, 
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University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP at passage 
number 60. It was generally co-cultured with irradiated 3T3 cells. 
 
2.1.9.5 3T3 
3T3 are an immortalized fibroblast cell line that originated from Swiss albino mouse 
embryos and was established in 1962 by George Todaro and Howard Green. 3T3 cells 
were γ-irradiated or mitomycin C treated and used as a bed of feeder cells for culturing 
primary keratinocytes and NIKS (256).  
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2.1.10 shRNA vectors 
All vectors were obtained from UCL Openbiosystems. Vectors have a pGIPZ backbone 
which contains an ampicillin resistance cassette, a puromycin resistance cassette and 
a turbo-GFP marker.  
Name Oligo_ID Sequence 
Scrambled (scr) control V3LHS_314459 TGAACTCATTTTTCTGCTC 
shRNA1 V2LHS_77306 ATGTCTATAATCCACTGAT 
shRNA2 V3LHS_330322 TCAAGAATCTGTTGTTCCA 
shRNA3 V3LHS_330320 TCAGTAACAAGATCCTCTA 
shRNA4 V3LHS_330321 TGGGCGTCAGAATTGTCGT 
Table 13: shRNA vectors 
 
 
2.1.11 Others reagents  
Reagent Company + Catalogue Number 
λ DNA-HindIII Digest New England Biolabs 
N3012S 
1 Kb Plus DNA ladder LifeTechnologies 
10787-026 
Amersham Full-Range Rainbow Molecular 
Weight Marker 
GE Healthcare Life Science 
RPN800E 
Biotin-16-dUTP Roche 
110 93 070 910  
BD Vacutainer® K2E (EDTA) BD Biosciences  
367525 
BrdU Cell Proliferation Assay Kit Cell Signaling 
#6813 
Donkey serum Sigma Aldrich  
D9663-10ML 
EasyTides® Adenosine-5’-triphosphate [γ 
32P] 
Perkin Elmer 
BLU502Z250UC 
GeneAmp® RNA PCR Core Kit Life Technologies 
N808-0143 
Human Cot I DNA Gibco 
15279-011 
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Hybond™ N+ GE Healthcare 
RPN303B 
Immobilon-P Membrane, PVDF, 0.45 µm Millipore 
IPVH00010 
ODN 2216 (TLR9 ligand) Miltenyi Biotec  
130-100-243 
Protease Inhibitor Cocktail Roche  
1 697 498  
QIAGEN Plasmid Maxi Kit QIAGEN 
12163 
QIAPrep Spin Miniprep kit QIAGEN 
27106 
NuPAGE® Novex® 4-12% Bis-Tris Gels, 
1.0 mm, 10 well    
 
LifeTechnologies  
NP-0321BOX 
Proteome Prolifer™ 
Human Cytokine Array Panel A 
R&D Systems 
ARY005 
Salmon sperm DNA, sheared LifeTechnologies 
AM9680 
Sso Fast™ Probes 
Supermix with ROX 
Biorad 
100-19549  
SuperSignal® West Pico Chemiluminescent 
Substrate (ECL) 
Thermo Scientific Fisher 
#34087 
Taq DNA polymerase  Roche  
11 145 173 001 
TRIzol Reagent LifeTechnologies 
15596-018 
Table 14: Other reagents  
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2.2 Methods 
 
2.2.1 Cell and tissue culture 
2.2.1.1 Culturing of cells 
Primary keratinocytes as well as keratinocyte cell lines were cultured in E-medium. 
60 Gy irradiated or mitomycin C treated 3T3 cells were added as feeder. 293T, 3T3 
cells and primary skin fibroblasts were cultured in DMEM with 10% FCS. 293FT cells 
were cultured in DMEM with 10% FCS, 1x non-essential amino acids, 1x sodium 
pyruvate and 500 µg/ml G418. EF-1-F cells were cultured in F-12 medium with 
10% FCS. ED-7R cells with and without γ-chain were cultured in RPMI medium with 
10% FCS. All cells were kept at 37 °C in an incubator with 5% CO2. 
 
2.2.1.2 Passaging cells 
To split adherent cells when they reached confluence, they were detached from cell 
culture flasks/dishes and re-seeded. The culture media were removed and the cells 
were washed once with PBS without calcium and magnesium. 0.05% trypsin/EDTA 
solution was added and cells were incubated with trypsin at 37 °C with 5% CO2 until 
cells started to detach. Once the cells detached, culture medium was added and cells 
were washed from the plate and transferred to a Falcon tube and pelleted. The medium 
was removed and cells were resuspended in appropriated media. Cells were counted 
using a haemocytometer and seeded as required.  
 
2.2.1.3 Isolation of primary keratinocytes  
Patient skin biopsies were obtained with consent from procedures carried out at Great 
Ormond Street Hospital. Sterile skin biopsies were wrapped in the gauze soaked with 
saline and put in a container and transported from the theatre to the lab. In the hood, 
the biopsy was removed from the container and placed onto a 10 mm dish containing 
PBS. Excess dermis and connective tissue underneath the epidermis were removed 
using a sterile blade. The epidermis was cut into smaller pieces and transferred into a 
tube containing 0.25% trypsin-EDTA and incubated for 3 – 4 hours at 37 °C in a 10% 
CO2 incubator. During this time, the tube was shaken every 30 minutes. After the 
incubation, the contents in the tube were transferred into a tube with DMEM + 10% 
FCS. The mixture was filtered through a 100 µm cell strainer into a fresh tube. The 
resulting suspension was centrifuged for 10 minutes at 590 x G. The cells were 
resuspended in E-medium, 60 Gy irradiated 3T3 cells were added and they were 
cultured as previously described (2.2.1.1). 
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2.2.1.4 Lentiviral preparation  
293T cells were seeded the day before transfection to reach approximately 90% 
confluency on the day of transfection. For transfection, two mixes were prepared in two 
separate tubes. 1 µl of PEI (10 mM) per flask was added to 5 ml of Optimem. In 
another tube 17.5 µg pMD.g2 vector (PlasmidFactory), 32.5 µg p8.74 vector 
(PlasmidFactory) and 25 µg of the vector construct (2.1.10) were mixed with 5 ml 
Optimem. The two mixes were filtered separately through 0.22 µm filters. They were 
mixed at equal volumes and incubated at room temperature for 20 minutes. 
The 293T cells were washed once with Optimem, the medium was removed and 9 ml 
of the transfection mix was pipetted into each flask. Flasks were topped up with 2 ml of 
Optimem to ensure full coverage of the bottom of the flask. 5 hours later the 
transfection mix was removed and replaced with 17 ml of DMEM + FCS. 
24 hours after transfection the medium was replaced with 17 ml of fresh DMEM + FCS.  
A further 24 hours later the medium was collected and replaced with fresh DMEM + 
FCS. The virus containing medium was centrifuged for 5 minutes at 2360 x g and 
filtered through 0.22 µm filters. Subsequently, the supernatant was aliquoted into 
centrifuge tube and left to spin for 2 hours at 4 °C at 50,000 x g. The supernatant was 
then removed and 100 µl of Optimem was added to the virus pellet and left on ice for 
30 minutes. The pellet was then resuspended in the Optimem and the concentrated 
virus was aliquoted at 20 µl each. The procedure was repeated the next day. 
 
2.2.1.5 Titration of lentiviral particles by FC 
293T cells were seeded at 1 * 105 cells/well on a 24-well plate. 24 hours after seeding, 
the concentrated virus was serial diluted five-fold in DMEM + FCS and the different 
virus concentrations were added to the cells. 5 hours after transduction the virus-
containing medium was replaced with fresh DMEM + FCS.   
72 hours after transduction the 293T cells were detached from the plate by trypsinising 
them. They were washed with PBS and then analysed by FC. The sample where the 
amount of GFP positive cells was between 1 – 5% was used to calculate the titre. 
 
2.2.1.6 Lentiviral transduction of the NIKS cell line 
NIKS cells were seeded at a concentration of 1 * 105 cells per well on a 12 well plate. 
The following day, virus was added with defined number of virus particles in 300 µl of 
E-medium. 6 hours later, the media containing virus was removed and replaced with 1 
ml of fresh medium. 72 hours post transduction, the cells were trypsinised and seeded 
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into a T25 flask and grown to confluency before they were FACS sorted according to 
GFP intensity to enrich transduced cells. If the vector contained a puromycin resistance 
gene, cells were selected as in 2.2.1.7.  
 
2.2.1.7 Puromycin selection of NIKS cells 
To assess the correct puromycin concentration, untransduced (UT) NIKS were seeded 
on 12 well plate and different concentrations of puromycin were added to the wells. The 
cells were assessed every other day to check for cell death. The concentration was 
chosen as the one where all cells were dead after 4 days which was equivalent to 2 
µg/ml puromycin. 
If the vector contained a puromycin resistance gene, the cells were selected 72 hours 
after transduction using puromycin at the determined concentration of 2 µg/ml. The 
medium was changed every 3 days and cells were selected for a week. Then the 
media containing puromycin was removed and the cells were grown normally in E- 
medium.  
 
2.2.1.8 Proliferation Assay using BrdU incorporation and FC 
Cells were incubated for 1 hour with 20 μM BrdU at 37 °C. Then they were detached 
from the plate and pelleted at 250 x g for 5 minutes. Cells were resuspended in 1 ml of 
ice-cold 90% ethanol and incubated in the fridge overnight. Cells were washed in PBS 
and pelleted at 300 x g for 5 minutes. To release the nuclei and remove the RNA, cells 
were treated with 2N HCl containing 0.5% triton x-100 for 30 minutes and 0.1 M sodium 
tetraborate was added to neutralise the acid. Cells were pelleted at 600 x g for 10 
minutes and washed twice with PBS with 0.5% Tween-20 and 1% BSA (PBS-TB). 
Tween-20 prevents the nuclei and BSA prevents the DNA from clumping. To remove 
RNA, the released nuclei were resuspended in 1 ml RNase A (10 μg/ml) in PBS-TB 
and incubated for 30 minutes at 37 °C. They were pelleted at 600 x g for 5 minutes and 
washed with PBS-TB once. To stain the nuclei, they were resuspended in 100 μl of a 
1:50 dilution of the anti-BrdU antibody and either incubated for 90 minutes at room 
temperature or overnight at 4 °C. They were washed with PBS-TB and resuspended in 
1:250 dilution of anti-mouse-Alexa-488 antibody and incubated in the dark at room 
temperature for 30 – 45 minutes. They were washed again in PBS-TB and 
resuspended in PBS. They were filtered through mesh prior to analysing them by FC.  
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2.2.1.9 Proliferation Assay using BrdU incorporation and a platereader 
NIKS cells were seeded at 10,000 cells per well on a 96-well plate. They were left 
overnight to adhere, the following day they were starved in 1:3 medium for 6 hours 
before 100 ng/ml IL-7 and IL-15, respectively, were added as well as 10 μM BrdU. 16 
hours later they were analysed with the BrdU Cell Proliferation Kit 
The cell proliferation kit was used according to the manufacturer’s instructions. In brief, 
the medium was removed and cells were fixed for 30 minutes at room temperature 
using the provided Fixing/Denaturing Solution. The solution was removed and 1x 
Detection Antibody as added and the plate was kept for 1 hour at room temperature. It 
was washed three times with washing buffer before 1x HRP-conjugated secondary 
antibody was added. After a 30 minute incubation at room temperature, the antibody 
was removed and the wells were washed three times with washing buffer. The TMB 
Substrate was added and the plate was incubated for 20 – 30 minutes at room 
temperature while the colour change was observed. To stop the reaction STOP 
Solution was added. Colour change was analysed with a plate reader. The absorbance 
was read at 450 nm. Differences in proliferation were calculated as differences in 
absorbance. 
 
2.2.1.10 Production of HPV Virus-Like-Particles (VLP) 
293FT cells were seeded on 10cm dishes at a density of 5.6 * 106 cells per plate in 
DMEM with 10% FCS without antibiotics the day before transfection. Per plate, 15 µg 
pShell and 15 µg of expression plasmid, e.g. pLuc or recircularised HPV18 plasmid 
(see 2.2.3.7), were mixed in 750 µl Optimem. In a second tube, 750 µl Optimem was 
mixed with 65 µl Lipofectamine. Both tubes were incubated at room temperature for 
5 minutes, then they were mixed and incubated a further 30 minutes at room 
temperature. The medium was removed from the 293FT cells and replaced with 1.5 ml 
of transfection mix per plate. The cells were incubated for 5 hours at 37 °C and then 
5 ml fresh 293FT medium was added. 48 hours after transfection, cells from 6 plates 
were harvested and pooled together, washed with DBPS with 9.5 mM MgCl2 and 
transferred to siliconised tubes. For the maturation, the cells were pelleted, the size of 
the cell pellet estimated and supplemented with 1.5 times the volume of DPBS with 
9.5 mM MgCl2, 1/25
th of the volume of 10% Brij-58, 1/40th of the volume of 1 M 
ammonium sulfate pH 9.1 and 5 units of RNase A. The mix was incubated at 37 °C for 
24 hours under rolling conditions. The following day, the matured cell lysate was cooled 
to 4 °C for at least 10 minutes and the cells pelleted by centrifugation at 8.000 x g at 
4 °C for 10 minutes. The supernatant was added to a three-step Optiprep gradient, 
which was prepared 2 – 4 hours prior and it was centrifuged for 3.5 hours at 
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235,000 x g at 16 °C. The tube was punctured using a 23G needle and different 
fractions were collected whereby the first fraction was made up of approximately 600 µl 
and fractions 2 – 16 of 200 µl, the remaining volume was discarded. The virus particles 
were stored at -80 °C.  
To analyse in which fractions contained the virus particles, 10 µl of each virus fraction 
were mixed with 2 µl 6x SDS loading dye, boiled for 5 minutes and then separated on 
an SDS PAGE. The gel was stained with Coomassie stain overnight and de-stained for 
several hours the following day until bands became visible. The fractions containing a 
band of 55 kD (corresponding to the size of L1) were further analysed by Southern blot. 
For the blot, 10 µl of virus lysis buffer were mixed with 10 µl of virus fractions and 
incubated at 56 °C for 30 minutes. 1 µl of loading dye was added and the lysate was 
added to a 0.6 % agarose gel together with weight standards and separated by 
electrophoresis, the gel was stained with SYBR green and used for a Southern blot 
analysis (2.2.3.9) to estimate viral concentration.   
 
2.2.1.11 Infectivity assay 
Cells were seeded at a density of 10,000 cells per well on two 96 well plates. The 
following day they were infected with HPV pseudovirions at an virus concentration of 1 
and 10 viral genome equivalents (vge) per cell in quadruplets. Four wells of each cell 
type were left uninfected as control. 48 hours after infection, one plate was used for the 
Luciferase Assay (E1500, Promega) and the other plate was used for the viability 
assay using CellTiter-Glo® (G7570, Promega). Both assays were carried out following 
the manufacturer’s instructions. In brief, for the luciferase assay the medium was 
removed, the cells were washed with PBS and then lysed in 20 μl of 1x lysis reagent 
per well. They were briefly frozen at  -80 °C to ensure cell lysis and then read using the 
Microlumat Plus (Perkin Elmer instruments) which injected 100 µl of Luciferase Assay 
Reagent per well. Luminescence was read for 3 s per well. For the cell viability assay, 
a volume of CellTiter-Glo® reagent equal to the volume of cell culture medium present 
was added to each well and the sample was incubated for 10 minutes at room 
temperature. Luminescence was measured for 1 s. 
For the infectivity assay with cytokine stimulation, cells were seeded at a density of 
10,000 cells per well in E-medium. The following day, the medium was changed to 
Optimem and the cells were incubated for 6 hours at 37 °C. The medium was changed 
to Optimem containing the indicated amounts of cytokines. Cells were infected 
24 hours after addition of the cytokines by adding virus containing medium to the 
cytokine containing medium. The luminescence was read 48 hours after adding the 
virus.  
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2.2.1.12 Transfection of NIKS with HPV18wt vector 
NIKS were seeded at 5 * 105 on 6-well plates the day before transfection. On the day of 
transfection, the medium was changed to low Ca2+ medium and the cells were 
incubated for 4 hours. For transfection, pcDNA1 (which contains a blasticidin 
resistance cassette) and HPV18wt plasmid were mixed at a weight ratio of 1.2 to 3 in a 
total volume of 155 µl Optimem. 10 µl of Fugene HD® reagent were added and mixed 
by pipetting. The mix was incubated for 10 minutes at room temperature. The medium 
was removed from the cells and replaced with 3 ml of fresh low Ca2+ medium. 150 µl of 
transfection mix were added to each well and incubated overnight. The following day, 
the cells were transferred to 10 cm dish feeder plates. 48 hours after transfection, 
selection with Blasticidin was started at a concentration of 7 µg/ml. Selection was 
carried out for 96 hours before cells were grown in normal E-medium. Mitomycin C 
treated 3T3 cells were added to the cells when needed.  
 
2.2.1.13 Making organotypic rafts 
In order to make organotypic rafts, first a collagen raft was made using transwell inserts 
with a 0.4 μm polyester membrane placed into deep well plates. A collagen premix to 
make six rafts was prepared by mixing 2.5 ml 10X F-12 media, 6 µl 10 N NaOH, 250 µl 
P/S, 2.5 ml FCS and 20 ml collagen I solution. Everything was mixed carefully to avoid 
bubbles and centrifuged for 5 minutes at 4 °C. 1 ml of collagen premix was added to 
each transwell insert and incubated for 5 – 10 minutes at 37 °C. 600 µl of a 7.5 * 105 
cell/ml EF-1-F fibroblast solution was added to the remaining collagen mixture and 
mixed carefully. 2.5 ml of the collagen-cell-suspension was added to the transwells and 
incubated until gelled (approx. 30 – 60 minutes) in an incubator at 37 °C. 20 ml of EF-
1-F medium was added to the outer well and the collagen rafts were incubated at 5% 
CO2 and 37 °C for 6 days. After the gels had contracted to the appropriate shape, 
150 µl of a 1.4 * 106 cells/ml solution of NIKS in keratinocyte plating medium was 
layered onto the collagen raft. The rafts were incubated for 2 hours at 37 °C to allow 
the cells to attach, then 20 ml of keratinocyte plating medium were added to the outer 
well. After two days, the medium was removed from the outer and inner well and 
replaced by fresh keratinocyte plating medium. On day 4 after plating the keratinocytes, 
the medium was removed and the transwell inserts were lifted onto three cotton pads. 
Cornification medium was added to the outer well so that the inner well was left dry and 
the cotton pads were soaked in medium. The rafts were fed every other day with 
cornification medium. At day 15 after plating the keratinocytes, the medium was 
supplemented with 10 µM BrdU and the rafts incubated for 8 hours. They were 
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harvested and embedded in 2% agar/1% formalin and incubated overnight at 4 °C. The 
agar blocks were transferred into 10 % buffered formalin overnight at 4 °C, followed by 
an incubation at 4 °C overnight in 70% ethanol. After fixation they were embedded in 
paraffin by the Histology department, cut and stained appropriately (see section 2.2.4).    
 
2.2.1.14 Isolating peripheral blood mononuclear cells (PBMCs) from whole 
blood  
CD4+ and CD8+ T cells and CD14+ cells were isolated from PBMCs purified from 
whole blood. Blood was obtained from healthy volunteers with consent and collected 
into a BD Vacutainer® tube which contained EDTA to stop coagulation. The blood was 
diluted with 1 part of medium. To separate the PBMCs, the same amount of Ficoll as 
blood obtained was pipetted into a tube and the diluted blood was slowly layered on 
top. The tube was centrifuged for 25 minutes, 400 x g using no brake at the centrifuge. 
The middle white layer of PBMCs was removed carefully and the remaining liquid was 
discarded. The suspension containing the PBMCs was washed with medium and the 
cells pelleted at 300 x g for 7 minutes and used for further isolations.  
 
2.2.1.15 Isolation of CD14+ cells and differentiation to DCs 
CD14+ cells were isolated from PBMCs using CD14+ MicroBeads and following the 
manufacturer’s instructions. In brief, cells were resuspened in cold MACS buffer, 
CD14+ selection beads were added and the mix incubated in the fridge for 15 minutes. 
MACS buffer was added, the cells were washed, centrifuged at 300 x g for 5 minutes 
and then resuspended in 500 μl of MACS buffer. In the meantime, an MS MACS 
column placed in an MACS magnet was calibrated using 3 ml of MACS buffer. The cell 
suspension was added and the flow through discarded. The column was washed three 
times and the flow through discarded. The column was then removed from the magnet 
and placed above a fresh 15 ml tube, 1 ml of MACS buffer was added and the plunger 
was rapidly pushed down to harvest the positive cells and counted. 
To induce dendritic cells, 1 * 106 cells were seeded per well of a 6 well plate. They 
were grown in RPMI supplemented with 100 ng/ml GM-CSF and 25 ng/ml IL-4. Fresh 
medium was added on Day 3 after harvest. They were used for experiments on Day 6.  
 
2.2.1.16 Isolation of CD4+ and CD8+ T cells 
CD4+ and CD8+ T cells were isolated from PBMCs using the CD4+ or CD8+ T cell 
isolation kit, respectively, and following the manufacturer’s instructions. In brief, cells 
were resuspened in cold MACS buffer, CD4+/CD8+ T Cell Biotin-Antibody Cocktail was 
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added and the mix incubated in the fridge for 5 minutes. Additional MACS buffer and 
CD4+/CD8+ T Cell MicroBead Cocktail were added and the mix incubated in the fridge 
for 10 minutes. An additional 500 μl of MACS buffer were added and the mix used for 
magnetic separation. The cell suspension was added to a calibrated MS column and 
the flow through collected as this represented the enriched CD4+/CD8+ cells. The 
column was washed once using 500 μl MACS buffer and this flow through collected as 
well. The cells were then used for experiments. 
 
2.2.1.17 Isolation of neutrophils 
Neutrophils were isolated for migration assays from 4 ml blood collected into an EDTA 
tube. They were then isolated using the MacsXpress Separator kit following the 
manufacturer’s instructions. In brief, to 4 ml of EDTA blood 2 ml of MACS bead cocktail 
were added and incubated at room temperature for 5 minutes using a MACSmix Tube 
rotator. The tube was then placed into a MACSxpress Separator for 15 minutes. 
Leaving the tube inside the separator, the supernatant was removed and washed by 
adding fresh RPMI medium and spinning them down at 300 x g for 7 minutes. The cells 
were then resuspended in RPMI, counted and used for further experiments.   
 
2.2.1.18 Migration experiments using neutrophils 
For migration experiments with neutrophils, Dunn Chambers (Hawksley, Medical & 
Laboratory Equipment) were used. Coverslips were coated with fibrinogen at 25 mg/ml 
and incubated for 1 hour at 37 °C. The fibrinogen was removed and 1 * 105 neutrophils 
were seeded onto each coverslip and incubated for further 1 hour at 37 °C to allow for 
adherence of neutrophils. The outer ring of the Dunn chamber was filled with 100 μl of 
chemoattractant solution prepared in a 1% solution of low melting agarose. The inner 
ring was filled with 50 μl of chemoattractant-free solution. Coverslips were carefully 
placed on top of the Dunn chambers with the cell-side facing down. The edges of the 
coverslip were sealed using hot wax. The chambers were imaged using the Zeiss 
Axiovert 135 time-lapse microscope for 1 hour at 37 °C taking images every minute. 
fMLP was used at 100 nM as positive control. Analysis was carried out using Icy (257). 
 
2.2.1.19 Migration experiments using DCs 
Migration experiments with dendritic cells were carried out using the μ-Slide 
Chemotaxis 3D (Ibidi) according to the manufacturer’s instructions. In brief, 6 μl of a 
3 * 106 cells/ml cell suspension was seeded per slide and the cells left to adhere for 4-5 
hours. Then, 65 μl of chemoattractant-free medium was filled into one side first and 
sealed. Into the other side, first 65 μl of chemoattractant-free medium was filled and 
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then 2 * 15 μl of a 2x chemoattractant solution. All ports were sealed and the slide 
imaged overnight using the time-lapse microscope at 37 °C taking pictures every 
5 minutes. Migration was analysed using the Manual Tracking plugin from ImageJ.   
 
2.2.1.20 Migration experiments using CD4+ and CD8+ T cells 
Isolated CD4+ and CD8+ T cells were used for transwell migration experiments using 
transwells with a 5.0 μm polycarbonate membrane. The chemoattract solution was 
filled into the bottom of the wells and 100 μl of a 1 – 2 * 106 cells/ml suspension was 
plated on top of the insert membrane. The plate was incubated at 37 °C for 2 hours. 
The inserts were removed and placed into a separate plated filled with PBS to wash 
their bottoms and then transferred into a trypsin filled plate. The plate was incubated to 
detach cells that were attached to the bottom of the insert. The chemoattractant 
solution which contained migrated cells was pooled with the trypsin solution which 
contained cells detached from the membrane. Cells were centrifuged at 300 x g for 
5 minutes and the supernantant removed. The cell number was determined using the 
CyQUANT® NF cell proliferation assay kit following the manufacturer’s instructions. In 
brief, cell pellets were resuspended in 50 μl of 1 x HBSS buffer and transferred to a 
black-bottom 96-well plate. Then, 50 μl of 2x dye binding solution was added to each 
well and the plate was incubated at 37 °C for 1 hour before fluorescence was read 
using 490 nm as excitation wave length and 540 nm at emission detection. Fold-
migration was calculated using relative fluorescence levels.    
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2.2.2 Protein Biology  
 
2.2.2.1 Cell lysis and sample preparation for Immunoblotting 
Depending on the experiment, cells were either pelleted after harvesting them from 
their plate using trypsin or scraped off the plate in lysis buffer using cell scrapers. For 
cell pellets, approximately 100 µl lysis buffer per 1 * 106 cells were used to lyse the 
cells. For cells in plates, 100 µl per well of a 12 well plate and 200 µl per well of a 6 well 
plate were used. Cells were resuspended in cold lysis buffer and incubated on ice for 
10 minutes. They were then centrifuged at 14,000 x g for 10 minutes at 4 °C. The 
supernatant was transferred into a new tube and the pellet was discarded. The 
appropriate volume of 5x SDS Page Loading Buffer was added to the supernatant and 
the sample was boiled for 5 minutes at 95 °C and was used for electrophoresis or 
stored at -20 °C for future use. 
 
2.2.2.2 SDS-PAGE and Immunoblotting 
SDS-PAGE gels were purchased at a Bis-Tris concentration of 4-12% from 
LifeTechnologies. Samples were loaded onto the gel and separated for 45 minutes at 
200 V. The gel cast was removed and a blot sandwich consisting of two blot papers 
soaked in transfer buffer, a PVDF membrane, the gel and another two blot papers 
soaked in transfer buffer was prepared. A wet transfer was carried out for 75 minutes at 
25 V. The membrane was then incubated in 5% BSA in TBS-T for 60 minutes and then 
the appropriate antibody (see 2.1.3.2.1) was added and the blot was incubated 
overnight at 4 °C. The following day the blot was washed three times for five minutes 
with TBS-T and then the secondary antibody (see 2.1.3.2.2) was added and incubated 
for 1 hour. Afterwards the blot was again washed three times for five minutes in TBS-T 
and then developed using ECL solution. For loading control antibodies such GAPDH, 
the incubation with the primary antibody was reduced to 2 – 3 hours at room 
temperature.  
 
2.2.2.3 Surface Staining for FC 
If cell surface markers were stained, cells were detached from the flask by using trypsin 
or accutase. When trypsin was used, it was neutralised using DMEM + FCS. PBS was 
used to dilute the accutase. The cells were pelleted at 250 x g for 5 minutes and 
resuspended in PBS. They were pelleted again and resuspended in 100 µl PBS per 
sample and the appropriate amount of antibody (see 2.1.3.1.1 for isotype controls and 
2.1.3.1.2 for specific immunogens) was added. The samples were incubated on ice, in 
the dark for 45 to 60 minutes. Afterwards, they were washed once in PBS and 
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resuspended in 150 µl of PBS to run on the FC. All FC data was analysed using 
FlowJo.  
 
2.2.2.4 Intracellular Staining for FC  
If samples were analysed for the expression of intracellular markers, cells needed to be 
permeabilised before staining with antibodies. Cells were detached and washed as 
described as before (2.2.2.3). After washing the PBS supernatant was discarded and 
the cells were resuspended in 2 ml warm 1x Lyse-Fix buffer and incubated at 37 °C for 
10 minutes. The tube was topped up with 3 ml of PBS and the cells were pelleted by 
centrifugation for 5 minutes at 250 g. Afterwards, 1 ml of ice-cold Perm Buffer III was 
added and the cells were incubated on ice for 30 minutes. The cells were then washed 
in 3 ml PBS and pelleted again, the supernatant was discarded and the cells were 
resuspended in the remainder of the liquid. Just as staining for surface molecules, 
antibodies were added and cells were incubated for 45 to 60 minutes on ice, then 
washed again and resuspended in PBS and analysed by FC.  
 
2.2.2.5 Analysis of JAK/STAT signalling by FC  
To test STAT5 phosphorylation NIKS cells were seeded onto 6 plates and were grown 
until they were approximately 80% confluent. They were then starved overnight in 1:3 
medium without any supplements. The following day the cells were used for the 
pSTAT5-assay. In order to detach the cells, they were washed once with PBS and then 
1 ml of accutase solution was added per well. The cells were incubated at 37 °C until 
they detached. 1 ml of PBS was added and the cells were pelleted at 250 x g for 
5 minutes. They were then resuspended in 100 µl of 1:3 medium and transferred to FC 
tubes. The interleukins were added to these tubes and the cells were incubated for 
10 minutes at 37 °C. Directly to these tubes 2 ml of 1x Lyse-Fix buffer was added. The 
cells were then prepared as described in 2.2.2.4 intracellular staining for FC.  
 
2.2.2.6 Sample preparation for analysis of pAKT by immunoblotting 
Cells were seeded onto 12 well plates and grown in the incubator until they were 80% 
confluent. They were then starved overnight in 1:3 medium. The following day, the cells 
were washed once in PBS and then 300 µl of 1:3 medium supplemented with different 
concentrations of the appropriate interleukin were added. One well was left 
unstimulated. The cells were incubated for 10 minutes at 37 °C. The medium was 
removed and the cells were washed once with 500 µl ice cold PBS, the PBS was 
removed and 100 µl of ice-cold lysis buffer was added. The cells were scraped off the 
plate using cell scrapers. The samples were incubated for 15 minutes on ice and then 
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they were centrifuged 2 min at 14,000 x g to pellet cell debris. The supernatants were 
transferred to a new tube and stored at – 20 °C until they were used for immunoblot 
analysis (2.2.2.2).  
 
2.2.2.7 Cytokine Array  
The supernatants were collected from cells after 24 hours under the appropriate culture 
conditions and used for the Proteome Prolifer™ Assay. The assay was carried out 
according to the manufacturers’ instructions. In brief, the membranes from the kit were 
incubated for 1 hour at room temperature in Array Buffer 4 on a rocking shaker. The 
800 μl of the supernatant were added to 200 μl Array Buffer 5 and 500 μl Array Buffer 
4. 15 μl of Detection Antibody Cocktail was added to the prepared samples. They were 
mixed and incubated at room temperature for 1 hour. Array Buffer 4 was removed from 
the membranes and the samples were added and incubated overnight at 4 °C on a 
rocking shaker. The following day, the membranes were washed three times with 1x 
wash buffer before the 1x Streptavidin-HRP antibody added. The membranes were 
incubated 30 minutes at room temperature on a rocking shaker. They were washed 
again three times with 1x wash buffer and then developed with Chemi Reagent Mix 
using autoradiography film in a dark room.  
 
2.2.2.8 Luminex assay  
Cells were seeded at 3 * 105 on 6-well plates and grown to confluency. They were 
grown under the appropriate culture conditions. The supernatants were collected after 
24 hours in culture, centrifuged to remove cell debris and stored at -20 °C until they 
were used. The Luminex assay was carried out according to the manufacturer’s 
protocol. In brief, supernatants and standards were mixed with the microparticles and 
incubated for 2 hours in the dark under shaking. The plate was washed and the biotin 
antibody cocktail was added and the mix incubated for 1 hour in the dark under 
shaking. The plate was washed again and then streptavidin-PE was added and 
incubated for 30 minutes. The plate was washed again and the beads were 
resuspended in wash buffer and it was read with a Luminex 100 analyser. Values were 
calculated using the standard curve.  
 
 
  
92 
 
2.2.3 Molecular Biology  
 
2.2.3.1 Isolation of RNA 
Isolation of RNA was carried out using TRIzol reagent following the provided protocol. 
In brief, cells were trypsinised and pelleted. 1 ml TRIzol reagent was added per 1 * 106 
cells and the pellet was homogenised by pipetting up and down multiple times. 
Afterwards, the sample was incubated for 5 minutes at room temperature and then 
0.2 ml chloroform were added and the tube was shaken for 15 seconds and then 
further incubated for 2 minutes at room temperature. The sample was centrifuged at 
12,000 x g for 15 minutes at 4 °C. It then separated into three layers. The top layer was 
transferred to a new tube and 0.5 ml of 100% isopropanol were added and incubated 
for 10 minutes at room temperature before the sample was centrifuged at 12,000 x g 
for 10 minutes at 4 °C. The supernatant was removed and the pellet was washed with 
1 ml of 75% ethanol. The tube was centrifuged at 7,500 x g for 5 minutes at 4 °C. The 
supernatant was discarded, the pellet was air dried and then resuspended in water.  
 
2.2.3.2 Reverse transcription 
Reverse transcription of RNA samples was carried out using the GeneAmp® RNA PCR 
Core Kit following the provided protocol. In brief, the provided chemicals were mixed to 
the following final concentrations: 5 mM MgCl2, 1x PCR buffer, 1 mM of dGTP, dATP, 
dCTP and dTTP each, 1 U/µl RNA inhibitor, 2.5 U/µl MuLV reverse transcriptase, 
2.5 mM random hexamer primers and 1 µg isolated RNA in 20 µl total volume. 
Everything was mixed and incubated for 10 minutes at room temperature. Afterwards, 
the tubes were placed in a thermocycler and run for one cycle at 42 °C for 45 minutes, 
99 °C for 5 minutes and 5 °C for 5 minutes. Once the run was completed, samples 
were either stored at -20 °C or used for PCR. 
 
2.2.3.3 Polymerase chain reaction (PCR) 
To amplify the reverse transcribed cDNA PCR was carried out using Taq polymerase 
and PCR buffer from Roche. Reagents were mixed in 22.5 µl total volume to the 
following final concentrations: 1X PCR buffer, 100 µM dNTPs, 0.15 µM forward primer, 
0.15 μM reverse primer and 0.625 U Taq DNA polymerase. To this mix 2.5 µl of the 
prepared cDNA were added. Tubes were placed in the thermocycler and amplified 
using the following protocol: 94 °C for 2 min, then 30 cycles of 94 °C for 30 s, 55 °C for 
30 s, 72 °C for 30 s, followed by a final annealing step of 72 °C for 10 minutes.  
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2.2.3.4 Quantitative PCR (qPCR) 
RNA Samples that were to be used for qPCR where isolated and 1 μg of total RNA was 
reverse transcribed as previously described. Primers were used at a final concentration 
of 1 µM and the probe at 500 nM. The standards were prepared to contain 1 * 108 to 
1 * 101 copies of the product of interest. Primers and probe were mixed with the Sso 
Fast™ Supermix to make up a mastermix and 19 µl was pipetted into each well. 1 µl of 
the reverse transcription reaction was added per well. The run was carried out with the 
following programme: 50 °C for 2min followed by 95 °C 10min and 40 cycles of 95 °C 
15 s and 60 °C 1 min. All results were normalized to the GAPDH values and presented 
as copies of the product of interest compared to 1,000 copies of GAPDH.  
 
2.2.3.5 Agarose gels  
DNA samples were separated using 1% agarosegels in 1x TAE. Ethidiumbromide was 
added to the agarose solution at a concentration of 0.5 μg/ml. 15 µl of each sample 
were loaded alongside 10 µl of DNA ladder and separated at 100 V.  
 
2.2.3.6 Plasmid DNA preparation 
Plasmid DNA was obtained from Open Biosystems UCL shRNAmir clone service, 
which provides shRNA already cloned into a pGIPZ vector. The samples were bought 
as GIPZ hairpin containing bacteria streaked onto a solid LB agar stab culture 
containing 100 µl/ml carbenicillin. A pipette tip was used to streak bacteria from the top 
of the stab culture onto an LB agar plate which contained ampicillin (100 µg/ml). The 
plate was cultured at 37 °C in an incubator overnight. The following day, colonies were 
picked and then transferred into 5 ml of LB medium with ampicillin (100 µg/ml) and 
grown at 37 °C with shaking overnight. Afterwards, plasmid mini preps were performed 
using the QIAPrep Spin Miniprep kit following the manufacturer’s instructions. The 
isolated plasmid DNA was sequenced to check if it contained the right hairpin. If it did, 
bigger overnight cultures (250 ml) were grown in LB medium with ampicillin (100 µg/ml) 
and plasmid DNA was isolated using the QIAGEN Plasmid Maxi Kit. The isolated DNA 
was used for lentiviral preparations.  
 
2.2.3.7 Preparation of HPV18wt re-circularised plasmid 
For experiments with the HPV18wt vector, the bacterial backbone needs to be 
removed from the HPV18 plasmid. The plasmid then needs to be re-circularised and 
the bacterial backbone needs to be removed, before the plasmid is purified again. The 
normal protocol (http://home.ccr.cancer.gov/Lco/production.asp) was modified for 
preparation of larger quantities of plasmid. 
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In order to obtain enough re-circularised plasmid, the HPV18wt vector was maxi-
prepped as previously described. 50 µg of the plasmid was restriction digested with 
20 U NcoI as the bacterial backbone is flanked by NcoI sites at 37 °C overnight in 
250 µl total volume. It was checked the following day for the presence of two bands at 
3,000 bp and 7,900 bp indicating complete digestion of the plasmid. The whole mix 
was used for the ligation. It was diluted to a final volume of 6 ml (<10 ng/μl of DNA) to 
enhance the chances that particles would only self-ligate and the appropriate volumes 
of T4 ligase buffer and 2,000 U T4 ligase were added and the sample was incubated 
overnight at 16 °C. It was checked for the presence of re-circularised plasmid by 
agarose gel electrophoresis. Then, 6 ml 5 M ammonium acetate and 22.5 ml 95% 
ethanol were added to the sample and it was incubated overnight at 4 °C to allow for 
efficient DNA precipitation. The following day, the mix was centrifuged for 1 hour at 
room temperature and 5.000 x g, the supernatant was removed and the pellet was 
washed once with 2 ml of 70% ethanol and centrifuged again for 10 min at 5.000 x g. 
The pellet was air-dried and resuspended in 100 µl of TE and 100 µl of water. 22 µl of 
NEB buffer 4 and 60 U XmnI were added and the sample was incubated 45 minutes at 
37 °C. This was done as only the bacterial backbone has an XmnI restriction site 
whereas the HPV18 genome does not contain such a restriction site. ATP was added 
to a final concentration of 1 mM as well as 30 U PlasmidSafe DNase (Exonuclease V = 
ExoV) and incubated for 45 minutes at 37 °C. PlasmidSafe only digests linearized DNA 
but not circularized plasmids. Then 1200 U T4 DNA ligase were added and the sample 
was incubated for 1 hour at room temperature. To inactivate the present enzymes, 3 µl 
each of 0.5 M EDTA, 10% SDS and 20 mg/ml proteinase K were added and the 
sample was incubated for 20 min at 56 °C. 1 ml of buffer PB from the Qiagen mini-prep 
kit was added to the sample. The sample was split in two parts and each part was put 
onto a miniprep column. It was centrifuged, the flow through was discarded and the 
column washed with buffer PE. Then the column was spun without adding any further 
buffer to remove residual wash buffer. The DNA was eluted in 50 µl of sterile water. It 
was checked for successful removal of the bacterial backbone by test disgesting 1 µl of 
sample with NcoI and running it on an agarose gel.  
 
2.2.3.8 Isolating extrachromosomal DNA (HIRT-DNA) 
Cells were trypisined, counted and spun down. The resulting cell pellet was either 
stored at -20 °C or directly resuspended in 600 µl Hirt Resuspension Buffer. 2.4 ml of 
Hirt Lysis buffer was added and the cell suspension was incubated at 37 °C for 
3 hours. The tube was then incubated at 4 °C overnight. The following day the solution 
was centrifuged at 65,000 x g for 30 minutes at 4 °C. The supernatant was collected 
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and 2.5 x volume of cold 100% ethanol were added and the solution was incubated 
at  -20 °C overnight. The next day, the DNA solution was centrifuged for 30 minutes at 
7.000 x g and 4 °C. The supernatant was removed and the cell pellet dried at room 
temperature and then resuspended in 300 µl TE. 60 µg RNAse A were added and 
incubated at room temperature for an hour. To extract the DNA, an equal volume of 
phenol was added and the mix centrifuged for 4 minutes at 20,000 x g. The top layer 
was transferred into a new tube and an equal volume of chloroform-isoamylalcohol 
(24:1) was added, mixed and then centrifuged for 4 minutes at 20,000 x g. To 
precipitate the DNA, 2.5x volumes of 100% cold ethanol and 0.1x volumes of 3 M 
sodium acetate were added and the solution was incubated at -20 °C overnight. The 
following day, it was centrifuged for 30 minutes at 4 °C and 20,000 x g. The pellet was 
washed once with 70% ethanol followed by another centrifugation for 10 minutes. The 
pellet was dried at room temperature and resuspended in 50 µl TE.  
 
2.2.3.9 Southern Blot 
The isolated HIRT DNA samples were adjusted for their cell number so that equal 
amounts of cells were used for digestion. The samples were digested with DpnI and a 
single cutter (NcoI) or a non-cutter (HindIII) of HPV18 DNA overnight at 37 °C. The 
DNA as well as HPV18 standards were separated on a 0.8% agarose gel and the gel 
was stained to check for successful DpnI digestion and DNA separation. The DNA was 
depurinated by incubating the gel for 15 minutes in Depurination buffer, then it was 
denaturated by in Denaturation buffer twice or 45 minutes and then naturalized twice 
for 45 minutes in Neutralisation buffer. The Hybond membrane was activated and then 
washed in 2x SSC buffer. A blot sandwich was assembled by first putting a filter paper 
bridge as a connection to a reservoir of 10x SSC, followed by the gel, the Hybond 
membrane and two filter papers. Paper towels were placed on top of the filter papers 
as well as a weight. The transfer was carried out overnight at room temperature. The 
following day, the southern blot probe was made by mixing 5 mM DTT, 0.5 µM HPV18 
fistful, 1x T4 PNK buffer, 32P labeled ATP (Perkin Elmer) and 15 U T4 PNK. The mix 
was incubated for 5 hours at 37 °C. After the transfer, the membrane was crosslinked 
with UV light of 254 nm and 2 x 120 mJ using the UV Stratalinker 2400 (Stratagene) 
and then prehybridised at 48 °C for 15 minutes in 10 ml Church Hybridisation buffer. 
The probe was added directly to the hybridization buffer and the membrane incubated 
overnight at 48 °C. The next day, the membrane was washed three times for 
15 minutes with 20 ml Church Wash buffer at 52 °C before it was transferred into a 
Storage Phosphor Screen (Molecular Dynamics) developing cassette for 2 days. It was 
then read with a Typhoon 8610 Variable Mode Imager (GE Health Care).  
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2.2.4 Staining of paraffin embedded sections 
 
2.2.4.1 Haematoxylin and Eosin staining 
Slides were deparaffinized in three changes of xylene for two minutes each. They were 
rehydrated by dipping them slowly 30 times in two changes of absolute ethanol 
followed by 15 dips and 30 second incubations in 80% ethanol and 70% ethanol each. 
They were washed four times for 1 minute in water and transferred to Shandon Instant 
Hematoxylin for 10 minutes. They were washed under running tap water for 3 minutes 
and differentiated by dipping them three times in 1.0% alcoholic HCl  and rinsed again. 
The sections were blued in 0.4% sodium acetate, pH 7.25 for 3 minutes, rinsed by 
dipping them 30 times in three changes of water each and incubated for 30 seconds in 
50% ethanol. They were incubated in Eosin-multichrome stain for 2 minutes and 
washed by dipping them 30 times slowly into three changes of absolute ethanol. They 
were then dehydrated by incubating them 2 minutes in three changes of xylenes before 
a coverslip was mounted onto them.  
 
2.2.4.2 Immunofluorescent staining of paraffin embedded slides 
The slides were de-paraffinised using xylenes and rehydrated through a graded series 
of ethanols as for the haematoxylin staining (2.2.4.1). They were then soaked in PBS 
for 5 minutes followed by microwaving the slides in 10 mM citrate buffer pH 6.0 for 
20 minutes. After letting the slides cool, they were washed twice for 3 minutes with 
PBS. They were incubated at room temperature for 1 hour using 5% serum of the 
species in which the secondary antibody was raised. The primary antibodies were 
added at appropriate dilutions in 5% serum and incubated overnight at 4 °C (2.1.3.3.1). 
The following day, the slides were washed twice for 3 minutes with PBS before 1:500 
dilutions of fluorescently-labelled secondary antibodies were added for 60 minutes. The 
slides were stained with Hoechst dye for 5 minutes at room temperature, washed three 
times for 3 minutes with PBS before coverglasses were mounted onto the slides. 
 
2.2.4.3 Making the probe for fluorescence in situ hybridisation (FISH) 
To make the probe for FISH 1x NT buffer, 0.01 M beta-mercaptoethanol, 0.05 mM 
dATP, dGTP and dCTP each, 20 U E.coli polymerase, 0.02 U DNase I, 0.02 mM DTT, 
0.04 mM Biotin-16-dUTP and 1 µg recircularised HPV18 wt genome as template DNA 
were mixed and made up to a final volume of 100 µl. The mix was incubated for 
2 hours at 15 °C, denatured at 70 °C for 10 minutes and then kept at 4 °C. It was 
analysed for the presence of 300 – 600 bp fragments. If fragments were present, the 
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probe was precipitated, if not the mix was further incubated at room temperature for up 
to 30 minutes after another 0.01 U of DNase I were added. 
To precipitate the probe, to 20 µl of mix 4 µg Human Cot I DNA and 6 µg salmon sperm 
DNA were added and the final volume adjusted to 60 µl. 1/10th of the volume of 3 M 
sodium acetate and 2.75x the volume of cold ethanol were added and the tube 
centrifuged for 20 minutes at room temperature and 20,000 x g. The supernatant was 
removed and the pellet air-dried. 
The pellet was resolubilised in 21 µl CEP hybridization buffer for every 20 µl used in 
the precipitation. The probe was denatured at 70 °C for 10 min, 4 °C for 5 minutes and 
then kept at 37 °C until it was used. 
 
2.2.4.4 FISH 
For FISH, the slides with the rafts were baked overnight at 65 °C. The following day, 
they were cooled to room temperature and then deparaffinised by incubating them 
three times 5 minutes in Xylene and rehydrated twice for 5 minutes in 100 % ethanol 
and air dried. They were boiled 25 minutes with 10 mM sodium citrate and cooled to 
room temperature. The slides were incubated in pre-hybridisation solution for 30 
minutes at room temperature and then dehydrated through an ethanol series by 
incubating them for 2 minutes each in ice cold 70%, 80% and 95% ethanol. They were 
then incubated for 5 minutes at 50 °C before they were transferred for 2 minutes into 
denaturation solution at 72 °C and the ethanol series was repeated as before. The 
slides were air dried and then 7 µl probe per slide were added and sealed by using a 
coverslip and parafilm. The slides were incubated overnight at 37 °C in a moist 
warming chamber. The following day, the coverslip and parafilm were removed and the 
slides were incubated in 50% formamide, 2x SSC for 30 minutes at 50 °C to remove 
unbound probe. They were then transferred to 2x SSC for another 30 minutes at 50 °C. 
Both washes were repeated once. A drop of Detection reagent was applied and 
covered with parafilm and the slides were incubated for 30 minutes at 37 °C. They 
were washed three times in 4x SSC, 0.05% triton-x100 for 5 minutes, they were then 
stained with Hoechst dye for 10 minutes and washed three times for 5 minutes in PBS 
before a coverslip was mounted onto the slides. They were kept at -20 °C until images 
were acquired.  
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2.2.5 Animal experiments  
All animal experiments were carried out in the animal facilities at the University of 
Wisconsin-Madison under the animal licence of Prof. Paul Lambert and under the 
supervision of Amy Liem or Aayushi Uberoi. Theoretical and practical courses were 
carried out at the university to obtain approval to work with animals. All animal 
experiments were performed using B6.129S4-Il2rgtm1Wjl/J (The Jackson Laboratory, 
Stock: 003174, γ-chain knock-out mice) and C57/BL6 as WT control.  
 
2.2.5.1 Infection with MmuPV1 particles 
MmuPV1 particles were isolated from wart lesions by homogenising the tissue and 
purifying virions by gradient-centrifugation as described for VLP in 2.2.1.10. Infections 
were carried out in a bio-safety level 2 facility. Mice were anaesthetised using 
isoflurane. The skin on tail, ears and/or grafts was abraded using the tip of a needle to 
create micro-abrasion but not going below epidermis and without causing bleeding. 
MmuPV1 solution was applied onto the abraded site and allowed to dry before the 
animal was revived. During the procedure, reflexes were tested to ensure that the 
animal was in a state of anaesthesia, breathing was monitored and the animal was 
kept warm and its eyes moist. Infected animals were monitored for general health 
according to local protocols and were examined weekly to detect and measure wart 
lesion formation.  
 
2.2.5.2 Grafting of ear skin onto the back of WT animals 
Graft donors were euthanized using CO2, both ears were excised, dorsal and ventral 
surfaces separated and underlying cartilage scraped off using a scalpel. The tissue 
was kept in PBS until it was used for grafting. The graft recipients (WT mice) were 
anaesthetised using ketamine (80-100 mg/kg)/xylazine (5-10 mg/kg), their backs 
shaven and sterilised using ethanol. The epidermis and dermis were incised down to 
the panniculus carnosus which was conserved. The recipient skin was removed. Donor 
skin was fitted onto the graft site and surgical cement was applied. The graft was 
covered with Vaseline gauze and held in place with stretch adhesive tape. Each 
recipient received two grafts with one being placed on each side of the back and one of 
a WT donor and one from a knock-out donor. During the procedure, reflexes were 
tested to ensure that the animal was in a state of anaesthesia, breathing was 
monitored and the animal was kept warm and its eyes moist. After the procedure, mice 
were monitored twice a day for signs of distress or ill health and the adhesive tape 
loosened if they showed signs of distress or breathing difficulties. Seven days post-
transplant, the dressing was removed by anaesthetising the animals using isoflurane 
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and cutting off the bandages using curved scissors. The graft was infected with 
MmuPV1 one month post-transplantation.  
 
 
2.2.6 Data analysis and statistics 
 
Images of agarose gels, immunoblots and the cytokine array were analysed by 
densitometry using ImageJ. Number of BrdU positive cells, FISH positive cells and total 
number of nuclei in organotypic rafts were counted using the ImageJ “Analyze 
Particles” feature. FC data was analysed using FlowJo. Migration for neutrophils was 
tracked using Icy. Migration of DCs was manually tracked using ImageJ. The manual 
tracking data was analysed using a previously created Matlab template (258). All 
graphs were plotted using GraphPad Prism 5, shown are mean ± SEM if not indicated 
otherwise. Data was analysed using statistical tests according to data-sets, e.g. 
Kruskal-Willis test for multiple groups and Mann-Whitney test to compare two groups.  
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3. The common -chain is 
expressed and functional in 
keratinocytes  
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3.1 Introduction 
Keratinocytes are the main cell type affected by HPV infections and they are not 
replaced by BMT or GT which is why they are one of the most likely cell types to play a 
role in the greater susceptibility of X-SCID patients to HPV. However, the role of the 
common γ-chain has only been studied in detail in haematopoietic cells where it has 
been shown to be expressed in T, NK and B cells as well as DCs. At the beginning of 
this project, there was limited data showing whether keratinocytes express γ-chain and 
whether signalling mediated by γ-chain takes place in these cells. Moreover, as signals 
via the common γ-chain can only be transmitted when it forms one of its heterodimers 
and heterotrimers, the expression of these receptors also needed to be examined in 
detail, which had not been done before. There were only a few reports of single studies 
showing that γ-chain signalling played a role in keratinocyte biology and no systemic 
study had been done. Specifically, it was shown that the PI3K and ERK1/2 pathways 
are activated after stimulation with IL-15 leading to increased proliferation (259). 
Expression of IL-7R has been shown as well as IL-21R expression and the pro-
proliferative effect of IL-21 (221, 222). IL-9 signalling in keratinocytes was reported very 
recently leading to an increase in secretion of IL-8 (223). IL-4 signalling is also present 
in keratinocytes, however, this can occur by two separate pathways (260), making it 
difficult to distinguish between γ-chain dependent and independent IL-4 signalling.  
Various JAK and STAT molecules are expressed in keratinocytes which is important as 
γ-chain signals via the JAK-STAT pathway (261).  
To examine which interleukin signals mediated by γ-chain are present in keratinocytes 
and to analyse the effects of the common γ-chain in keratinocytes, it was a crucial step 
to generate a cell model with common γ-chain knock-down or knock-out when the 
project started. As primary keratinocytes have a limited life-span and there are few 
samples available from X-SCID patients due to the low patient number and young age 
at transplant, we chose a keratinocyte cell line known as NIKS, a commonly used cell 
line in HPV research in this study (255). In order to establish the vital knock-down cell 
line for this project without which no further studies into the role of the common γ-chain 
would have been possible, an shRNA approach was used to knock-down γ-chain in 
NIKS cells using lentiviral vectors. 
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3.2 The γ-chain is expressed in keratinocytes 
Haematopoietic cells are known to express the common γ-chain confirmed at both 
mRNA and protein levels. There is no previous data showing whether keratinocytes 
express γ-chain. To confirm γ-chain expression in keratinocytes, human primary 
keratinocytes (HPKC) and the keratinocyte cell line NIKS were analysed by reverse 
transcription PCR (RT-PCR) for mRNA expression and by flow cytometry (FC). ED-7R 
cells were used as negative control as they do not express the common γ-chain. We 
also used an ED-7R + γc cell line which was genetically modified to express γ-chain as 
a positive control (see 2.1.9). 
RT-PCR was carried out using a primer set specific for the common γ-chain. No band 
was detected in the negative control, but a strong band in the positive control and 
bands with the same size as the positive control in both NIKS and HPKC. No other 
bands were detected on the gel. GAPDH expression was used as internal control 
(Figure 7a). The results indicate that γ-chain mRNA is expressed in HPKC and NIKS. 
To assess surface expression of the common γ-chain protein, NIKS and HPKCs were 
stained with a specific antibody for γ-chain conjugated with APC. Histograph analysis 
showed that there was a clearly shifted trace in NIKS and HPKC compared to the 
isotype control. HPKC and NIKS both expressed γ-chain, with HPKC γ-chain 
expression at a higher level. In contrast, there was no difference in negative control 
ED-7R cells which do not express γ-chain (Figure 7b). 
In summary, common γ-chain is expressed in human keratinocytes at both protein and 
mRNA level.  
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a)  
 
 
b) 
  
Figure 7: Expression of γ-chain mRNA and protein in keratinocytes  
RNA of NIKS and primary keratinocytes was isolated and RT-PCR was performed using γ-chain 
specific primers; GAPDH RNA was amplified as internal control (a); γ-chain was stained and 
analysed by FC in i) HPKC,  ii) NIKS cells, iii) ED-7R and (iv) ED-7R + γc, representative 
pictures from n = 4 (b).  
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3.3 Multiple γ-chain co-receptors are expressed in 
keratinocytes 
There is not only a lack of previous data showing the expression of the common γ-
chain in keratinocytes but it has also not been examined whether keratinocytes express 
all γ-chain co-receptors, such as the specific α-chains for IL-2R, IL-4R, IL-7R, IL-9R, IL-
15R and IL-21R and IL-2Rβ. Therefore, NIKS and HPKC were examined for the 
expression of these co-receptors by RT-PCR, FC and immunoblotting.  
RNA was isolated from HPKC and NIKS, and RT-PCR was carried out with specific 
primers for the different co-receptors. It was found that the PCR products generated by 
the primers specific for IL-2Rβ, IL-4R, IL-7Rα, IL-9R, IL-15Rα and IL-21R showed a 
band in both NIKS and HPKC of the same size as the positive control. This suggests 
that these receptors were expressed in both HPKC and NIKS. There were no bands 
observed in the PCR product generated by IL-2Rα-specific primers in HPKC and NIKS. 
This was confirmed by a second pair of primers which also showed no band, 
suggesting that IL-2Rα is not expressed in HPKC and NIKS (Figure 8). 
The expression of IL-2Rα, IL-2Rβ, IL-4R, IL-7Rα, IL-9R, IL-15Rα and IL-21R co-
receptors in keratinocytes was further analysed by FC and/or western blot. NIKS were 
stained with antibodies for IL-2Rα, IL-4R, IL-9R, IL-15Rα and IL-21R and analysed by 
FC. Histograph analysis showed that there was a clearly shifted trace in NIKS for IL-
4R, IL-9R, IL-15Rα and IL-21R compared to the isotype control. No shift was observed 
for IL-2Rα. These results illustrate that keratinocytes express IL-4R, IL-9R, IL-15Rα 
and IL-21R but not IL-2Rα (Figure 9a).  
The expression of IL-2Rβ and IL-7Rα was analysed by western blot in both HPKC and 
NIKS. Corresponding bands of IL-2Rβ and IL-7Rα could be detected in both cell 
lysates (Figure 9b). 
In summary, common γ-chain co-receptors IL-2Rβ, IL-4R, IL-7Rα, IL-9R, IL-15Rα and 
IL-21R are expressed on keratinocytes, which was confirmed for both mRNA and 
protein, whereas there is no IL-2Rα expression indicting that keratinocytes can only 
assemble a low affinity IL-2R and not the high affinity heterotrimer.  
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Figure 8: Expression of γ-chain co-receptors mRNA  
RNA of ED-7R (positive control), NIKS and HPKC was isolated and RT-PCR was performed 
with primers specific for IL-2Rα, IL-2Rβ, IL-4R, IL-7Rα, IL-9R, IL-15Rα and IL-21R. The RT-
PCR products were separated on a 1% agarose gel. 
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a) 
 
b) 
 
Figure 9: Expression of γ-chain co-receptors  
NIKS were stained with antibodies for IL-2Rα, IL-4R, IL-9R, IL-15Rα and IL-21R and analysed 
by FC; representative pictures from n = 4 (a); cell lysates of NIKS and HPKC were run in SDS-
PAGE, transferred onto PVDF membranes and detected by anti-IL-2Rβ and -IL-7Rα antibodies, 
GAPDH was used as internal control (b).  
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3.4 Stimulation with γ-chain cytokines induces 
phosphorylation of STAT5 in keratinocytes 
To further understand, which interleukins play a role in skin immunity, interleukin 
signalling mediated by γ-chain in keratinocytes was analysed by FC. The signalling 
pathway linked to common γ-chain signalling is the JAK-STAT pathway with STAT5 
being the most commonly phosphorylated STAT protein. As STAT5 phosphorylation 
can also be induced by other factors such as growth hormone and prolactin which are 
present in FCS, cells were cultured in serum-free medium overnight to eliminate this 
influence on phospho-STAT5 levels. The following day, the cells were stimulated with 
IL-2 (200 ng/μl) for 10 minutes and then harvested and stained with a STAT5 (pY694) 
antibody for FC analysis.  
Analysis showed a small but significant increase in the median fluorescence intensity 
after stimulation with IL-2, indicating that IL-2 signalling occurs in keratinocytes albeit at 
lower levels than seen in leukocytes which express the high affinity receptor for IL-2 
(Figure 10a+b).  
As keratinocytes do not express IL-2Rα and cannot form the high-affinity IL-2R, IL-2 
may not be the best cytokine to stimulate STAT5 phosphorylation mediated by γ-chain. 
Therefore, phosphorylation of STAT5 following stimulation with other γ-chain cytokines 
such as IL-7, IL-9, IL-15 and IL-21 was examined.   
The same experiment was performed in NIKS cells following stimulation with IL-7, IL-9, 
IL-15 and IL-21. Compared to the IL-2 study described above, the challenge levels of 
these cytokines were 200-fold lower (1 ng/μl). Stimulation with IL-7, IL-15 and IL-21, 
but not IL-9 induced a small but significant increase in median fluorescence intensity 
(Figure 10c+d). There was a small increase in phospho-STAT5 after stimulation with 
IL-9 which was, however, not significant.  
In summary, stimulation with multiple common γ-chain cytokines led to a small increase 
in phosphorylation of STAT5 in NIKS. A significant change could be seen in NIKS with 
IL-2, IL-7, IL-15 and IL-21. This indicates that the γ-chain is functional on keratinocytes.  
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a)         b) 
  
c) 
 
d)  
 
Figure 10: Phosphorylation of STAT5 NIKS cells after stimulation with γ-chain cytokines  
NIKS were cultured in serum-free media overnight and then stimulated for 10 minutes with 
different cytokines, stained with a STAT5 (pY694) antibody and analysed by FC, representative 
FC plots for stimulation with 200 ng/μl IL-2 are shown in a), mean ± SEM of changes in median 
FI for IL-2 stimulation in b), *p < 0.05, Mann-Whitney test, n = 5; c) representative FC plots for 
stimulation with 1 ng/μl of of IL-7, IL-9, IL-15 and IL-21, respectively and d) increase in median 
FI, mean ± SEM, *p < 0.05, Kruskal-Willis, followed by Dunn’s multiple comparison test, n = 6.   
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3.5 Stimulation with γ-chain cytokines induces 
phosphorylation of AKT in keratinocytes 
As pSTAT5 levels induced by γ-chain cytokines were relatively low, we wanted to 
measure a second readout for γ-chain signalling to confirm our results. As it had been 
published before, that IL-15 stimulation leads to phosphorylation of AKT (pAKT) in a 
dose-dependent manner (259), we wanted to tested whether this was true for different 
γ-chain cytokines in our study.  
NIKS were cultured in serum-free medium overnight and stimulated with different γ-
chain cytokines at 100 ng/ml for 10 minutes the following day. Post stimulation, cells 
were lysed and analysed by western blot for the expression of pAKT and GAPDH as an 
internal control. 
An increase of pAKT levels by 2- to 3-fold compared to unstimulated was observed in 
cells challenged with IL-7, IL-9, IL-15 or IL-21 (Figure 11). This indicates again that the 
γ-chain is functional in keratinocytes.  
 
 
Figure 11: Phosphorylation of AKT after stimulation with γ-chain cytokines 
NIKS were cultured in serum-free medium overnight, the following day they were stimulated with 
100 ng/ml of the different cytokines for 10 min at 37 degrees, lysed and analysed by Western 
blot for the expression of pAKT. AKT and GAPDH were analysed as an internal controls, 
representative image from n  = 4.  
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3.6 Generation of a common γ-chain knock-down cell line: 
Screening of shRNAs using the ED-7R cell line 
To examine the effects of the common γ-chain in keratinocytes, a keratinocyte cell line 
with loss of γ-chain function was generated. An shRNA approach was used to knock-
down γ-chain in NIKS cells. Four shRNAs with complimentary sequences to γ-chain in 
pGIPZ lentiviral vector were obtained from UCL Open Biosystems. The pGIPZ lentiviral 
vector contains a puromycin resistance cassette to select positive cell clones and a 
Turbo-GFP marker to fluorescently mark the transduced cells.  
The four shRNAs were tested in ED-7R + γc cells to screen the most potent shRNA. 72 
hours post transduction, the expression of γ-chain was assessed by FC in the GFP 
positive cells. shRNA2, 3 and 4 showed a clear reduction of γ-chain expression. 
Compared to the scrambled (scr) control, the greatest knock-down (KD) of γ-chain was 
seen in the cells transduced with shRNA3, followed by shRNA4 and shRNA2. shRNA1 
only showed a small change (Figure 12). As shRNA3 and 4 showed the most potent 
effect, these two shRNAs were further used in NIKS cells.  
 
 
Figure 12: Knock-down of γ-chain in ED-7R + γc cells  
ED-7R + γc were transduced with lentiviruses coding for shRNAs against γ-chain as well as a 
scr control, 72 hours after transduction the cells were stained with a γ-chain specific antibody 
and analysed by FC, expression of γ-chain in ED-7R + γc transduced with different shRNAs are 
compared to ED-7R (γ-chain negative population).  
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3.7 Generation of a common γ-chain keratinocyte knock-
down cell line 
NIKS were transduced with the lentiviruses encoding shRNA3 and shRNA4 to knock-
down γ-chain; the scrambled shRNA was used as control. 72 hours after transduction, 
NIKS cells were treated with puromycin for a week to select positively transduced cells 
(see 2.2.1.7). FC analysis showed >95% GFP positive cells after one week of 
puromycin selection. Selected cells were stained with anti γ-chain antibody and 
analysed by FC to confirm common γ-chain expression. 
Transduction with the scr control did not alter the expression of γ-chain compared to 
untransduced cells, whereas cells transduced with shRNA3 showed clear reduction in 
γ-chain expression compared to that in untransduced cells. However, cells transduced 
with shRNA4 did not show a reduction in γ-chain expression in NIKS cells (Figure 13). 
To further confirm the reduction of γ-chain expression after shRNA3 transduction, the 
expression of γ-chain mRNA was also examined by RT-PCR. RNA was isolated from 
cells transduced with scr control or shRNA3 and for untransduced cells. RT-PCR was 
performed with γ-chain primers used before. The intensity of the bands was compared 
using ImageJ and normalised to the intensity of the band obtained from untransduced 
cells. 
The results showed a significant reduction of the band intensity by more than 75% 
compared to untransduced cells and scr control cells (Figure 14). 
In summary, cells expressing shRNA3 show a reduction of γ-chain mRNA and protein 
expression confirmed by RT-PCR and FC.   
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Figure 13: Knock-down of γ-chain protein using shRNA3  
NIKS were transduced with shRNAs against γ-chain and selected with puromycin for a week 
starting 72 hours after transduction; γ-chain expression in untransduced (UT) and cells 
transduced with scr control shRNA or shRNAs 3 and 4 were analysed by FC, representative 
images from, n = 8. 
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a)      b) 
 
Figure 14: Knock-down of γ-chain mRNA  
RNA was isolated from different NIKS cell lines and RT-PCR was performed using γ-chain 
specific primers, GAPDH RNA was amplified as internal control, representative image (a) and 
bar charts showing the compared intensities of the bands obtained using ImageJ compared to 
UT (b), mean ± SEM, *p < 0.02, Mann-Whitney test, n = 4.  
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3.8 Signalling mediated by γ-chain is defective in knock-
down keratinocyte cell line  
To test, if the reduction in γ-chain expression led to a functional change, 
phosphorylation of AKT after stimulation with IL-15 was analysed as we saw previously 
that pAKT gives a clearer and stronger signal than pSTAT5. 
Untransduced NIKS and NIKS transduced with either scr control or shRNA3 were 
cultured in serum-free medium overnight and then stimulated with IL-15 (10 ng/ml) for 
10 minutes the following day. The samples were analysed for the expression of pAKT 
by Western blot. The protein bands in the blot were analysed by densitometry and the 
relative pAKT expression in unstimulated and IL-15 stimulated samples was calculated 
by normalising to the total protein levels using GAPDH as internal control. 
A significantly increased pAKT level after IL-15 stimulation was observed in 
untransduced samples and scr control as expected. In contrast, cells transduced with 
shRNA3 demonstrated no change in pAKT levels, indicating absence of IL-15 
signalling in these cells (Figure 15).  
In summary, the expression of γ-chain mRNA and protein were reduced in the cells 
with γ-chain knock-down. The reduced expression further led to significantly impaired 
γ-chain signalling capability as shown by reduced levels of phosphorylated AKT after 
IL-15 stimulation. Cells transduced with shRNA3 were used for further experiments and 
are referred to in future chapters as “KD cells”.  
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a) 
 
b) 
 
Figure 15: pAKT levels in γ-chain knock-down and control cells after IL-15 stimulation 
Untransduced NIKS and cells transduced with scr control or shRNA3 were cultured in serum-
free medium overnight and then stimulated for 10 minutes with 10 ng/ml IL-15. Cell lysates were 
analysed by western blot for the expression of pAKT. AKT (run on a second gel) and GAPDH 
were used as internal controls, representative western blot images (a) and densitometry results 
normalised to GAPDH (b) showed the relative increase of pAKT in untransduced and scr control 
cells after stimulation with IL-15 but not in cells with shRNA3 expression, mean ± SEM, *p < 
0.05, Kruskal-Willis test, followed by Dunn’s multiple comparison test, n = 6.  
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3.9 Discussion 
To analyse the role of γ-chain in keratinocytes, it first needed to be confirmed that γ-
chain and its co-receptors are expressed in keratinocytes, as limited literature existed. 
Kagami et al. showed the expression of γ-chain at mRNA level in the HaCaT 
keratinocyte cell line but no data has shown the expression of γ-chain protein in 
primary keratinocytes and other cell lines (262). In addition, from the γ-chain co-
receptors, the expression of IL-4R, IL-9R, IL-15Rα and IL-21R in different human 
keratinocyte cell lines or primary keratinocytes has been described mainly as single 
reports (223, 260, 263, 264). However, our study is the first to test the expression of all 
common γ-chain receptors in one study and to examine their expression in the NIKS 
cell line. 
RT-PCR and FC were used to show the expression of γ-chain in HPKC and the NIKS 
cell lines at mRNA and protein levels. The specificity of these tests was shown by using 
the ED-7R cell line which does not express γ-chain and a genetically modified ED-7R 
cell line which overexpresses γ-chain. In addition, expression of all γ-chain co-
receptors except IL-2Rα was also shown in HPKC and NIKS. This confirmed that a 
broad range of γ-chain receptors are expressed in both cell types and suggests that the 
high affinity IL-2 receptor cannot be formed on keratinocytes although the low affinity 
IL-2Rβ/γ-chain heterodimer can be assembled. 
While this project was undertaken, Luff et al. published a paper about the expression of 
γ-chain and its co-receptors in canine keratinocytes. They observed the expression of 
IL-4R, IL-7R, IL-15Rα and low levels of IL-2Rα. However, in contrast with the results 
shown here, IL-9R and IL-21R were not expressed in their study (265). This may be 
explained by different species which might have different expression profiles of certain 
receptors. Technical limitations could also give rise to discrepancies but in support of 
the data shown here, expression of IL-9R and IL-21R has been described in human 
keratinocytes in other studies (223, 264).  
As γ-chain and most of its co-receptors were expressed in keratinocytes, it seemed 
very likely that there would be a relationship between γ-chain containing-receptors, 
keratinocyte function and possibly immunity in the skin. We, therefore, went on to test 
whether we could detect signalling via the common γ-chain in keratinocytes. As in 
haematopoietic cells, signalling pathways activated by γ-chain cytokines are the 
JAK3/STAT-pathway, the PI3K/Akt and the RAS-mitogen-activated MAPK pathways, 
we decided to analyse the phosphorylation of downstream molecules of these 
pathways (168, 266).  
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When cells were stimulated with different γ-chain dependent cytokines, 
phosphorylation of downstream signalling molecules was observed. A small but 
significant increase in pSTAT5 levels was observed after stimulation with IL-2, IL-7, IL-
15 and IL-21. The change seen with IL-9 was not significant. That means that even 
though IL-2Rα was not expressed in keratinocytes, signalling via IL-2 was still possible 
because the IL-2Rβ and γ-chain receptors from an intermediate receptor, which can 
transduce signals. The magnitude of pSTAT5 was relatively low compared with 
published results for leukocytes stimulated with the same cytokines (233, 267, 268). 
There may be a number of reasons for this, e.g. that the expression of γ-chain is lower 
in keratinocytes than in leukocytes.  
It has been previously reported that IL-15 stimulation leads to an increase in 
phosphorylation of AKT and ERK1/2 in HaCaT cells (259). Therefore, we went on to 
measure pAKT levels which are downstream of JAK/STAT signalling and could benefit 
from amplification of the signalling pathway. In support of the pSTAT5 data, IL-7, IL-9, 
IL-15 and IL-21 led to robust and significant increases in pAKT levels. This suggests 
that signalling via different γ-chain dependent receptors is present in keratinocytes.  
Even though, we detected IL-4R mRNA and protein in keratinocytes, we decided to 
exclude IL-4 from further analysis as it has been described that many effects of IL-4 in 
keratinocytes are independent of JAK3 as IL-4R can additionally heterodimerise with 
IL-13Rα and signal through JAK1 and STAT6  (260, 262).  
In conclusion, these experiments suggest that γ-chain is not only expressed in 
keratinocytes but is also functional and can transmit signals to downstream target 
genes, although these target genes in keratinocytes remain to be identified.  
In order to analyse the effects of γ-chain in human keratinocytes, it was crucial to 
generate a keratinocyte cell line with γ-chain knock-down. In order to establish this 
important tool for this project, an shRNA approach was used to knock-down γ-chain in 
NIKS. FC and RT-PCR analysis showed that cells transduced with one of the shRNAs 
led to a significant decrease in γ-chain expression by at least 75% compared to 
untransduced cells and cells transduced with scr control. This resulted in almost 
complete abrogation of signalling in these cells, evidenced by failure to increase pAKT 
levels after stimulation with IL-15. These results show that we successfully created a 
common γ-chain knock-down keratinocyte cell line which has not been done before. 
This cell line as our most important tool for this project was used in all further chapters 
to examine the role of the γ-chain in the keratinocytes in HPV-related immunity.    
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4. Infectivity with pseudo- and 
quasivirions is increased in -
chain deficient cells  
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4.1 Introduction 
One of our hypothesises to explain the increased susceptibility of patients with X-SCID 
to severe HPV infections after BMT or GT, even with successful restoration of T cell 
compartment, is that patients’ keratinocytes are more easily infected than those of 
healthy individuals. A higher infection rate could explain the higher number of affected 
individuals as well as the high number of affected sites seen in X-SCID patients 
compared to the rest of the population.  
In order to test this hypothesis, live HPV virions needed to be prepared for cell 
infections. It is difficult to isolate live virus as it can only be obtained from wart lesions 
where it can only be retrieved in relatively small amounts (269, 270). In addition, only 
certain low risk HPV types such as HPV1 and HPV2 can be isolated from warts but not 
high-risk α-types HPV such as HPV16 and 18. Therefore, researchers have attempted 
to make virus in vitro.  
Initially, PV virus-like particles (VLP) were produced in vitro using vaccinia virus 
recombinants expressing L1 and L2 capsid proteins and plasmid DNA containing an 
SV40 origin of replication. When PV DNA was transfected and the cells infected with 
the vaccinia virus, the DNA was successfully encapsidated into particles inside the 
cells. The resulting particles were shown to be infectious as they could transport the 
encapsidated DNA into a number of different cell types. This process was used to 
make HPV16, 18, 33 and BPV1/2 VLPs (271-273).  
It is also possible to harvest virions from organotypic rafts made with HPV transfected 
cells as they provide the level of epithelial differentiation that is needed for the 
synthesis of virions. These virions have the typical virion morphology which has been 
shown by electron microscopy for HPV18 and HPV31. However, when isolating virions 
from rafts, a high number of rafts are needed to provide sufficient quantity of PV 
particles for experiments (274-276). Thus the in vitro production of virions is not very 
efficient and is very laborious and technically demanding.  
In the past decade, more efficient methods were developed for intracellular production 
of HPV VLPs using 293 cells. Two different plasmids are required to make the HPV 
VLPs: a plasmid coding for HPV L1 and L2, e.g. the pShell plasmid and the 
recircularised full-length HPV genome. The pShell plasmids are bicistronic L1/L2 
expression plasmids which contain stuffer DNA to increase their size to 10.8 kb. In 
order to make replication deficient virions, the pShell plasmid must not be packaged in 
to the PV particle after co-transfection. The packaging process is a promiscuous 
process which is sequence-independent, however, efficient packaging occurs only with 
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plasmid DNA with a size smaller than 8 kb. Therefore, pShell which is 10.8 kb is 
inefficiently packaged into PV particles. The size restriction makes it essential to 
remove the bacterial insert from PV plasmids prior to vector production to reduce its 
size to < 8kb (277). After transfection, the Shell plasmid is transcribed and translated 
inside the 293 cells, separately from the PV plasmid. The proteins L1 and L2 are 
produced and form a capsid for encapsidating the plasmid DNA (278).  
As HPVs are not actively released from keratinocytes but shed from dying cells the 293 
cells need to be lysed in order to obtain the virus. The resulting cell lysate contains 
immature HPV virions which need to be incubated overnight at 37 °C for maturation. 
Maturation is associated with an increase in multimeric L1 forms and loss of L1 
monomers due to the formation of disulphide bonds. Mature virions are smaller in size 
and more regular than immature particles as observed by electron microscopy. Overall, 
the maturation process of PVs takes several hours compared to seconds or minutes for 
most other viruses (99, 277).  
The resulting virion containing supernatant also contains cell debris and proteins. 
Therefore, it needs to be further purified to obtain high quality virions to use for 
experiments. There are two ways for purification of the cell lysate: 
a) density-gradient centrifugation using iodixanol (sold as OptiPrep™) or caesium 
chloride  
b) size exclusion chromatography using agarose gel filtration.  
A single partially diffused iodixanol gradient is efficient at separating virions from 
cellular proteins in 293 lysates. In addition, separation of empty capsids and DNA-
containing capsids is achieved with good recovery of viral titre (277).  
Size exclusion chromatography relies on the fact that the produced VLP capsids are 
larger than all other complexes in the clarified lysate. A pore size of 50- to 150-μm can 
be used as this is slightly smaller than the VLP capsids and the capsids are excluded 
and directly eluted. Using ultracentrifugation higher purity can be achieved but it is 
more technically challenging (278).  
VLPs were subsequently used for experiments investigation the early steps in PV 
infection, examining for example which cell surface receptors mediate the uptake of 
PVs into cells, whether certain cytokines affect infectivity with PVs and which 
downstream molecules are activated after infection.  
No published studies have analysed whether the common γ-chain or its cytokines have 
any influence on the uptake of PVs into keratinocytes and therefore, we set out to test 
121 
 
this using both VLPs containing a reporter gene and ones containing a HPV plasmid. In 
addition, the influence of γ-chain and some of its cytokines on proliferation was 
examined as the level of proliferation can alter infectivity.  
X-SCID patients are often affected by infections with the cutaneous HPV β1 types 
HPV5, HPV14 and HPV36 or the α4 type HPV2. Shell plasmids for HPV14 and HPV36 
are currently not available. For virions made with HPV5 pShell a high particle to 
infectivity ratio and for virions made with HPV2 pShell essentially no infectivity on 
tested keratinocyte cell lines was described 
(http://home.ccr.cancer.gov/lco/plasmids.asp). In addition, in a publication from 2014 
the cutaneous VLPs used had lower infectivity than mucosal types in 293TT cells. 
However, in skin cell lines, the cutaneous types showed minimal or undetectable 
signals (279).  As VLPs made with capsid proteins from mucosal types show more 
robust infection, we decided to use the previously successfully used pShell plasmid 
from HPV16 for our experiments to ensure that we would observe infection. Moreover, 
we used HPV18 plasmid in our quasivirion experiments and later transfection 
experiments because it is an easily detectable HPV type as it is usually replicated in 
high quantities in transfected or infected cells.  
In this chapter, “pseudovirions” refer to VLPs comprising the capsid formed of L1 and 
L2 and Luciferase as a reporter gene and “quasivirions” to particles containing the full-
length HPV18 genome. The Luciferase plasmid codes for firefly luciferase under the 
control of the CMV promoter leading to constitutive expression in cells when the 
plasmid has entered the cell. As this type of work is not done at ICH, I spent five 
months in the laboratory of Prof. Paul Lambert at the University of Wisconsin-Madison 
where I obtained the following results.   
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4.2 Preparation of HPV18 wt plasmid 
For transfection with the HPV18 wild-type (wt) genome as well as to produce VLPs, the 
bacterial sequences need to be removed from the HPV18 plasmid. In order to do this, 
the original protocol from C. Buck (http://home.ccr.cancer.gov/Lco/production.asp) was 
modified and optimised to increase the amount of recircularised vector obtained and to 
reduce the amounts of enzymes used (see 2.2.3.7).  
First, the HPV18 plasmid was digested with NcoI to remove the bacterial sequences. 
Before digestion, the supercoiled and open circular circularized plasmid at around 6.2 
kb and > 16 kb was observed, respectively (Figure 16b, Lane 1). Following digestion, 
two bands could be seen. From previous work, the band at 7.9 kb is known to be the 
HPV genome and 3.0 kb the bacterial sequences (Lane 2). After re-ligation the re-
circularised genomes could be seen as multiple bands. The sizes abound 6.2 kb and 
>16 kb corresponded to the supercoiled and open circular forms of the HPV genome 
plasmid and the sizes between 1.8 kb and 3.2 kb to the supercoiled and open circular 
forms of the bacterial sequences (Lane 3). The bands around 23 kb were head to tail 
concatomers of the HPV genome. The re-ligated sample was precipitated (Lane 4) and 
digested with XmnI, an enzyme which only linearised the bacterial backbone (Lane 5). 
After digestion, bands which were same size as the HPV18 genome after ligation (6.2 
kb and >16Kb) and the linearised bacterial backbone (3.0 kb) were obtained (Lane 5). 
This sample was digested with Exonuclease V which only digested the linearized 
bacterial backbone but not circularized HPV18 genome. After digestion, the HPV18 
genome was still present whereas the linearised bacterial backbone at 3.0 kb 
disappeared (Lane 6). The sample was further incubated with ligase to re-seals nicks in 
the open circular HPV18 genomes. The size of the product after ligation was same as 
lane 6 (Lane 7). The sample was then purified to remove enzyme and salts using a 
Qiagen Miniprep column. During the purification, concatomers were also partly 
removed as the miniprep column only allows <30kb DNA to pass through (Lane 8). To 
confirm, whether the product contained only HPV18 genomes, a restriction enzyme 
(NcoI) that only cuts the HPV18 genome once was used. After digestion, only a band at 
7.9 kb was observed suggesting that the sample contained only HPV18 genomes 
(Lane 9). These recircularised HPV18 genomes were used for further studies.  
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a) 
 b)  
 
Figure 16: Reconstruction of HPV18wt plasmid 
The HPV18wt plasmid was digested with NcoI, to remove the bacterial backbone, re-ligated, 
precipitated, digested with XmnI which only cuts the bacterial backbone and treated with ExoV 
which only digests linearised DNA, a) flow-chart showing the process, b) agarose gel picture 
showing in Lane 1) uncut HPV18wt plasmid including bacterial backbone; Lane 2) after digest 
with NcoI; Lane 3) after religation; Lane 4) after precipitation; Lane 5) after digest with XmnI; 
Lane 6) after digest with ExoV; Lane 7) after T4 ligase treatment; Lane 8) after purification; 
Lane 9) test digest with NcoI to confirm the product was HPV18 wt plasmid.  
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4.3 Making HPV quasivirions  
Using the recircularised HPV18 plasmid HPV quasivirions were made for further 
experiments. The virus was produced as described in 2.2.1.10 and then purified using 
an iodixanol gradient. The separation was done in two separate tubes to test the effect 
of benzoase treatment prior to purification (tube B). Benzoase removes any residual 
DNA that had bound to the capsids. 15 fractions were collected from each tube by 
puncturing the tube and collecting eluent drops.  
To identify which fractions contained the virus particles, the expression of L1 protein 
around ~55 kD was checked as L1 is the only protein present in abundance in HPV 
virions. In addition, the presence of other proteins representing cellular protein 
impurities was examined. A small aliquot was used for an SDS-PAGE and stained with 
Coomassie blue. A single protein band of 55 kD corresponding to L1 was observed in 
fractions 2 – 6 of tube A and fractions 2 – 4 of tube B and no additional bands were 
seen (Figure 17). The difference in the number of fractions containing the virus 
particles is due to the fact that the first fractions of tube A were smaller in volume than 
for tube B. The total virus containing volume was similar for both tubes. 
As the virions had to consist of both the capsid particles and the HPV DNA, the 
fractions were further examined for presence of HPV18 DNA. The particles from each 
fraction were lysed and run on an agarose gel. Linearised HPV18 plasmids with 
various dilutions were used as standards. Due to high viscosity of the DNA samples 
extracted from virus particles, these samples ran differently from the pure linearised 
HPV18 plasmid DNA. Therefore the observed sizes did not accurately reflect the size 
of HPV18 DNA. The results from the gel showed that tube B fractions contain only two 
bands which are the supercoiled and open circular circularized forms of the HPV 
plasmid, whereas tube A contains additional DNA bands (Figure 18a).  As Tube B was 
treated with Benzoase prior to gradient centrifugation, this result indicated that 
nuclease treatment was efficient at removing DNA bound to the virus particles. These 
results suggested A2 – A6 and B2 – B4 contained viral quasivirions.   
The viral titre was assessed using Southern Blot. Two bands representing the 
supercoiled and open circular circularized plasmid forms could be observed in tube A 
and B fractions. The titre was calculated based on the intensity of bands by 
densitometry and compared to the standards. It was around 2 * 107 viral genome 
equivalents (vge) per μl (Figure 18b). As fractions from tube B were cleaner they were 
used for subsequent experiments. For most experiments, fraction B2 was used as it 
showed the highest viral titre.  
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Figure 17: Identifying HPV18 quasivirions containing fractions 
HPV18 quasivirions were purified using an Optiprep gradient. For two different sets, 15 fractions 
each were collected. 10 μl of each fraction were supplemented with SDS loading dye and boiled 
to lyse virus particles and separated on an SDS-PAGE gel. The gel was stained for Coomassie 
blue and bands were visualised after destaining. The size of the L1 protein (55 kD) is indicated 
by arrows.  
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a)  
 
b) 
 
Figure 18: Titering HPV18 quasivirions 
HPV quasivirions were lysed using proteinase K, SDS and EDTA. These were run, along with 
standards of different concentrations on a 0.6% agarose gel; HPV18 bands are indicated with 
red arrows, additional bands with green arrow; fractions B were treated with Benzoase prior to 
quasivirions purification (a). The gel was used for Southern blot and the blot was probed using 
an anti-HPV18 probe (b). Viral-genome equivalents (vge) per µl are shown beneath each 
fraction as calculated compared to the indicated standard using densitometry.   
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4.4 Infectivity using pseudovirions is increased in γ-chain 
deficient keratinocytes  
To examine whether absence of the common γ-chain in keratinocytes changes the 
initial phase of the HPV infectious life cycle, infectivity in scr control NIKS and KD NIKS 
was analysed using pseudovirions. As the pseudovirions expressed the reporter gene 
luciferase, the infectivity was evaluated by luciferase activity 48 hours post infection. 
NIKS cell lines were infected with the pseudovirions at a virus concentration of 1 and 
10 vge/cell.  
An increase in luciferase activity of 60% was observed with both viral concentrations in 
the KD cells compared to scr control cells (Figure 19). This suggests that reduction of 
γ-chain expression could cause an increased susceptibility to HPV virion infection. 
 
 
 
 
Figure 19: Levels of infectivity in NIKS cell lines 48 h post pseudovirion infection 
Scr control and KD NIKS cell lines were seeded on 96 well plates, infected with pseudovirions 
at viral concentrations of 1 or 10 vge/cell. Luciferase activity was measured 48 hours later. 
Relative light units (RLU) were normalised to cell numbers and to scr control values, mean ± 
SEM, *** p < 0.001, Kruskal-Wallis test, followed by Dunn’s multiple comparison test, n = 4, 
each in quadruplets.   
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To further examine whether signalling mediated by the γ-chain can influence infectivity 
with HPV virions, cells were stimulated with IL-7 and IL-15 prior to the virion infection. 
Before carrying out the study, a serum free culture system was established because i) 
components in FCS such as prolactin can activate γ-chain related signalling pathways 
(such as the STAT5 pathway) and ii) excluding serum from the normal growth medium 
(“E-med”) leads to significant cell death in less than 24 hours. Two serum-free media 
were tested – Optimem and Keratinocyte SFM. Untransduced NIKS were seeded in E-
med. The medium was removed the following day and cells were washed with PBS to 
remove traces of media. The medium was replaced with Optimem or KSFM or 
remained in E-med. 6 hours later pseudovirions were added at a viral concentration of 
1 vge/cell and luciferase activity measured 48 hours later.  
Luciferase activity was reduced in both Optimem and KSFM compared to E-med. 
However, it was noticed that proliferation rates were also reduced in cells cultured with 
Optimem and KSFM compared to E-med. Therefore, the luciferase activity was re-
calculated after normalisation for cell number. The results showed similar levels of 
luciferase activity for cells cultured with E-med and Optimem. In contrast, the luciferase 
activity was still significantly reduced when cells were grown in KSFM (Figure 20). 
Based on these results, Optimem medium was chosen for the study.   
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Figure 20: Levels of infectivity in NIKS cultured in different media 
Cells were seeded in E-medium onto 96 well plates, the following day the medium was changed 
and pseudovirions were added 6 hours later at a concentration of 1 vge/cell. Luciferase activity 
was measured 48 hours later; shown are RLU normalised to E-medium in a) and normalised to 
cell number in b), mean ± SEM, ***p < 0.001, Kruskal-Wallis test, followed by Dunn’s multiple 
comparison test, n = 3 in quadruplets.  
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To analyse the effect of pre-stimulation with IL-7 and IL-15 on infectivity, control cells 
were seeded in E-medium and the medium was changed to Optimem the next day. 
After 6 hours, the cytokines were added at 100ng/ml to the Optimem. 24 hours post-
stimulation, the cells were infected with pseudovirions at a concentration of 5 vge/cell. 
Luciferase activity was measured 48 hours post-infection. Cells challenged with IFN-β 
were used as a positive control as infectivity with HPV pseudovirions is reduced by this 
stimulation (280). 
The results showed that infectivity was reduced following stimulation with IFN-β. In 
contrast, no differences in infectivity were observed in cells challenged with IL-7 or IL-
15 compared to unchallenged cells (Figure 21), suggesting that neither IL-7 nor IL-15 
provided a protective effect from HPV infection.  
 
 
 
Figure 21: Infectivity with pseudovirions after stimulation with γ-chain cytokines 
Control cells were seeded onto 96 well plates, the following day the medium was changed to 
Optimem and cytokines were added at 10 ng/ml (low) and 100 ng/ml (high) 6 hours later, the 
following day cells were infected with a concentration of 5 vge/cell and luciferase activity was 
measured 48 hours later, values were normalised to unstimulated, mean ± SEM, * p < 0.01, 
Kruskal-Wallis test, followed by Dunn’s multiple comparison test, n = 3, in quadruplets. 
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4.5 Proliferation is not changed between different NIKS 
cell lines 
As cells need to be proliferating in order for a PV infection to be established (281), it 
was possible that differences in proliferation might explain infectivity differences. To 
test this, cell proliferation was compared between the scr control cells and KD cells. 
BrdU – a synthetic analogue of thymidine – incorporation assays were carried out as 
these are indicative of DNA synthesis (see 2.2.1.8 and 2.2.1.9).  
There were no differences in proliferation rate between the scr control and KD cells, as 
seen in two different BrdU incorporation assays lasting for 1 and 18 hours, respectively.  
There was also no difference in proliferation rate in cells stimulated with IL-7 or IL-15 
(Figure 22). This suggested that the differences in viral susceptibility in KD cells with γ-
chain deficiency are not due to hyper-proliferation of the cells.   
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Figure 22: Proliferation of NIKS cell lines 
Monolayer NIKS were incubated with BrdU for 1 h, fixed and stained with an anti-Brdu-Alexa-
488 antibody, representative FC plots (a) and quantification of FC experiments (b), mean ± 
SEM, n = 6, in duplicates; NIKS were seeded on 96 well plates, cultured under serum-free 
conditions for 6 hours and then 100 ng/ml IL-7 and IL-15, respectively, were added as well as 
BrdU. Incorporation of BrdU was detected 18 hours later using a colorimetric reaction measured 
using a plate reader (c), mean ± SEM, n = 3 in quadruplets.   
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4.6 Infectivity using quasivirions is increased in γ-chain 
deficient keratinocytes  
Following the result of the increased infectivity in KD NIKS by pseudovirions, the 
infectivity in KD NIKS by quasivirions was investigated for further confirmation. The 
quasivirions contained the full-length HPV18 genome but no reporter genes such as 
luciferase or eGFP. Therefore, the infectivity cannot be assessed by simple reporter 
gene assays or using GFP expression. One possibility would be to analyse HPV 
genome copy number. However, it is difficult to exclude virions bound to rather than 
contained within the cell using this method. Therefore, the expression of the early 
transcript E1^4 was analysed by qPCR and used as a read-out for HPV infection.  
For the qPCR, a standard was used which corresponded to the 130 bp sequence of the 
HPV18 genome that is flanked by the designed qPCR primers and where the probe 
binds. Serial dilutions of this standard were used to generate a standard curve with an 
R-value of 0.986 and used for determination of E1^4 copy number by qPCR (Figure 
23a).  
To validate the assay, untransduced NIKS were infected with HPV18 quasivirions using 
three different viral concentrations (10, 50 and 100 vge/cell). RNA was collected 48 
hours post infection, reverse transcribed and used for qPCR. The results showed 
increasing E1^4 copies with an increase in viral concentration used (4.9, 14.7 and 35.7 
E1^4 copies per 1,000 GAPDH for concentrations 10, 50 and 100 vge/cell, 
respectively) (Figure 23b). No copies (< 0.3) were detected in the negative, uninfected 
control samples.  
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Figure 23: Validation of E1^4 qPCR assay 
E1^4 primers and a probe were designed and tested using a geneBLOCK standard; the 
standard curve is showing: standards as open circles and tested samples as crosses (a); 
untransduced NIKS were infected with HPV18 quasivirons at concentrations of 10, 50 and 100 
vge/cell, RNA was isolated 48 hours later and used for qPCR, shown are E1^4 copy numbers 
per 1,000 GAPDH copies (b), mean ± SEM, n = 4.  
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The validated qPCR was used to assess infectivity using HPV18 quasivirions. Scr 
control and KD cells were seeded onto 96 well plates and infected with HPV18 
quasivirions. Samples were collected 48 hours later for qPCR analysis. 
There was a significant increase of copy number (34%) in the KD cells compared to scr 
control cells (Figure 24). These results, along with the results obtained from 
pseudovirion infection suggested that γ-chain KD cells are more easily infected than 
scr control cells.  
 
 
 
 
Figure 24: Infectivity in NIKS cell lines using HPV18 quasivirions 
Scr control cells and KD cells were infected with HPV18 quasivirions; 48 hours post infection, 
RNA was isolated and the copy number of E1^4 versus GAPDH were assessed by qPCR, 
mean ± SEM,  *p = 0.03, Wilcoxon matched-pairs signed rank test, n = 6, run in duplicates. 
 
 
  
136 
 
4.7 Discussion 
Even though extensive research has been done to understand how PVs enter the cell, 
the process of infection has still not been fully understood, in particular which receptors 
and mechanisms are involved in the procedure. Pseudovirions and quasivirions have 
been a useful tool for PV research as they enable investigation of the initial stages of 
PV infection such as attachment and entry into the cells. For example, they have been 
used to analyse which cellular factors and receptors are necessary for the infectivity of 
papillomaviruses. It is known that differences in proliferation or autophagy, stimulation 
with IFN-β and blocking certain signalling pathways can affect infectivity. For example, 
an increase in proliferation leads to increased infectivity whereas stimulation with IFN-β 
decreases it. Blocking autophagy also enhances infectivity whereas blocking EGFR, 
PKC and PI3K completely or partially blocked infection (91, 280-282). 
In this chapter, we set out to test whether γ-chain knock-down alters HPV infectivity. 
Infectivity with VLPs was analysed in control and γ-chain deficient keratinocytes. 
Increased infectivity in KD cells infected with pseudovirions was confirmed by 
measuring luciferase activity. Similar results were observed in KD cells infected with 
quasivirions assessed by the copies of the E1^4 mRNA. This suggests that absence of 
γ-chain leads to an increase in HPV infectivity in keratinocytes. We, next, carried out 
experiments to identify the reasons for the differences in infectivity seen. We initially 
postulated that cytokine signalling through the γ-chain could alter HPV infectivity but, 
pre-stimulation with IL-7 and IL-15 did not affect the infectivity in WT KC.  
Differences in proliferation can account for differences in infectivity as cell cycle 
progression is necessary for viral establishment in cells (281). However, we did not 
observe any differences in proliferation rate as measured by BrdU incorporation 
between scr control and KD cells in our system. In addition, we also did not see any 
changes of BrdU incorporation after IL-7 or IL-15 stimulation in our study. This is in 
agreement with results from Ruckert et al., who saw that IL-15 stimulation did not affect 
proliferation but inhibited apoptosis in primary human foreskin keratinocytes (283). 
However, Yano et al. reported that stimulation of the keratinocyte cell line HaCaT with 
IL-15 for 24 hours led to a significant increase in BrdU incorporation (259). They further 
found that the use of inhibitors MEK or PI3K could block the effect of IL-15 stimulation, 
so concluded that the effect on cell proliferation was due to the activation of the 
MEK/ERK1/2 and PI3K/AKT pathway. The different results might be explained by the 
use of different cell lines in both studies. Here, we used NIKS and Yano et al. 
employed HaCaT. Both cell lines are spontaneously immortalised keratinocytes but 
they have distinct genetic changes from wild-type cells and are derived from different 
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parts of the body: HaCaT cells were isolated from full thickness adult male human skin 
and NIKS transformed from new-born human foreskin (255, 284). Therefore, both cell 
lines are genetically different and these differences might lead to differences in the 
response to IL-15 stimulation.  
Although our data suggests increased infectivity in γ-chain deficient keratinocytes, the 
mechanism for this could not be determined within the time frame of this project. 
Potential mechanisms could be that γ-chain affects a) uptake or one of the signalling 
pathways involved, b) autophagy or c) regulation of expression of receptors that are 
important for HPV uptake.  
For HPV16, whose capsid was used in the pseudovirions experiments, it was shown 
that entry is clathrin-, caveolin-, flotillin-, cholesterol- and dynamin-independent but 
rather dependent on actin dynamics and tyrosine and serine/threonine kinase 
signalling. In addition, PAK-1, PKC and PI3K signalling was required for the endocytic 
internalisation (91). Signalling via the γ-chain can impact signalling of PI3K and other 
kinases, therefore, this might be the link with the increase of infectivity in KD cells. In 
addition, an increased host autophagy leads to a reduction in infectivity (282). No link 
has been described between γ-chain signalling and autophagy but this is a potential 
route of experiments that can be followed in future work. 
As it is not known which secondary receptor is necessary for successful entry of HPV 
(90) a potential involvement of the γ-chain and its co-receptors on the level of binding 
and/or entry cannot be ruled out. Therefore, it would be of interest to examine HPV 
surface binding and internalisation into the endocytic compartment using fluorescently 
labelled PV pseudovirions and super resolution microscopy (91, 285).  
In addition, as briefly mentioned in the introduction to this chapter, we used the pShell 
plasmid of a mucosal HPV type for these experiments and not of a cutaneous HPV 
type. Therefore, the results obtained here cannot be directly translated to cutaneous 
HPV types. The number of experiments done with cutaneous HPV types especially in 
comparison to mucosal types is limited. In a recent publication, Kwak et al. compared 
different mucosal and cutaneous HPV types and different inhibitors and their effect on 
infectivity using pseudovirions (279). They identified differences between mucosal and 
cutaneous HPV types in response to various inhibitors using 293TT cells. This 
potentially explains the different tissue tropism of the HPV genera due to potentially 
different cell surface receptor interactions. As these variations in interactions might 
impact the results obtained in this chapter, it will be necessary to repeat experiments 
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using different types of packing plasmids even though there are still difficulties using 
VLP made with capsid proteins from cutaneous HPV types in keratinocyte cell lines.  
As the main effect analysed here is due to the packing plasmids and therefore cell 
entry, the use of the HPV18 plasmid in the quasivirion experiments compared to using 
a cutaneous type virus might be negligible. Here, we did not analyse the effect of 
HPV18 expression on the cell itself. However, HPV18 – as a strong mucosal type – 
might be more highly expressed than cutaneous HPV types therefore making detection 
easier. To rule out any effects the use of the HPV18 genome might have had, it would 
be best to repeat these experiments using both pseudovirions made with pShell 
plasmids from cutaneous types and with quasivirions expressing both packing and 
expression plasmids from cutaneous types.     
In conclusion, this chapter shows first evidence that the absence of the γ-chain can 
lead to an increased infectivity with HPV particles. This result is interesting, as 
increased infectivity in X-SCID patients could explain the high number of patients 
affected compared to healthy populations as well as give an explanation for the great 
number of affected sites. However, further work needs to be done in order to 
understand the mechanisms of this defect.  
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5. Control of HPV is altered in 
keratinocytes lacking 
functional -chain 
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5.1 Introduction 
The HPV life cycle is closely linked to the differentiation programme of keratinocytes 
(55). In order to investigate the influence of HPV on keratinocyte biology, it is therefore 
necessary to use systems which allow for keratinocyte proliferation and differentiation 
to recapitulate the full viral life cycle. 
The use of organotypic rafts generated using the immortalised NIKS keratinocyte cell 
line has made this possible. NIKS are a spontaneously immortalised human foreskin 
keratinocyte cell line that displays normal differentiation properties. They can be 
cultured in the organotypic raft system which allows cells to undergo proliferation and 
differentiation processes. These processes have been shown to support the life cycle 
of different HPV types including HPV16, 18 and 58 (101, 255, 286). In addition, it was 
confirmed that NIKS cells express wild-type p53 and pRb which are two of the main 
cellular proteins influenced by HPV (287).  
In order to mimic skin using raft cultures, a collagen-fibroblast matrix is used to 
represent the dermis (“dermal equivalent”) onto which keratinocytes are seeded. Once 
the keratinocytes reach confluency to form a continuous layer representing the basal 
skin layer, the raft is lifted so that the keratinocytes are exposed to an air/liquid 
interface. This leads to cell differentiation and two weeks post lifting, a cornified layer is 
formed (287).  
To examine the HPV life cycle, rafts can be stained for different HPV life cycle markers 
such as the surrogate marker for HPV E6/E7 minichromosome maintenance protein 
(MCM) 7 and the HPV proteins L1 and E4 using immunofluorescence techniques. 
Presence of the capsid protein L1 detects the virus assembly. Alternatively, 
fluorescent-in-situ-hybridisation (FISH) can be used to detect the onset of HPV genome 
amplification. In addition, parameters for HPV activity such as suprabasal DNA 
synthesis can be examined. Clinically, tissues from patients can be stained in the same 
way and the expression of these markers used to examine disease severity. E4 
expression declines when lesions progress to higher severity and can be absent in 
high-grade clinical lesions, but E7 expression and therefore MCM7 and p16 are still 
present or increased (55, 288, 289).  
As we hypothesized that absence of γ-chain has an influence on HPV in situ, we 
examined whether the HPV life cycle in rafts made with γ-chain deficient cells differs 
from the life cycle in rafts made with control cells. The rafts in this chapter were made 
according to the protocol by Lambert et al. (287). As for the VLP experiments in the 
previous chapter, we used HPV18 for the experiments using rafts. This is because 
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NIKS do not always maintain the cutaneous HPV types when they are transfected 
which is a vital requirement for raft studies (personal communication P.F. Lambert). In 
addition, HPV18 – as previously mentioned – is an easily tractable system as it is 
usually replicated in high quantities in transfected cells and antibodies for its E4 protein 
and probes for its detection by Southern blot and FISH were available for this project.  
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5.2 γ-chain deficiency in keratinocytes does not influence 
keratinocyte proliferation and differentiation in 
organotypic raft cultures  
Before analysing the effects of HPV on keratinocyte growth in organotypic rafts, 
proliferation and differentiation markers were first examined to see whether there were 
any differences between rafts using scr control or γ-chain deficient keratinocytes. 
Rafts were made, harvested and H&E stained to check for correct tissue processing 
and differentiation of keratinocytes (Figure 25). They were then immunofluorescence 
stained with antibodies for BrdU, Keratin-10 (K10), Keratin-14 (K14) and Loricrin (see 
2.2.1.13 and 2.2.4).  
Keratinocyte proliferation and differentiation markers K14, K10 and Loricrin were 
expressed in the rafts within their expected localisation (Figure 26a). K10 staining was 
evenly distributed throughout all layers except the basal layer as it is a marker for 
commitment to differentiation. K14 staining was strong in the basal layer and its 
intensity decreased towards more differentiated layers. Loricrin – a marker for terminal 
differentiation – was expressed in the upper layers of the rafts. No differences were 
observed between the control and the KD cells indicating that γ-chain deficiency does 
not affect keratinocyte differentiation without HPV present (Figure 26a). 
In addition, rafts were stained with an anti-BrdU antibody as their culture medium was 
supplemented with BrdU 8 hours prior to harvesting. The results showed that only cells 
in the basal and parabasal layers were positively stained for BrdU incorporation but no 
BrdU positive cells were found in the suprabasal layers as proliferation under normal 
circumstances only occurs in the basal layer. There was no significant difference in 
terms of BrdU positive cells between rafts made with scr control cells or KD cells 
(Figure 26b).  
These results suggested that γ-chain does not affect keratinocyte proliferation and their 
differentiation process.   
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Figure 25: H&E staining of HPV negative rafts 
Scr control and KD cells were used to make organotypic raft cultures. Rafts were harvested and 
H&E stained, representative image for each raft.  
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Figure 26: Keratin-10, Keratin-14, Loricrin and BrdU staining in HPV negative rafts 
Scr control and KD cells were used to make organotypic raft cultures. 8 hours before 
harvesting, growth medium was supplemented with BrdU. Rafts were harvested and stained for 
K10, K14 and Loricrin (green), BrdU (red on the images with K10) and DAPI (blue), 
representative images (a) and quantification of BrdU positive cells (b), six images per raft were 
analysed, n = 3.  
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5.3 HPV genomes are maintained over multiple passages 
in scr control and KD NIKS 
Once HPV infects cells, HPV genomes are maintained in cells as episomes. For 
research purposes, keratinocytes are transfected with HPV genomes in order to mimic 
this phenotype. In order to establish HPV genomes in NIKS, cells were transfected with 
the recircularised HPV18 genome (see Chapter 4.2) as well as a blasticidin plasmid to 
enable selection. Extrachromosomal DNA was extracted from blasticidin-selected cells 
and analysed for the presence of HPV genomes by Southern blot (see 2.2.3.8 and 
2.2.3.9). 
For both the scr control and the KD cells presence of HPV genomes were shown by 
Southern blot. The HPV18 genome is replicated extrachromosomally as indicated by 
the presence of the open circular and supercoiled forms in both samples (Figure 27a, 
HindIII digested samples showing the plasmid in undigested forms as HindIII does not 
cut the HPV genome). The linearised sample (NcoI digested) was used to calculate the 
copy number compared to the loaded standards. For both control and KD cells, the 
copy number was approximately 5 copies per cell (Figure 27a).  
To examine whether the HPV genome was maintained in transfected cells over a 
prolonged period of time, NIKS were cultured with mitomycin C treated 3T3 feeder cells 
and propagated for 9 passages. Extrachromosomal DNA was isolated from cells at 
each passage and subjected to Southern blot analysis. HPV18 genomes were 
maintained in transfected cells for at least 9 passages. The copy numbers were around 
5 copies per cells for all samples tested. No differences were observed between scr 
control and KD cells. Variation in the band intensities were due to differences in DNA 
amount loaded as seen on the agarose gel (Figure 27b). 
In conclusion, HPV18 genomes were maintained in both control and KD cells at similar 
levels for prolonged time periods. This result suggests that γ-chain deficiency does not 
influence HPV maintenance in cells under these conditions. 
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a)  
 
 
b)      c) 
 
Figure 27: Maintenance of HPV18 genomes in transfected NIKS cells 
Scr control and KD NIKS were transfected with recircularised HPV18 genomes and a blasticidin 
resistance plasmid and selected with blasticidin. Blasticidin resistant cells were used for 
experiments. Extrachromosomal DNA was isolated and digested with NcoI which cuts the 
HPV18 genome once or HindIII which does not cut the HPV18 genome. Samples were also 
digested with DpnI which cuts only bacterial DNA. Digested DNA samples were separated by 
agarose gel electrophoresis and further used for Southern blot with a probe against the HPV18 
genome. Linearised plasmid DNA was used as standards (labelled with copy number), shown 
are passage 0 (a) and multiple passages (b, only digested with NcoI + DpnI), (c) shows agarose 
gel for (b).  
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5.4 HPV does not affect the proliferation in γ-chain 
deficient keratinocytes cultured as a monolayer  
HPV infection of keratinocytes can affect cell proliferation and therefore, we wanted to 
test if presence of HPV can affect the proliferation of cells in monolayer. Similarly to the 
experiment in Chapter 4.5., a BrdU incorporation assay was performed to analyse DNA 
synthesis in NIKS grown in monolayers.  
No difference was seen between scr and KD cells transfected with HPV18 (Figure 28), 
suggesting that at least in cells grown in monolayers, which would be representative of 
the basal cells in the skin, γ-chain absence does not affect cell proliferation.  
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Figure 28: DNA synthesis in HPV18 positive NIKS cell lines infected with HPV18 
NIKS cells cultured as monolayer were incubated with BrdU for 1 h, fixed and stained with an 
anti-Brdu-Alexa-488 antibody. Representative FC plots (a) and quantification of FC experiments 
are shown (b), mean ± SEM, n = 6, in duplicates. 
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5.5 Presence of HPV18 affects the differentiation and 
proliferation of rafts made with γ-chain deficient 
keratinocytes  
We, then, used the HPV18 positive NIKS cells to make organotypic rafts. They were 
used to assess differentiation and proliferation using immunofluorescence staining for 
BrdU, K10, K14 and loricrin in the same way as for HPV negative rafts. 
The rafts generated using HPV18 positive NIKS showed similar morphology to HPV 
negative rafts as seen from H&E stained sections. In addition, no obvious differences in 
morphology were observed between scr control and KD cells (Figure 29a).  
In order to assess, proliferation and differentiation markers, we stained for K10, K14, 
Loricrin and BrdU. K14 staining seemed to be more intense in HPV18 positive rafts 
compared to HPV18 negative rafts (Figure 29b compared to Figure 26) but there were 
no differences between the scr control and KD rafts. For Loricrin, the staining seemed 
to be in fewer cells in HPV18 positive cells compared to HPV negative cells, but again 
there were no differences between the scr control and KD rafts. This suggests that 
differentiation occurs in rafts despite presence of HPV18 but that HPV is able to disturb 
this process. However, absence of γ-chain does not affect expression of these two 
markers.  
We then analysed the expression of K10 in these rafts. Similarly to K14 and Loricrin, 
K10 expression differed in HPV18 positive rafts. Here, it was not as even as seen in 
HPV negative rafts showing again HPV18’s ability to disturb the differentiation of 
keratinocytes (Figure 30 compared to Figure 26). When examining the images in more 
detail, it became apparent that in KD rafts the staining was more disturbed than in 
control rafts. The different staining patterns were grouped into three categories: i) 
“organised” which meant even staining similar to the staining observed in HPV negative 
rafts; ii) “slightly disorganised” where strong staining was present throughout the rafts 
but differed in the different layers and was generally patchy and iii) “extremely 
disorganised” which meant staining that was very weak or missing in large part of the 
images analysed. The differences between the images grouped into each category was 
significantly different indicating that differentiation is more disturbed by the presence of 
HPV genomes in the absence of γ-chain compared to the control cells (Figure 30 a + 
b).  
The number of BrdU positive nuclei was analysed to see actively proliferating cells. In 
contrast to HPV negative rafts where no positive nuclei were seen in suprabasal layers, 
a high proportion of them was seen in the HPV positive rafts. This shows how the 
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presence of HPV dysregulates the normal life cycle of keratinocytes. When the total 
number of BrdU positive cells was compared, no differences were seen between the 
control and the KD cells. However, when we compared suprabasal DNA synthesis, a 
significantly higher number of BrdU positive nuclei was present in KD cells compared to 
control cells (1.96 ± 0.25% vs. 3.18 ± 0.54%) (Figure 31).  
In conclusion, in γ-chain deficient cells suprabasal DNA synthesis is increased and 
differentiation is more disturbed than in control cells which suggests that γ-chain in 
cells is important for the control of HPV induced effects.  
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b)
 
Figure 29: H&E staining and Keratin-14 and Loricrin staining of HPV18 positive rafts 
Scr control and KD cells transfected with HPV18 were used to generate organotypic raft 
cultures. Rafts were harvested and a) H&E stained and b) stained for K14 and Loricrin (green) 
and DAPI (blue), representative images, six images per raft were analysed, n = 4. 
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Figure 30: Keratin-10 and BrdU staining of HPV18 positive rafts  
Scr control and KD cells transfected with HPV18 were used to generate organotypic raft 
cultures. 8 hours before harvesting, growth medium was supplemented with BrdU. Rafts were 
harvested and stained for K10 (green), BrdU (red) and DAPI (blue), representative images for 
each of the three categories (a) and categorisation of K10 staining (b), six images per raft were 
analysed, n = 4. 
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Figure 31: Quantification of BrdU positive cells in HPV18 positive rafts 
The number of BrdU positive nuclei was counted and compared to the total number of cells, for 
all layers (a) and for the suprabasal layers only (b), *p < 0.05, Mann-White test, six images per 
raft were analysed, n = 4.  
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5.6 γ-chain deficiency in keratinocytes does not affect 
HPV18 life cycle in organotypic rafts 
After seeing differences in the differentiation marker K10 and suprabasal DNA 
synthesis between rafts made with γ-chain deficient and scr control NIKS, we wanted 
to confirm whether HPV could undergo its normal life cycle in cultured rafts and 
whether any changes were observed here. To do this, matured rafts were stained for 
MCM7 and E4 protein expression and FISH for HPV18 genome amplification was 
performed.  
E4 protein was expressed in the upper layers of the HPV18 positive rafts whereas 
MCM7 (a surrogate marker for expression of the HPV E7 protein) was expressed in 
these rafts through all layers in the cell nuclei. MCM7 is a cellular protein which is 
upregulated by the expression of HPV and very faint expression of it was also seen in 
the nuclei of cells in the lower layers of HPV negative rafts (shown with white arrows 
pointing to positive cells). There were no differences in the expression of HPV18 E4 as 
well as MCM7 between the scr control and KD rafts (Figure 32a).  
As HPV DNA synthesis is strongly upregulated in the upper layers of the skin shortly 
before virions are packaged and shed, FISH positive cells were detected in the 
suprabasal layers of the rafts. This indicates presence of HPV genomes in many cells 
in the upper layers of the raft. The number of FISH positive cells was counted and 
compared to the number of total cells. There was no significant difference between the 
control and KD cells (15.25 ± 1.08% vs. 12.97 ± 1.19%, p = 0.2), suggesting γ-chain 
deficiency does not affect HPV life cycle (Figure 32b) under these conditions.  
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Figure 32: Expression of HPV markers E4 and MCM7 and fluorescent-in-situ 
hybridisation (FISH) for HPV18 genome expression in matured rafts 
Organotypic raft cultures were generated using HPV18 positive or HPV negative NIKS cells as 
control. Matured rafts were stained with antibodies against HPV18 E4 (green, a) and MCM7 
(red, white arrows pointing to positive cells in negative control, a). FISH assay was performed 
using a probe against HPV18 (red, a). The number of FISH-positive cells was counted and 
calculated as a percentage of all cells in the optical image (b), six images per raft were 
analysed, n = 4.   
155 
 
5.7 Discussion 
Rafts are a useful tool to analyse the complete HPV life cycle in a 3D setting and have 
led to vital discoveries about the role of the HPV oncogenes E6 and E7 and their ability 
to influence the host cells. They were, for example, used to show that the E7 protein of 
HPV16 is important for the productive stage of the HPV life cycle (290). 
Here, we show that in rafts made using γ-chain deficient cells or control cells without 
HPV expression, there are no differences in differentiation and proliferation markers 
tested. In contrast, when γ-chain deficient cells transfected with HPV18 are used to 
make rafts, suprabasal DNA synthesis is increased and normal expression patterns of 
K10 are more disturbed than in rafts made with HPV18 positive control cells. In 
contrast, neither K14 and Loricin nor any of the HPV markers analysed (E4 expression, 
MCM7 as marker for E6/E7 expression and FISH for HPV genome amplification) 
showed any differences. These results suggest that even though the life cycle of 
HPV18 itself is not different in γ-chain deficient keratinocytes, its presence leads to a 
more pronounced effect on keratinocyte proliferation and differentiation.  
It has been long known that HPV16 and 18 in particular are able to alter the expression 
of proliferation and differentiation markers in raft cultures but that the effect was also 
dependent on the cell line used for the study (291). Especially the function of E7 has 
been linked to the uncoupling of differentiation and proliferation leading to suprabasal 
DNA synthesis which is not observed in HPV negative rafts (292). 
However, there are – to our knowledge – no previous studies looking at the effect of 
the γ-chain or any of its associated cytokines in organotypic rafts. In fact, cytokine 
signalling has not been studied using organotypic rafts. Therefore, no comparisons with 
other publications can be made. 
There are a few studies looking at the changes of differentiation using rafts but mostly 
both K10 and K14 expression are disturbed. Interestingly, in a study using primary 
keratinocytes transduced with E7 proteins of the low-risk HPV types such as HPV1, 4 
and 38, rafts displayed changes in K10 expression but K14 expression was normal. In 
addition, they also observed an increase in the proliferation of the basal layer using 
these cells. However, the paper did not make any statements about the reasons for the 
changes in differentiation (293).  
It is important to also consider that NIKS are spontaneously immortalised cells. That 
means even though they are very similar to primary foreskin keratinocytes in many 
aspects, it is still unknown which cellular processes are disrupted and are contributing 
to their immortalisation. Therefore, it would be necessary to use primary keratinocytes 
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to repeat this experiment to rule out any influences of the used cell line. In addition, it 
would be useful to obtain tissue samples from X-SCID patients, especially from areas 
affected by warts and stain them. Doing so was initially planned for this project. 
However, due to difficulties, the previously collected patient samples were not available 
for staining until the end of this project. 
In addition, whereas the use of the HPV18 plasmid in the VLP experiments might have 
low impact on the comparability with cutaneous HPV types, it is important in the 
organotypic rafts as here the effects of the virus on the cell itself were analysed. The 
mucosal types, especially HPV16, 18 and 31, have been widely studied and most 
effects of the HPV E6 and E7 proteins on cellular proteins such as p53 and pRb are 
only observed using the high risk mucosal types but not low risk mucosal HPV types or 
cutaneous HPV types. This means that the results obtained in this chapter are only true 
in the context of HPV18 infection and cannot directly be transferred to cutaneous HPV 
types and therefore infections in X-SCID patients. As it can be assumed that the effect 
of cutaneous types would be reduced compared to HPV18 and as some of the effects 
seen here were relatively mild, the effects of cutaneous HPV types in γ-chain deficient 
cells compared to healthy control cells might be negligible and not relevant in a patient 
setting. However, this remains to be tested.  
This means that further work is needed to confirm the results and to identify potential 
reasons for the changes in proliferation and differentiation observed, e.g. which of the 
HPV proteins is responsible. To test this, it would be possible to transduce 
keratinocytes with retroviral or lentiviral vectors expressing either E6 or E7 
oncoproteins to identify the effects they have on these processes. 
In conclusion, we observed changes in proliferation and differentiation in rafts made 
using γ-chain deficient HPV18 positive compared to control cells. This could explain a 
more severe phenotype seen in patients as the disruption of normal skin morphology 
was more disturbed in the γ-chain deficient setting.  
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6. Chemokine secretion in -
chain deficient keratinocytes 
is altered and reduces 
immune cell recruitment  
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6.1 Introduction 
Keratinocytes are important immune sentinels and they are able to secrete a variety of 
chemokines and cytokines when they are stimulated. These chemokines, e.g. IP-10, 
Mig, RANTES and Mip-3α, can recruit a wide range of immune cells to the site of 
infection (45).  
Chemokines and cytokines are important to fight infection and HPVs have developed 
strategies to interfere with their secretion. It has been shown for HPV16, 18 and 31 that 
they can repress the secretion of IL-8 and Mip-3α after stimulation with TLR9 ligands 
(108, 109, 124) resulting in reduced numbers of immune cells in HPV positive lesions.  
The involvement of common γ-chain cytokines in the stimulation of chemokine and 
cytokine secretion has been shown for other cell types. In a patient with a mutation in 
IL-21R, the secretion of GM-CSF, IFN-γ, IL-10, Mip-3α and TNF-α from T cells was 
reduced compared to healthy control cells after stimulation with IL-21 (233). Studies 
have also shown that IL-15 signalling induces MCP-1, TNF-α and RANTES secretion in 
myeloid cells (294). Therefore, changes in the secretion of cytokines and chemokines 
might be of importance in X-SCID patients leading to their susceptibility to HPV 
infections.   
Regressing wart lesions are usually associated with an influx of T cells. In various 
animal models (BPV-4, CRPV-2 and COPV), both CD4+ and CD8+ T cells are present 
in regressing lesions with CD4+ T cells being the dominant type and double knock-out 
of CD4+ and CD8+ T cells is required for formation of wart lesions in all mouse models 
(133-135, 144, 151). In humans, CD4+ T cells have also been reported to be the cell 
type associated with mucosal wart regression (136, 295-297). 
We, therefore, hypothesized that there are changes in chemokine and cytokine 
secretion either after infection with HPV quasivirions, after stimulation with γ-chain 
dependent cytokines or in cells stably transfected with HPV18. These changes might 
lead to differences in migration of various immune cells such as neutrophils, dendritic 
cells and T cells. We used cytokine arrays and Luminex assays to assess the secretion 
of chemokines and cytokines from control and KD cells after various stimuli and 
examine their influence on immune cell migration.  
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6.2 Cytokine and chemokine secretion is not changed after 
infection with HPV quasivirions  
First, cytokine secretion in NIKS cell lines 24 hours post infection with HPV quasivirions 
was tested. The quasivirions described in Chapter 4.3 were used for this experiment. 
To identify potential target cytokines for further experiments, the Proteome Prolifer™ 
assay which includes a membrane upon which 36 different capture antibodies have 
been spotted in duplicate was used. The intensity of the detected spots was analysed 
by ImageJ using densitometry. The media from scr control cells infected with 
quasivirions at a viral concentration of 100 vge/cell or uninfected cells was collected 24 
hours post-infection. The collected supernatants were analysed for cytokine secretion 
(Table 15). 
MIF, IL-8, Gro-α, Serpin E1 and low levels of IL-1ra were detected in the supernatant of 
the keratinocytes. However, none of these cytokines showed a different secretion 
pattern in the virus infected cells compared to the uninfected cells (Figure 33). 
Therefore, initial virus infection was not shown to alter cytokine secretion at early time 
points.  
 
Figure 33: Secreted cytokines and chemokines after infection with HPV18 quasivirions 
Scr control cells were infected with HPV18 quasivirions at a viral concentration of 100 vge/cell. 
24 hours after infection, cell culture supernatants were collected and used for a cytokine array 
according to suppliers guidelines, RS = reference spot.    
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Table 15: Chemokine and cytokine secretion after quasivirion infection 
Full list of cytokines tested in the cytokine array. Y = yes, N = No. 
Coordinate Target/Control Present? (Y/N) Differences 
A1, A2 Positive Control Y N 
A3, A4 C5/5a N -- 
A5, A6 CD40 Ligand N -- 
A7, A8 G-CSF N -- 
A9, A10 GM-CSF N -- 
A11, A12 Gro-α Y N 
A13, A14 I-309 N -- 
A15, A16 sICAM-1 N -- 
A17, A18 IFN-γ N -- 
A19, A20 Positive Control Y N 
B3, B4 IL-1α N -- 
B5, B6 IL-1β N -- 
B7, B8 IL-1ra Y N 
B9, B10 IL-2 N -- 
B11, B12 IL-4 N -- 
B13, B14 IL-5 N -- 
B15, B16 IL-6 N -- 
B17, B18 IL-8 Y N 
C3, C4 IL-10 N -- 
C5, C6 IL-12 p70 N -- 
C7, C8 IL-13 N -- 
C9, C10 IL-16 N -- 
C11, C12 IL-17 N -- 
C13, C14 IL-17E N -- 
C15, C16 IL-23 N -- 
C17, C18 IL-27 N -- 
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D3, D4 IL-32α N -- 
D5, D6 IP-10 N -- 
D7, D8 I-TAC N -- 
D9, D10 MCP-1 N -- 
D11, D12 MIF Y  N  
D13, D14 Mip-1α N -- 
D15, D16 Mip-1β N -- 
D17, D18 Serpin E1 Y N 
E1, E2 Positive Control Y N 
E3, E4 RANTES N -- 
E5, E6 SDF-1 N -- 
E7, E8 TNF-α N -- 
E9, E10 sTREM-1 N -- 
E19, E20 Negative Control N -- 
  
162 
 
6.3 Cytokine array shows cytokines and chemokines 
differentially secreted after IL-7 and IL-15 stimulation 
Because changes in cytokine secretion after infection with HPV quasivirions were 
seen, we decided to test whether stimulation with γ-chain cytokines would lead to 
changes in secretion. This is particularly relevant as in a model for epidermal injury 
upregulation of IL-15 was shown and HPV is only able to enter the skin via micro-
injuries (298). Therefore, it is likely that there would be an increase in the IL-15 
concentration at the site of viral entry.  
Untransduced NIKS were cultured for 6 hours in serum free medium and then 
stimulated with 100 ng/ml IL-7 and IL-15, respectively, in serum free medium for 24 
hours. The supernatants were analysed using the same Proteome Prolifer™ assay as 
in the previous experiment.  
On all membranes we detected – similarly to the previous experiment – Gro-α, IL-1ra, 
IL-8, MIF and Serpin E1 as well as the three positive reference spots after short 
exposure times indicating high concentrations of these cytokines present. Out of these 
five cytokines, IL-1ra increased 1.2-fold following IL-7 and 1.3-fold following IL-15 
stimulation. Gro-α was increased 1.3-fold and IL-8 1.2-fold in IL-15 stimulated cells but 
no change was seen in IL-7 stimulated cells. MIF and Serpin E1 did not show any 
differences in the secreted levels following stimulation (Figure 34 and Table 16).  
In order to detect cytokines that were present at lower levels, we developed the 
membrane longer to increase the intensity of detected spots. CD40 ligand, sICAM-1, 
IL-1α, IL-6, IL-13 and IP-10 were detected in all samples. IL-13 was not influenced by 
any of the stimuli whereas the other cytokines were increased to varying extents 
following stimulation (Table 16). 
IL-23, IL-27, RANTES and TNF-α were not detected in the unstimulated samples but 
they were detected after both IL-7 and IL-15 stimulation, while GM-CSF, I-309, IL-16 
and I-TAC were only detected in IL-15 stimulated samples. 
These results suggest that stimulation of keratinocytes with γ-chain cytokines can 
induce changes in cytokine and chemokine secretion. 
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Figure 34: Secretion of cytokines in untransduced NIKS after IL-7 and IL-15 stimulation  
NIKS cells were cultured in serum-free medium for 6 hours and then stimulated with 100 ng/ml 
IL-7 and IL-15, respectively. The samples were analysed using a cytokine array. Shown are 
cytokine arrays developed for 1 minute (left) or 10 minutes (right).  
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Table 16: Quantification of the cytokine array after IL-7 and IL-15 stimulation  
The cytokine array was analysed with densitometry using ImageJ; N = not present, Y = present; 
if present in unstimulated samples the fold change for stimulated samples are shown in the 
respective fields of the table; cytokines secreted following stimulation but not present in 
unstimulated cells are indicated with a Y in the relevant column, cytokines increased following 
stimulation are marked with a green square; marked in bold are strongly expressed cytokines. 
 
Coordinate Target/Control Unstim IL-7 IL-15 
A1, A2 Positive Control Y  Y  Y  
A3, A4 C5/5a N  N  N  
A5, A6 CD40 Ligand  Y   2.3x _ 1.6x _ 
A7, A8 G-CSF N  N  N  
A9, A10 GM-CSF  N  N  Y _ 
A11, A12 Gro-α Y 1.0x 1.3x _ 
A13, A14 I-309 N  N  Y _ 
A15, A16 sICAM-1 Y  1.1x _ 1.4x _ 
A17, A18 IFN-γ N  N  N  
A19, A20 Positive Control Y  Y   Y  
B3, B4 IL-1α Y  1.1x _ 1.6x _ 
B5, B6 IL-1β N  N  N  
B7, B8 IL-1ra Y  1.2x _ 1.3x _ 
B9, B10 IL-2 N  N  N  
B11, B12 IL-4 N  N  N  
B13, B14 IL-5 N  N  N  
B15, B16 IL-6 Y  1.0x 1.3x _ 
B17, B18 IL-8 Y  1.0x 1.2x _ 
C3, C4 IL-10 N  N  N  
C5, C6 IL-12 p70 N  N  N  
C7, C8 IL-13 Y  1.0x 1.0x 
C9, C10 IL-16 N  N  Y _  
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C11, C12 IL-17 N  N  N  
C13, C14 IL-17E N  N  N  
C15, C16 IL-23 N  Y _ Y _ 
C17, C18 IL-27 N  Y _ Y _ 
D3, D4 IL-32α N  N  N  
D5, D6 IP-10 Y  1.7x _ 2.4x _ 
D7, D8 I-TAC N  N  Y _ 
D9, D10 MCP-1 N  N  N  
D11, D12 MIF Y  1.0x 1.0x 
D13, D14 Mip-1α N  N  N  
D15, D16 Mip-1β N N  N  
D17, D18 Serpin E1 Y  1.0x 1.0x 
E1, E2 Positive Control Y  Y  Y  
E3, E4 RANTES N  Y _ Y _ 
E5, E6 SDF-1 N  N  N  
E7, E8 TNF-α N  Y _ Y _ 
E9, E10 sTREM-1 N  N  N  
E19, E20 Negative Control N  N   N  
 
  
166 
 
6.4 IL-8, Mip-3α and Gro-α are induced following 
stimulation with IL-15 
To confirm the cytokine array results, the expression and changes detected in the 
screen were assessed further using a Luminex assay.  
We chose to analyse Gro-α and IL-8 as they were highly expressed in keratinocytes 
and upregulated by IL-15 stimulation. The other two strongly expressed chemokines, 
MIF and Serpin E1 were not further tested as we did not see a change after stimulation 
in the cytokine array.  
From the lower expressed molecules, we picked GM-CSF and TNF-α for further 
analysis as these two are important immune cell regulators and their expression was 
induced by stimulation with γ-chain cytokines. RANTES – a T cell and monocyte 
attractant – which was induced by γ-chain cytokines and IP-10 which was the most 
highly induced chemokine after stimulation were also evaluated. IL-1α was chosen as it 
is often implied to play a role in keratinocyte biology. Additionally, we included Mip-3α 
which was not part of the screen but is known to be released by keratinocytes, modified 
in HPV infection and has been implied to be γ-chain dependent in other cell types (45, 
125, 233).   
Initially, untransduced, scr control and KD cells were used. They were cultured in 
serum-free medium for 24 hours and then stimulated with 100 ng/ml IL-7, IL-15 and 
IFN-γ for 24 hours. Supernatants were collected and analysed for cytokine presence 
using the Luminex system.  
The levels of GM-CSF and TNF-α were below the detection limit in this experiment and 
were therefore defined as not present. Expression of IL-1α was not significantly 
changed by any of the stimuli whereas IP-10 and RANTES were upregulated by IFN-γ 
but not by IL-7 or IL-15 (Figure 35).  
IL-8, Gro-α and Mip-3α were analysed in scr control cells and KD cells after stimulation 
with 100 ng/ml IL-7 and IL-15 for 24 hours. All three chemokines were significantly 
induced after IL-15 stimulation in scr control cells. In contrast, no change was observed 
in KD cells. IL-7 stimulation did not lead to a significant increase in the secretion of 
these chemokines (Figure 36).  
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Figure 35: Secretion of IP-10, IL-1α and RANTES after different stimulations 
Untransduced, scr control and KD NIKS were cultured in serum-free medium for 24 hours, 
before they were stimulated with 100 ng/ml of IL-7, IL-15 and IFN-γ for a further 24 hours, 
supernatants were collected and analysed for the expression of IL-1α (a), IP-10 (b) and 
RANTES (c) using a Luminex bead assay. Results for IP-10 and RANTES are plotted with and 
without IFN-γ, mean ± SEM, n = 3. 
168 
 
a) Gro-α     b) IL-8 
p
g
/m
l
sc
r
sc
r 
+ 
IL
-7
sc
r 
+ 
IL
-1
5
K
D
K
D
 +
 IL
-7
K
D
 +
 IL
-1
5
0
5000
10000
15000
 *
p
g
/m
l
sc
r
sc
r 
+ 
IL
-7
sc
r 
+ 
IL
-1
5
K
D
K
D
 +
 IL
-7
K
D
 +
 IL
-1
5
0
1000
2000
3000
4000
*
 
 
c) Mip-3α 
p
g
/m
l
sc
r
sc
r 
+ 
IL
-7
sc
r 
+ 
IL
-1
5
K
D
K
D
 +
 IL
-7
K
D
 +
 IL
-1
5
0
200
400
600
800
1000
 *
p = 0.06
 
Figure 36: Secretion of Gro-α, IL-8 and Mip-3α after IL-7 and IL-15 stimulation 
Scr control and KD NIKS were cultured in serum-free medium for 24 hours, before they were 
stimulated with 100 ng/ml of IL-7 or IL-15 for a further 24 hours, supernatants were collected 
and analysed for the expression of Gro-α (a), IL-8 (b) and Mip-3α (c) using a Luminex bead 
assay, mean ± SEM, *p<0.05, Kruskal-Wallis test, followed by Dunn’s multiple comparison test, 
n = 6. 
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6.5 Levels of IL-8, Gro-α and Mip-3α secreted by 
keratinocytes are able to attract neutrophils  
As cytokine secretion is reduced after IL-15 stimulation in knock-down cells, it is 
possible that immune cells are attracted to a lesser extent to the site of infection which 
might explain the increased susceptibility of X-SCID patients to HPV infections. It is not 
fully understood which immune cell types are important for the regression of HPV 
induced lesions. From animals models it is known, that the influx of T cells is important 
for lesion clearance and recently, in a patient with Warts, Hypogammaglobulinemia, 
Infections and Myelokathexis (WHIM) syndrome the importance of the myeloid lineage 
was shown (151, 299). Therefore, migration of both myeloid and lymphoid immune 
cells towards the secreted cytokines was analysed. 
As the neutrophil migration assay is the best established migration experiment in our 
laboratory, we first wanted to examine if the secreted levels of IL-8, Gro-α and Mip-3α 
were sufficient to attract neutrophils. 
Neutrophils were isolated from healthy donor blood and used in Dunn Chamber 
experiments (see 2.2.1.18). Migration of neutrophils was tested towards the levels of 
cytokines released from control cells after stimulation with IL-15 (Gro-α: 10 µg/ml, IL-8: 
3 µg/ml and Mip-3α: 1 µg/ml in one mix). fMLP (N-Formylmethionyl-leucyl-
phenylalanine) was used as a positive control for chemoattraction of neutrophils. Data 
was analysed using Icy software, which automatically detects neutrophils as white dots 
over the black background, measures distances travelled and calculates speed and 
directionality.  
The migratory speed of the neutrophils was significantly increased in the presence of 
the cytokine mix compared to no chemoattractant present to similar levels as seen with 
the positive control fMLP. Moreover, the chemotactic index describing the directionality 
of migration was also significantly increased suggesting that the neutrophils migrated in 
a more directional manner (i.e. “in a straight line”) towards the chemokine source 
(Figure 37 and Figure 38). 
This result suggests that the levels of IL-8, Mip-3α and Gro-α secreted by keratinocytes 
are physiologically relevant and are able to significantly attract immune cells. 
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Figure 37: Neutrophil migration towards different chemoattractants 
Neutrophils were used for migration experiments using Dunn chambers. Cells were imaged 
every minute for an hour. a) Cytopsin of neutrophils before plating them on coverslip, black 
scale bar equivalent to 25 μm. The other images show overlays made using ImageJ of all 
captured images with blue being the first image and white being the last image in the time 
series. The highest chemoattractant concentration is located at the top of picture. b) control 
without chemoattract added, c) positive control fMLP used at 100 nM, d) neutrophils migrating 
towards the cytokine mix of 10 μg/ml Gro-α, 3 μg/ml IL-8 and 1 μ/ml Mip-3α. Representative 
images from n = 4 are shown.   
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Figure 38: Neutrophil migration towards different chemoattractants 
Neutrophil migration from Dunn chambers was tracked using Icy. Shown is quantification for 
migration for one donor (a) where each point represents one cell and the mean values of 
individual donors (b) where each dot represents one donor. “Control” = no chemoattractant, 
“cytokines” = cocktail of 10 μg/ml Gro-α, 3 μg/ml IL-8 and 1 μ/ml Mip-3α, fMLP was used at 
100 nM as a positive control, error bars are mean ± SEM, *p<0.05, ***p<0.001, Kruskal-Wallis 
test, followed by Dunn’s multiple comparison test, n = 4. 
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6.6 Dendritic cell migration is stimulated by IL-8, Mip-3α 
and Gro-α 
After seeing a positive effect on neutrophil migration using of IL-8, Gro-α and Mip-3α, 
we went on to test migration of DCs cells towards these cytokines.  
DCs were generated from CD14+ positive cells (see 2.2.1.15) and used for migration 
experiments using the Chemotaxis Slide from Ibidi. Migration was manually tracked 
using ImageJ (see 2.2.1.19).  
For this experiment, we again used the levels of cytokines released from control cells 
after stimulation with IL-15 (Gro-α: 10 µg/ml, IL-8: 3 µg/ml and Mip-3α: 1 µg/ml). This 
time, we compared them to the levels of cytokines released from KD cells stimulated 
with IL-15 (Gro-α: 5 µg/ml, IL-8: 1.5 µg/ml and Mip-3α: 0.5 µg/ml) which were 
approximately equivalent to half quantities released from IL-15 stimulated control cells. 
As DCs migrate slower than neutrophils, images were taken every five minutes and 
acquired overnight.  
The higher concentrations of IL-8, Gro-α and Mip-3α used induced a significant 
increase in DC migratory speed whereas the lower concentrations of the chemokines 
did not. Directionality of migration was not changed for either condition (Figure 39). 
This suggests that in initial stages of infection, DCs might not be recruited as efficiently 
to the site of infection in X-SCID patients compared to healthy individuals resulting in 
an ineffective initial response to infection.  
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Figure 39: Dendritic cell migration towards Gro-α, IL-8 and Mip-3α 
DCs were generated from CD14+ positive cells and used for migration experiments using 
Chemotaxis Slides from Ibidi. Cells were imaged every five minutes overnight, cell migration 
was manually tracked using ImageJ, shown is quantification for migration for one donor (a) 
where each dot represents one cell tracked and the means of all donors (b) where each dot 
represents results from an individual. “None” = no chemoattract, “half” = cytokine cocktail of 
5 μg/ml Gro-α, 1.5 μg/ml IL-8 and 0.5 μ/ml Mip-3α, “full” = cytokine cocktail of 10 μg/ml Gro-α, 
3 μg/ml IL-8 and 1 μ/ml Mip-3α, error bars are mean ± SEM, *p<0.05, Kruskal-Wallis test, 
followed by Dunn’s multiple comparison test, n = 4. 
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6.7 IL-8, Mip-3α and Gro-α are able to attract CD4+ T cells 
After seeing a positive effect of IL-8, Mip-3α and Gro-α on the migration of both DCs 
and neutrophils, we next wanted to look at CD4+ T cells. Most animal models describe 
mainly an influx of CD4+ T cells to sites of PV infection compared to CD8+ T cells 
which are present in lower numbers (133-135, 144, 151). 
As Dunn Chamber and Chemotaxis Slides from Ibidi can only be used with adherent 
cells, transwell migration assays were used to examine T cell migration instead.  
As for DCs, we compared the use of 10 μg/ml Gro-α, 3 μg/ml IL-8 and 1 μ/ml Mip-3α to 
half these concentrations to attract CD4+ T cells. Fractalkine was used as a positive 
control. CD4+ T cells were isolated from healthy donor blood and directly used for 
migration experiments using transwell inserts with 5.0 μm pores. Migration was carried 
out for 2 hours at 37 °C and cell number determined using the CyQuant NF Cell 
Proliferation Assay which measures fluorescence depending on DNA content (see 
2.2.1.20).  
A clear correlation between the cell number tested with the intensity of the fluorescence 
detected were confirmed initially (Figure 40a) indicating a direct correlation of the 
fluorescence intensity to the amount of cells present. Using the cytokine mix, we saw a 
significant increase in migration only with the full concentration of the three chemokines 
compared to the negative control but not with half the concentration. Half the 
concentration induced a small increase in migration which was not significant (Figure 
40 b).  
These results together with data from the neutrophil and DC migration experiments 
suggest that migration of several immune cell types towards γ-chain deficient 
keratinocytes might be reduced as a result of reduced chemokine secretion following 
IL-15 stimulation. This is especially relevant as IL-15 is upregulated in models for 
epithelial wounding and microwounds are necessary for entry of HPV (298).   
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Figure 40: CD4+ T cell migration towards different cytokines 
CD4+ T cell were isolated from whole blood and used for transwell migration assays using 
transwells with a 5.0 μm polycarbonate membrane. 1 – 2 * 10
5
 cells were used per transwell, 
migration was carried out for 2 h at 37 °C, cell number was determined using the CyQuant NF 
Cell Proliferation Assay, standard curve for the assay showing regression between cell number 
used and fluorescence detected (a) and results of migration assays (b), “half” = cytokine cocktail 
of 5 μg/ml Gro-α, 1.5 μg/ml IL-8 and 0.5 μ/ml Mip-3α, “full” = cytokine cocktail of 10 μg/ml Gro-α, 
3 μg/ml IL-8 and 1 μ/ml Mip-3α, Fractalkine was used as a positive control at 40 μg/ml; *p<0.05, 
**p<0.01, Kruskal-Wallis test, followed by Dunn’s multiple comparison test, n = 3, run in 
triplicate.   
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6.8 Gro-α secretion is increased in HPV18 positive control 
cells but not in γ-chain deficient cells  
In order to identify, whether there are differences in cytokine secretion in cells that are 
stably expressing HPV18, we used HPV18 transfected cells (see Chapter 5.3). This 
would be representative of the situation in later stages of infection where HPV is stably 
maintained in keratinocytes. As we previously identified Gro-α, IL-8 and Mip-3α as 
potential targets that are influenced by the absence of γ-chain, we selected these three 
chemokines for analysis. 
Supernatants were collected from scr control and KD cells stably transfected with 
HPV18 after 24 hours in culture and used for Luminex bead array to detect the 
expression of Gro-α, IL-8 and Mip-3α. 
Gro-α was the only one of the three chemokines that was affected by the presence of 
HPV18. Control cells transfected with HPV18 secreted significantly more Gro-α than 
KD cells transfected with HPV18 and untransfected control and KD cells. In contrast, 
there were no differences in secretion for IL-8 and Mip-3α (Figure 41). 
This suggests, that Gro-α might be a potential chemokine that could influence migration 
of immune cells in the later stages of infection. 
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Figure 41: Secretion of Gro-α, IL-8 and Mip-3α in HPV18 positive NIKS 
Supernatants from scr control and KD NIKS with and without HPV18 were collected after 24 
hours in culture and analysed for the expression of Gro-α (a), IL-8 (b) and Mip-3α (c) using a 
Luminex bead assay, mean ± SEM, *p<0.05, Kruskal-Wallis test, followed by Dunn’s multiple 
comparison test, n = 4.  
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6.9 Higher Gro-α concentrations attract less CD4+ T cells 
As secretion of Gro-α was increased in scr control cells transfected with HPV18 but not 
in KD cells transfected with HPV18, we wanted to test whether different concentrations 
of Gro-α are able to attract different amounts of CD4+ T cells. Only T cells were used 
for this experiment as it is thought that T cells more important in the later stages of 
infection than antigen-presenting cells and cells of the innate immune system. 
CD4+ T cells were isolated from healthy donor blood and used for transwell migration 
experiments as before. Gro-α was used at 10 µg/ml (as secreted by KD + HPV18 and 
untransfected cells) and 30 µg/ml (as secreted by scr + HPV18 cells).  
A significant increase in the number of CD4+ T cells that migrated could be seen with 
both concentrations of Gro-α. Interestingly, however, using Gro-α at 10 µg/ml lead to a 
significantly higher migration of CD4+ T cells than the higher Gro-α concentration of 
30 µg/ml (Figure 42). 
This result suggests that under these conditions higher levels of Gro-α lead to a 
reduction in CD4+ T cell migration. With this analysis, we were unable to support a 
simple mechanism whereby reduction in Gro-α alone by γ-chain deficiency leads to 
reduced CD4+ T cell recruitment.  
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Figure 42: Migration of CD4+ T cells towards different concentrations of Gro-α 
CD4+ T cells were isolated from whole blood and used for transwell migration assays using 
transwells with a 5.0 μm polycarbonate membrane. 1 – 2 * 10
5
 cells were used per transwell, 
migration was carried out for 2 h at 37 °C, cell number was determined using the CyQuant NF 
Cell Proliferation Assay, shown are results of migration assays with “Gro-α high” at 30 μg/ml, 
“Gro-α low” at 10 μg/ml; *p<0.05, ***p<0.001, Kruskal-Wallis test, followed by Dunn’s multiple 
comparison test, n = 3, run in triplicate.   
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6.10 HPV18 presence in control but not in γ-chain deficient 
cells leads to increased attraction of CD4+ T cells  
In our Luminex experiments, we only measured a certain subset of cytokines which 
came up as potential hits from the cytokine array and then used these levels of 
exogenous cytokines to attract immune cells. In these assays the potential synergistic 
or inhibitory effects of all cytokines secreted by keratinocytes cannot be accounted for. 
Therefore, in the final migration experiments using transwells, we used supernatants 
collected from keratinocytes after 24 hours in culture to attract T cells as a more 
biologically relevant target. 
CD4+ T cells were isolated as in previous experiments (see 2.2.1.20 and Chapter 6.7) 
and then they were resuspended in keratinocyte growth medium and filled into the 
inserts of the transwell plate. The collected supernatant was filled into the bottom of the 
transwells to attract the CD4+ T cells. 
For controls cells, stable transfection with HPV18 led to an increase in the attraction of 
CD4+ T cells compared to untransfected cells. While KD cells showed an increase 
chemoattraction at baseline compared to control cells, no increase in chemoattraction 
was seen after HPV transfection (Figure 43).  
This result suggests that only in control cells the presence of HPV18 leads to an 
increase in CD4+ T cell migration which does not occur for KD cells. The implication of 
this in a clinical setting could be that HPV infection in X-SCID patients does not lead to 
an increase in CD4+ T cells attraction compared to basal levels so that the infection 
response in these patients would not be as effective as in healthy individuals. This 
might be an important factor to explain the increased susceptibility to HPV infection 
seen in X-SCID patients.  
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Figure 43: CD4+ T cell migration towards supernatants from HPV positive and negative 
NIKS 
CD4+ T cell were isolated from whole blood and used for transwell migration assays using 
transwells with a 5.0 μm polycarbonate membrane. 1 – 2 * 10
5
 cells were used per transwell, 
migration was carried out for 2 h at 37 °C, cell number was determined using the CyQuant NF 
Cell Proliferation Assay, migration was measured towards supernatants harvested from scr 
control and KD cells with and without HPV18, migration compared to scr (a) and normalised to 
HPV18 negative samples (b), mean ± SEM, *p < 0.05, measured with four different sets of 
supernatants and two different blood donors, everything run in duplicate.  
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6.11 HPV18 presence only in γ-chain deficient but not in 
control cells leads to increased attraction of CD8+ T 
cells  
After seeing differences in migration of CD4+ T cells to supernatants of HPV negative 
and HPV18 positive control and γ-chain knock-down cells, we went on to repeat the 
experiments with CD8+ T cells as both T cell subsets have distinct roles in fighting 
infections. 
CD8+ T cells were isolated from PBMCs in a similar way to the isolation of CD4+ T 
cells for previous experiments. The migration experiment using collected supernatants 
was carried out as for CD4+ T cells. 
Interestingly, the results obtained with CD8+ T cells seemed to be the reverse to the 
results obtained with CD4+ T cells.  
The levels of attracted CD8+ T cells were lower using KD cell supernatant compared to 
control cell supernatant from HPV negative cells. For scr control cells, no difference in 
CD8+ T cell attraction was seen between HPV negative and HPV18 positive cells. 
Here, KD supernatants showed a significantly increased attraction of CD8+ T cells 
when they were HPV18 positive compared to HPV negative samples. The fold increase 
in chemoattraction between HPV negative and HPV18 positive cells was significantly 
higher in KD cells compared to scr control cells (Figure 44).  
This means that only in γ-chain deficient cells the presence of HPV18 leads to an 
increase in CD8+ T cell migration which is exactly the opposite result than the one 
seen with CD4+ T cells. In vivo, this could mean that X-SCID patient demonstrate an 
increase in CD8+ T cell recruitment to wart lesion and a decrease in CD4+ T cell 
recruitment.  
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Figure 44: CD8+ T cell migration towards supernatants from HPV positive and negative 
NIKS 
CD8+ T cell were isolated from whole blood and used for transwell migration assays using 
transwells with a 5.0 μm polycarbonate membrane. 1 – 2 * 10
5
 cells were used per transwell, 
migration was carried out for 2 h at 37 °C, cell number was determined using the CyQuant NF 
Cell Proliferation Assay, migration was measured towards supernatants harvested from scr 
control and KD cells with and without HPV18, migration compared to scr (a) and normalised to 
HPV18 negative samples (b), mean ± SEM, *p < 0.05, measured with four different sets of 
supernatants and two different blood donors, everything run in duplicate.  
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6.12 Discussion 
X-SCID patients are affected by severe HPV infections of the skin that normally do not 
regress over time and are extremely difficult to treat. The pathomechanism for the 
increased susceptibility, heightened disease severity and impaired immune response is 
currently unknown.  
In this chapter, we examined cytokine secretion from keratinocytes after infection with 
quasivirions, after stimulation with γ-chain cytokines and in cells stably transfected with 
HPV18 genomes.  
After infection with HPV quasivirions, we did not observe any changes in the secretion 
of the cytokines tested. Not many experiments have been done looking at cytokine 
secretion after infection with PVs. In one study, canine keratinocytes were infected with 
CPV-2. No changes in the mRNA expression of IFN-β, IL-6 and TNF-α or the pattern 
recognition receptors RIG-I, IFI16 and MDA5 were observed either 24 hours or 4 days 
post-infection (300). In another report by the same group comparing keratinocytes from 
normal and X-SCID dogs, no changes in the mRNA levels for the same targets were 
observed after stimulation with either poly(dA:T) or CPV-2 at 2 and 6 days. There was 
reduced expression of TNF-α and IFN-κ at 4 days after challenge with CPV-2 but no 
difference between X-SCID and control canine keratinocytes (265). These observations 
suggest that initial virus infection has either no significant influence on cytokine and 
chemokine secretion or that the appropriate chemokines and cytokines or time points 
were not analysed. Moreover, in natural infection with PV other factors, such as the 
necessity for micro-trauma, also play a role meaning that infecting monolayers of 
keratinocytes does not sufficiently mimic natural infection.  
Therefore, we next looked at the secretion of chemokines after stimulation with IL-7 
and IL-15 as the latter one is induced in epithelial wounding (298). A significant 
increase in the levels of Gro-α, Mip-3α and IL-8 was observed after stimulation with IL-
15 in control cells. The levels of these cytokines were physiologically relevant inducing 
migration of neutrophils, DCs and CD4+ T cells. Moreover, the cytokine levels released 
from IL-15 stimulated control cells induced significantly higher migration of DCs and 
CD4+ T cells than those released from knock-down cells stimulated with IL-15 
suggesting that after epithelial wounding more immune cells are recruited in healthy 
individuals than in X-SCID patients. Together these results suggest that following 
microwounding and initial HPV infection fewer immune cells may be recruited in X-
SCID patients.  
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Chemokines are important in the host defence because of their chemoattractant 
properties. They are involved in recruiting neutrophils, monocytes and lymphocytes. 
Chemokines are small 8 – 10 kDa molecules that are classified in four distinct families 
according to their sequence homologies: CC, CXC, CX3C and C. IL-8 (CXCL8) and 
Gro-α (CXCL1) are CXC chemokines that transmit their signals via CXCR1 and 
CXCR2 receptors. Mip-3α (CCL20/LARC) is a CC chemokine which binds and 
activates CCR6 (44).  
CXCR1 or CXCR2 are expressed on neutrophils, T cells, NK cells, monocytes and DCs 
(301-303). Therefore, Gro-α and IL-8 should theoretically be able to attract all these cell 
types. Gro-α and IL-8 are very well known chemoattractants for neutrophils and IL-8 
has also been shown to be able to attract T cells (304, 305). For Gro-α, attraction of NK 
cells and CXCR2 positive T cells was shown (306, 307). The data about the effect of 
IL-8 on DC migration is limited. One study showed no effect of IL-8 on the migration of 
DCs but in another study blocking IL-8 using a neutralising antibody led to a reduction 
of DC migration (303, 308). In the same study, blocking Gro-α had no effect on DC 
migration. CCR6 – the receptor for Mip-3α – is expressed memory T cells and DCs and 
Mip-3α is a known chemoattractant for these cells (309-311).  
Most of these studies used higher concentrations of the chemokines (usually around 
100 ng/ml) than we did, however, our results showed that lower chemokine levels – 
equivalent to those released from keratinocytes – were sufficient to attract immune 
cells. One publication showed that administrating Gro-α and IL-8 together led to an 
add-on effect of the chemoattracting properties towards macrophages showing that 
these cytokines can interact which is potentially true here as well (312).  
Our study is the first one to show that IL-15 can induce the secretion of IL-8, Gro-α and 
Mip-3α by keratinocytes and that this induction is γ-chain dependent. We also showed 
for the first time that relatively low concentrations of these chemokines are sufficient to 
attract immune cells. 
To further show that these chemokines in the concentrations released from 
keratinocytes after IL-15 stimulation are important for immune cell recruitment, these 
experiments should be repeated using supernatants from keratinocytes instead of 
exogenously supplying chemokines. In addition, migration experiments using blocking 
antibodies for IL-8, Gro-α and Mip-3α should be performed in future. These blocking 
antibodies should be used both separately and in combination to identify whether just 
one of the cytokines is important for the effect or whether the changes in all three are 
necessary to induce changes in immune cell migration.  
186 
 
After modelling the initial infection, we next looked at cells stably transfected with 
HPV18 to analyse later stages of infection. We analysed supernatants from cells 
transfected with HPV18 for the secretion of IL-8, Mip-3α and Gro-α. Only Gro-α was 
increased in HPV18 positive cells but under the conditions used, higher levels of Gro-α 
led to a reduction in CD4+ T cell migration. A simple mechanism whereby lower levels 
of Gro-α alone lead to reduced CD4+ T cell recruitment could not be supported. 
Therefore, we used supernatants collected from keratinocytes to attract T cells. In 
control cells, presence of HPV18 led to an increase in CD4+ T cell attraction with no 
changes in CD8+ T cell attraction. In contrast, for γ-chain deficient cells, transfection 
with HPV18 did not lead to changes in CD4+ T cell attraction but increased CD8+ T cell 
attraction.  
In the literature, CD4+ T cells are generally the cell type that is regarded to be the most 
important for regression of PV induced lesions but the role of CD8+ T cells is less 
clear. For example, in multiple studies looking at cervical intraepithelial neoplasia, E7-
specific CD4+ T cells responses were associated with regression whereas the data on 
CD8+ T cells was less clear or did not show any association with regression (295-297, 
313).  
In this aspect, our data is interesting as we saw that stable maintenance of HPV18 in 
control cells resulted in an increased migration of CD4+ T cells which was not seen for 
γ-chain deficient cells. This indicates that in X-SCID patients less CD4+ T cells might 
be recruited to the site of infection. As they are the main cell type found initially 
regression, wart lesion regression in X-SCID patients may be impaired. The data for 
the CD8+ T cells in this aspect was more surprising as they are also found in 
regressing lesions but in lower numbers and we saw a significant increase in CD8+ T 
cells migrating towards HPV positive γ-chain deficient cells compared to HPV negative 
ones. However, it is not clear yet which balance of CD8+ to CD4+ T cells is needed for 
regression or whether CD4+ T cell help is required for CD8+ T cell function in this 
setting. It is therefore possible, that the defect in X-SCID patients is due to an 
imbalance of infiltrating T cells due to changes in chemokine secretion. 
These results provided a possible explanation for the susceptibility of X-SCID to severe 
cutaneous HPV infections, however, so far this data was only gained with in vitro 
techniques. In future, it will be needed to use animal models to confirm these results. 
Another limitation of this work is that we used cells transfected with HPV18 which is a 
high risk α-HPV type but warts in X-SCID patients are formed by other HPV types. Use 
of other HPV types is technically challenging as transfection has only been established 
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using the high-risk α-types HPV16, 18 and 31 and for other types often only limited 
maintenance is observed. Moreover, further studies are needed into which cytokines 
are responsible for the differences in T cells recruitment seen between the control and 
γ-chain deficient cells. As we identified Gro-α as changed between control and γ-chain 
deficient cells transfected with HPV18, the migration experiments should be repeated 
using neutralising antibodies to Gro-α. In the experiments performed so far with Gro-α 
synergistic effects with other chemokines cannot be accounted for. Therefore, even 
though initial experiments did not seem to show that Gro-α is accountable for the 
changes seen in this model, this remains to be tested in detail.  
In conclusion, our data suggests that alterations in cytokine secretion and the resulting 
reduction in recruitment of immune cells is a significant contributory factor to the 
increased HPV susceptibility seen in X-SCID patients.  
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7. Final Discussion 
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7.1 The absence of the common γ-chain affects HPV 
infection at multiple stages 
X-SCID is caused by mutations in the common γ-chain and leads to an absence of T 
and NK cells. B cells are present but they are not functional. This leads to a complete 
absence of the adaptive immune system and therefore inability to fight infections. The 
disease can only be cured using bone marrow transplantation or gene therapy which 
has been done very successfully in the recent years with ever increasing survival rates 
(225). 
However, it was shown that a discrete immunodeficiency remains leaving the patients 
susceptible to severe cutaneous infections with HPV with approximately 50% of 
patients suffering from infections. The resulting warts are often impossible to eradicate 
with current treatments. Both through cosmetic effects and impairment of hand and foot 
function, this disease has a great impact on the quality of life of the affected patients. In 
the two main studies, the heightened susceptibility was not associated with any 
immunological or transplant specific factors (236, 237).  
In this thesis, we examined the possibility that γ-chain deficiency in keratinocytes is the 
reason for the remaining immunodeficiency. Keratinocytes are not replaced by the 
available treatment options and HPV exclusively infects them making them a likely 
candidate. This theory is further supported by the fact that they are immune sentinels 
which are able to detect infection, attract immune cells via the secretion of chemokines 
and cytokines and that they have antigen-presenting abilities. Prior to the start of this 
project, limited amounts of information about γ-chain and its expression and function in 
the skin were available. As a result of this work, we showed that 
a) γ-chain is expressed in keratinocytes 
b) most of its co-receptors are expressed in keratinocytes including IL-15Rα and 
IL-2Rβ; only IL-2Rα was not expressed 
c) signals are transmitted via the γ-chain leading to increases in phosphorylation 
of AKT and small changes of STAT5 phosphorylation 
As discussed in previous chapters, our results agreed with previously available 
literature and extended these findings by systematically examining γ-chain and its co-
receptors in one study. 
We hypothesized that the lack of the γ-chain could influence HPV infection at multiple 
stages, e.g. initial infection resulting in a higher permissiveness of cells to HPV 
infection, alterations in the viral life cycle once infection has been established leading to 
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hyperproliferation and changes in secretion of cytokines and chemokines decreasing 
the chemoattraction of professional immune cells. 
Our study is the first one to look in detail at the role of the common γ-chain in skin 
immunity and to provide detail about how keratinocyte γ-chain might contribute to the 
specific HPV immunity.  
We found effects of γ-chain deficiency in keratinocytes on all aspects examined: 
a) γ-chain deficient keratinocytes were more easily infected than control 
keratinocytes 
b) organotypic rafts made with γ-chain deficient, HPV positive cells displayed an 
increased suprabasal synthesis and changes in keratin-10 expression even 
though HPV life cycle markers were not affected 
c) chemokine secretion from γ-chain deficient cells was reduced after IL-15 
stimulation leading to reduced migration of neutrophils, DCs and CD4+ T cells 
d) supernatants from HPV18 positive, γ-chain deficient cells attracted different 
amounts of CD4+ and CD8+ T cells compared to control cells 
While future work is required, we propose that the effect of the γ-chain on HPV 
infections is a multi-step process. Based on our experimental data, we propose a 
model of HPV infection in the context of γ-chain deficiency (Figure 45). In this model, 
firstly, more virus can enter the cell which is then not combatted as effectively because 
immune cells are not recruited as efficiently in the early stages. This leads to 
establishment of infection at a greater level than in healthy individuals. Secondly, once 
the virus has established infection it has a greater influence on the cells leading to 
more proliferation and therefore increased disease severity. Thirdly, due to changes in 
chemokine secretion of still unknown nature the balance of CD4+ and CD8+ T cells 
which are recruited to the site of infection is disturbed leading to reduced resolution of 
the disease and therefore lack of regression. 
Some of the changes, e.g. the effect on suprabasal DNA synthesis, we saw were 
relatively small but they are potentially cumulative (suprabasal proliferation follows 
higher infection rate etc.) so that multiple changes amount to the severe phenotype 
seen in patients. 
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Figure 45: Model for the effect of γ-chain deficiency on HPV infection 
The absence of the common γ-chain has an impact on HPV progression at multiple stages of 
infection. It enhances viral entry and leads to an increase in suprabasal proliferation when the 
infection is established and alters the immune response in two phases. In the early stage of 
infection, IL-15 is released after wounding. As there is no γ-chain dependent signalling, 
chemokines such as Gro-α, IL-8 and Mip-3α are not induced and immune cells such as DCs 
and CD4+ T cells are not recruited. Therefore the infection is not cleared resulting in wart lesion 
formation. In the later stages, when the infection is already established, alterations in 
chemokine secretion lead to reduced CD4+ and increased CD8+ T cell migration. Due to the 
resulting imbalances in the T cell subsets, warts do not regress.  
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Even though we found evidence that the absence of γ-chain can have an effect on 
multiple stages of HPV infection, we favour that the influence on cytokine secretion is 
the main effect leading to increased HPV susceptibility. The reasons for this are that a) 
our experimental data is most robust for this and b) an alteration of the immune 
response can explain the clinical phenotype seen: the high incidence, the disease 
severity and lack of regression. Thirdly, we know that the immune response is key for 
HPV regression. Different strategies activating the immune response by different 
mechanisms can all be effective against HPV infections, e.g. using Candida Antigen or 
Contact Allergen Immunotherapy to non-specifically activate cell-mediated immune 
responses or using Imiquimod to induce cytokine secretion (314). The success of these 
therapies shows the importance of activating the immune system to fight HPV 
infections for the resolution of warts.  
Another question is why not all X-SCID patients present with warts even though they 
would all suffer from reduced anti-HPV responses due to γ-chain deficiency in 
keratinocytes. It seems unlikely that some individuals have no HPV colonisation 
however the virulence and pathogenicity of different HPV types may play a role. For 
others viruses such as EBV over 90% of individuals are infected but not everyone in 
the adult population (315). 
An additional factor that was proposed during the time frame of this work is that 
reduced NK cell reconstitution is responsible for the HPV infections (238). This 
observation was not made in other studies, however, there might have been slight 
variations in NK cell populations which did not reach statistical significance but might 
be biologically relevant. As reconstitution of NK cells is variable, this might also explain 
why not all X-SCID patients develop the severe HPV infections. It is interesting that 
CXCR1 and CXCR2, the receptors for both IL-8 and Gro-α, are also expressed on NK 
cells and Gro-α was shown to be a chemoattractant for NK cells (306). It is therefore 
tempting to speculate that NK cell recruitment is impaired in γ-chain deficient skin but 
this was not specifically tested here. As we are proposing a multi-step process for the 
effect of γ-chain deficiency on HPV infection, this might be another step predisposing 
patients. We could extend our proposed model that the heightened susceptibility of X-
SCID patients to HPV infections is due to an imbalance of immune cells infiltrates 
enhanced both via the inability of keratinocytes to secrete the right amounts of 
chemokines as well as variations in the available immune cells such as NK cells.  
 
  
193 
 
7.2 Potential treatment options of X-SCID 
Our findings raise the question how X-SCID patients can be treated as it has been 
proven to be difficult to eradicate the warts once established. BMT for X-SCID patients 
is usually performed without conditioning leading to incomplete reconstitution of the 
myeloid compartment, e.g. LCs and a proportion of dermal DCs stay of host origin (29, 
226, 248). As it has also been postulated that the absence of γ-chain in DCs/LCs could 
be responsible for the heightened susceptibility observed, it has been proposed that 
conditioning regimes should be amended for X-SCID patients to achieve myeloid 
engraftment and thereby reducing the likeliness of them developing HPV induced 
warts. However, given our results and the results from the NK cell study, it seems less 
likely that DCs and LCs play a role and therefore conditioning would not lead to an 
improvement of the clinical phenotype. As conditioning is associated with higher 
mortality, it is preferable to avoid it if it is not necessary for transplant success. 
The question then remains of how treatment for X-SCID patients might be improved. 
Usually destructive surgery such as using salicylic acid, cryotherapy or surgical 
removal are temporarily providing clinical benefits but as the infection is not cleared 
warts tend to form again quickly. Using immune stimulants such as Imiquimod is often 
not successful at inducting to wart regression, however, this might be due to the size of 
the wart. 
Imiquimod was approved by the FDA in the US in 1997 for the treatment of external 
genital and perianal warts. It does not have direct anti-viral effects but rather acts an 
immune stimulating agent via activating TLR7 and 8. This leads to activation of the 
innate immune system resulting in cytokine release (keratinocytes upregulate IFN-α, IL-
6 and IL-8), co-stimulatory molecule expression and T cell activation (316, 317).  
Imiquimod is used topically as a cream and it penetrates the top layers of the wart and 
therefore might not reach the lower, basal layers where an immune response would 
need to be induced. It might therefore be necessary to combine multiple measures for 
successful treatment of the wart lesions of X-SCID patients, e.g. first surgical removal 
of the wart followed by application of Imiquimod to induce clearance of infection. 
However, Imiquimod could stimulate the keratinocytes to release factors needed for 
immune cell stimulation and infiltration. We cannot exclude that γ-chain deficient 
keratinocytes display defects in chemokine and cytokine secretion in general that might 
impair the use of TLR ligands.  
It might be possible to use intralesional injections of cytokines to induce regression. As 
cytokines and chemokines are our suspected reason for the lack of regression seen, 
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replacing them might lead to the necessary immune cell attraction and therefore 
resolution of infection.  
In support of this concept, the use of cytokines has been shown to induce the 
resolution of HPV lesions in sporadic studies in immunocompromised patients. In one 
patient suffering from chronic lymphocytic leukaemia (CLL), HPV-induced lesions in the 
perianal area were treated using high-dose IL-2 (5 x 106 U) injected subcutaneously 
once daily in combination with topical cidofovir (3%) – a virus static agent. He did not 
develop new warts and generally reacted well to the treatment. Previously, the warts 
would regrow within 2 weeks of surgical removal, however after the high-dose IL-2 
treatment the patient did not show signs of regression after several months of follow-up 
(318). In another patient with CLL with HPV induced viral warts, IL-2 was also used 
successfully in therapy. The patient presented with extensive warts on hands, feet and 
knees which did not resolve in over six years. He was injected for 2 weeks once daily 
subcutaneously with 5 x 106 U of IL-2 and 24 days later, his warts regressed. The warts 
did not recur in the nine years of follow-up (319). 
These two studies indicate that administration of IL-2 to activate an immune response 
near the site of infection can be successful in treating HPV induced lesions. As IL-2 is 
already approved in clinic it might be a potential treatment for X-SCID patients. IL-2 is a 
γ-chain dependent cytokine but as its addition leads to activation of T cells which have 
been either replaced by BMT or corrected by GT use of this strategy could be 
successful even in X-SCID patients. 
However, as the cellular response of keratinocytes to micro-trauma and HPV infection 
cannot be corrected, it will only be possible to treat the disease once it occurs, e.g. 
when warts start to form, but a preventive therapy might not be possible. It will 
therefore remain to be tested if in X-SCID patients a long-lasting cellular response to 
HPV can be induced after infection, e.g. via the production of anti-HPV antibodies by 
stimulated B cells or using vaccines to reduce the risk of reactivation of disease. 
However, the currently available vaccines only protect against mucosal HPV types and 
not the types which are usually found in wart lesions. If X-SCID patients also display a 
higher susceptibility to mucosal HPV types is currently unknown but one patient with 
JAK3 deficiency in our cohort developed HPV related cervical neoplasia in early 
adulthood. It would seem a reasonable precaution to administer currently available 
HPV vaccines to reduce the risk of mucosal HPV infections.  
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7.3 Future experiments  
Our results suggest multiple reasons for the increased susceptibility of X-SCID patients 
to HPV infections. However, further experiments are needed to confirm our findings 
and to gain deeper understanding of the mechanisms involved. Some of these future 
experiments have already been described in previous chapters. 
As all our experiments were carried out using cell lines it will be useful to confirm the 
results using primary cells. However, due to the small number of X-SCID patients it is 
difficult to obtain sufficient amounts of material for studies using human primary cells 
especially as these cells have a limited life span. Another possibility would be to use 
primary mouse keratinocytes which can be isolated from tail skin and grown under low 
calcium conditions without the use of feeder cells (320). Preparation of MmuPV1 VLPs 
in vitro has also been performed and was successfully used to infect mice in vivo (321). 
However, until now no studies have been published using primary murine keratinocytes 
for infection studies using MmuPV1 particles in vitro. We have tried to infect a mouse 
keratinocyte cell line using MmuPV1 particles harvested from nude mice and were able 
to detect MmuPV1 E1^4 mRNA several days after infection (unpublished data). If the 
results from the initial infectivity studies can be confirmed using primary mouse 
keratinocytes, both these cells and the NIKS cell lines could then be used to identify 
why there was a change in infectivity, e.g. using super resolution microscopy and FC 
techniques (also see Chapter 4.7). 
In addition, HPV18 was used in most experiments which is a high risk mucosal and not 
a cutaneous HPV type which affects X-SCID patients. The effects, the use of this HPV 
type on the results might have, were discussed in detail in Chapters 4.7 and 5.7. In 
summary, cutaneous types generally have a less potent effect on cells than high risk 
mucosal HPV types and therefore, effects are probably less pronounced in a patient 
setting. Therefore, certain experiments should be repeated. It is possible to make HPV 
VLP using pShell plasmids for the cutaneous types HPV5 and 8 and other mucosal 
types such as HPV26, 51 and 58 even though they show sometimes limited infectivity 
(279, 321). Therefore, other types of packaging plasmids should also be used to 
confirm the results seen using HPV18 quasivirions. Similar experiments would in theory 
be possible for the raft studies. However, NIKS do not always maintain low risk HPV 
types when they are transfected and therefore, raft cultures are often not possible 
using these types (personal communication P.F. Lambert). In addition, protocols have 
not been established to make organotypic rafts using primary murine keratinocytes. It 
will, therefore, be challenging to confirm the results obtained in Chapter 5 with currently 
available techniques. 
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Even though the results obtained for the infectivity and life cycle are interesting and 
might give further insight into the regulation of HPV, the more important studies would 
be to further examine the cytokine and chemokine secretion and their influence on 
immune cell migration. Studies using animal models for PV infection have not yet 
shown a role for NK cells, but as the reconstitution of these cells has been implied to 
be correlated to HPV disease in X-SCID patients, migration studies in vitro should be 
carried out using NK cells. Further studies into which cytokines might be important for 
the changes in immune cell recruitment seen in cells stably transfected with HPV18 will 
be important to find out which cytokines and chemokines are leading to the differential 
recruitment of CD4+ and CD8+ T cells in our experiments. More cytokine arrays, 
ELISAs and Luminex assays will need to be carried out to this end. Mass spectrometry 
approaches may also be possible if larger amounts of supernatant protein can be 
obtained. Again, studies using cells transfected with other HPV types but HPV18 
should be performed but – as previously described – these are also impacted by the 
difficulty of maintaining cutaneous HPV types in NIKS cells.  
In addition, it would be interesting to see whether keratinocytes release factors that can 
activate immune cells, especially using cells transfected with HPV, as activation status 
can impact migration. We would propose analysing activation markers, e.g. co-
stimulatory and MHC molecules, on immune cells, such as DCs, T and NK cells, 
following incubation with supernatants collected from γ-chain deficient and control cells 
with and without HPV.  
The best way to confirm the results of this thesis would be to carry out in vivo 
experiments. A few of the issues were discussed in previous chapters (see Chapter 
8.5) such as the problem of creating a model where only the keratinocytes are γ-chain 
deficient. We discussed the pros and cons of using either BMT or skin engraftment 
studies. Both models have drawbacks and the ideal solution would be the creation of a 
skin-specific knock-out model, e.g. using a K14 specific promoter, to generate a mouse 
with γ-chain deficiency limited to keratinocytes. 
Using this knock-out model, it would be possible to examine the release of 
inflammatory molecules by keratinocytes after a) wounding, b) infection and in c) stable 
infection/wart lesions. As immune cells would be present, immune cell recruitment 
could be tracked over the course of time to identify infiltrating immune cell subsets and 
the differences seen between skin γ-chain knock-out and control mice. Furthermore, 
the mouse model could be used to test the different proposed treatment strategies, e.g. 
either injecting chemokines close to wart lesions or using IL-2 injections as these 
seemed to help in certain patients. 
197 
 
7.4 Relevance of this project to patients  
This project has originally arisen from the clinical problem of persistent warts after BMT 
and gene therapy for in X-SCID patients who have a ~50% chance of developing 
severe cutaneous HPV infections around 10 years after BMT. The resulting warts have 
a substantial impact on the quality of life of affected patients.  
Even though, this project has aimed to identify the underlying reasons for the increased 
susceptibility to HPV infection, many questions remain unanswered. Therefore further 
research is needed to be able to feed back to the clinic and to inform patient care. As 
there are still multiple hypothesis as to which cell type is main driver for the clinical 
phenotype, understanding whether HPV infection in γ-chain deficiency results from 
defects of haematopoietic cells or intrinsic keratinocyte defects will determine whether 
refinement of bone marrow transplant protocols, development of immune modulation 
treatments or new antiviral agents are the most appropriate avenue for better treatment 
of this disabling condition.  
In addition, the immune response to HPV responsible for latency or wart regression is 
poorly understood. Rare monogenic primary immunodeficiencies where severe HPV 
infection is a prominent feature provide a unique opportunity to study the importance of 
specific immune components for HPV control. Therefore, continuing this project will 
have importance for a) understanding skin immunology especially in relation to HPV 
and b) enabling the development of better future therapies for HPV. Given the high 
prevalence of cutaneous HPV infections in other immunosuppressed patient groups 
and the general population, further research might potentially have great impact.  
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8. Appendix – Using MmuPV1 in 
-chain deficient mice to 
study infection 
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8.1 Introduction 
It has been suggested that PVs are ubiquitously present in all amniotes, therefore, it 
was not surprising when MmuPV1 was found, the first PV that is able to infect 
laboratory mice (146). In the past years, advances have been made in order to 
characterise the tissue tropism of MmuPV1 and the susceptibility of different mouse 
strains to MmuPV1 infection.  
Lack of available animal models has impeded the study of PV infection in vivo using an 
X-SCID specific model. With the discovery of MmuPV1, studies about the role of γ-
chain have become possible as MmuPV1 can be used to infect X-SCID mouse models. 
X-SCID patients are commonly infected with cutaneous β-type HPVs. MmuPV1 – at the 
current state of research – most closely resembles β-type HPVs (151) and therefore it 
would be a suitable model to examine the reasons for increased susceptibility to HPV 
infections in X-SCID patients.  
In this chapter, a preliminary study of MmuPV1 infection using the C57/BL6 γ-chain 
knock-out strain B6.129S4-Il2rgtm1Wjl/J is presented. Experiments were performed at 
Prof. Paul Lambert’s lab, using the animal facilities of the University of Wisconsin-
Madison with the help and supervision of Aayushi Uberoi and Amy Liem under the 
licence held by Prof. Paul Lambert.   
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8.2 MmuPV1 infection can successfully be established in 
γ-chain KO mice 
In order to check whether MmuPV1 was able to induce wart formation in γ-chain knock-
out mice, both KO mice and wild type animals were infected with MmuPV1 at a 
concentration of 1 * 108 vge/site (“viral genome equivalents” as determined by 
Southern blot) and lesion formation was monitored once a week. 
Around 3 – 4 weeks after inoculation with the virus, 80% of KO animals had developed 
lesions. None of the lesions spontaneously regressed. In contrast, none of the WT 
animals developed lesions after infection with MmuPV1. 
This preliminary result suggests that MmuPV1 can be used to infect γ-chain knock-out 
mice which can be further used to examine the defects seen in X-SCID patients. 
 
 
 
Table 17: Formation of wart lesions in mice 
Genotype Application Animals tested Animals developing lesions 
IL2RG -/- MmuPV1 5 4 
WT BL6 MmuPV1 3 0 
WT BL6 PBS 2 0 
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8.3 Skin grafting model for studying HPV infection in X-
SCID skin   
Infecting γ-chain knock-out mice does not accurately reflect the situation in X-SCID 
patients post-BMT. Human patients are only lacking γ-chain in the skin as T cell 
immunity has been successfully restored. To further mimic the clinical setting, we 
aimed to develop a murine model in which γ-chain is only lacking in the skin.  
There are two different possibilities: a) transplanting bone marrow from WT mice into γ-
chain knock-out mice; b) grafting γ-chain knock-out mouse skin onto WT mice. As 
transplanting bone marrow in mice results in variable reconstitution of cellular 
immunity, we decided to employ a skin graft model. In addition, whether a skin graft is 
successful can be easily detected by just examining the transplanted skin patch, rather 
than analysing the blood of the mice as needed when doing BMT. 
Different parts of the mouse skin show different susceptibilities to MmuPV1 infection. 
Whereas tail, ears and muzzle are easily infected, trunk skin is not (150). In this study, 
ear skin from γ-chain knock-out mice was transplanted onto the trunk of WT mice. 
Each mouse was transplanted with two ear skin pieces, one from a γ-chain knock-out 
and one from an age-matched WT mouse as control (Figure 46).  
The engraftment of skin was checked one week after transplant by visual examination. 
Most grafts were successful; however, a few animals (~10%) did not survive the overall 
transplantation process.  
 
Figure 46: Successful skin transplant on a mouse 
Ear skin of donor mice was fitted onto a rectangular size patch onto the back of WT C57/BL6 
mice. One donor skin patch was fitted to each site, with total of two grafts per animal. The 
image shows the successfully engrafted skin a week after transplantation.  
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8.4 No lesions develop using the initial skin graft model 
for MmuPV1 infection studies 
Following successful skin transplantation of skin from γ-chain knock-out mice on WT 
mice, the grafted mice were infected with MmuPV1 a month post transplantation at the 
concentration of 1 * 108 vge/site as used in the previous experiment. The transplanted 
skin was carefully scarified and then virus was applied. None of the mice developed 
wart lesions even multiple months after virus inoculation.  
In an unpublished study from the Lambert lab, it was shown that 60% of 
immunocompetent FVB/NJ and Balb/c mice developed wart lesions at tails and ears 
after 3 months when they were subjected to UVB irradiation at 300 mJ/cm2 before 
infection with MmuPV1. Of these warts, a certain percentage regressed over time.  
Based on this, the mice engrafted with γ-chain knock-out mouse skin were treated with 
UVB at the dose of 300 mJ/cm2 and then infected with MmuPV1. However, there was 
no wart lesion formation in these transplanted animals treated with UVB.  
These results suggest that in order for us to use a transplantation model, it will be 
necessary to find conditions in which wart lesion formation is possible.    
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8.5 Discussion 
The discovery of MmuPV1 has had a big impact on the field of PV research as it allows 
for the development of new mouse models to study PV infection in vivo. To date, there 
are limited publications using this model to study the immune response to PV 
infections. We performed preliminary studies to show that γ-chain knock-out mice could 
be infected with MmuPV1 and that lesions formed in most animals. This result is not 
that surprising as these mice have a reduction in the absolute number of lymphocytes, 
limited numbers of mature B and T cells and completely lack NK cells (322) and as 
absence of T cells is associated with wart formation after MmuPV1 inoculation (151, 
153). It is, however, worth noticing that the remaining T cell populations in γ-chain 
knock-out mice are not sufficient to combat MmuPV1 infection. 
As X-SCID patients are only deficient for γ-chain in the skin, we aimed to create a skin 
graft model to mimic this situation. Grafting procedures were successful; however, 
none of the infected animals developed lesions even after UVB treatment. There are a 
number of possible reasons for this. As mentioned previously, the location of the 
inoculation with MmuPV1 is an important factor for the establishment of wart lesions 
with the back being one of the sites were lesions usually do not form. It has been 
hypothesized that this is due to unknown region-specific intracellular factors that 
influence the infection (150). Interestingly, a similar phenomenon was observed in X-
SCID patients. Certain areas of the body are more commonly infected than others. 
Nearly all patients display warts on their hands, with face and feet also being a 
common location for wart formation. In contrast, neck, back and trunk are only affected 
in a few patients (236).  
This site-specific susceptibility might also be accountable for the absence of lesion 
formation in our experiments. Full thickness skin from the ear of γ-chain knock-out mice 
was transplanted on the back of WT mice. It has been suggested that that region-
specific gene expression in the skin can be regulated by the dermal fibroblasts and by 
the hypodermis which is located underneath the dermis (151). As only the epidermis 
and dermis were transplanted, factors coming from the hypodermis could potentially 
still play a role and affect viral life cycle progression. There is, however, no other area 
on the animal that is large enough to place a potential transplant which is the limiting 
factor for this model.  
An alternative reason for the lack of wart formation could be the background mouse 
strain. The mice used were of the C57/BL6 background, which were the least 
susceptible mouse strain to MmuPV1 infection in different studies following partial 
immunosuppression or UVB treatment ((151) and unpublished data from the Lambert 
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lab). γ-chain knock-out mice are also available on a Balb/c background so it might be 
better to use this mouse strain as it has a higher susceptibility. 
In conclusion, these preliminary results will help to inform future experiments with 
MmuPV1 in γ-chain knock-out mice. If it is not possible to modify the graft model to 
achieve wart formation, bone marrow transplantation is an alternative model to analyse 
the defects seen in X-SCID patients.  
 
  
205 
 
9. References 
 
  
206 
 
1. Fuchs E & Raghavan S (2002) Getting under the skin of epidermal 
morphogenesis. Nature reviews. Genetics 3(3):199-209. 
2. Proksch E, Brandner JM, & Jensen J-M (2008) The skin: an indispensable 
barrier. Experimental dermatology 17(12):1063-1072. 
3. Ross MHP, W. (2015) Histology: A Text and Atlas (Wolter Kluwer Health) 7th 
Ed. 
4. Munde PB, Khandekar SP, Dive AM, & Sharma A (2013) Pathophysiology of 
merkel cell. Journal of oral and maxillofacial pathology : JOMFP 17(3):408-412. 
5. Agar N & Young AR (2005) Melanogenesis: a photoprotective response to DNA 
damage? Mutation research 571(1-2):121-132. 
6. Clausen BE & Kel JM (2010) Langerhans cells: critical regulators of skin 
immunity? Immunology and cell biology 88(4):351-360. 
7. Nestle FO, Di Meglio P, Qin JZ, & Nickoloff BJ (2009) Skin immune sentinels in 
health and disease. Nature reviews. Immunology 9(10):679-691. 
8. Rowden G (1975) Ultrastructural studies of keratinized epithelia of the mouse. 
III. Determination of the volumes of nuclei and cytoplasm of cells in murine 
epidermis. The Journal of investigative dermatology 64(1):1-3. 
9. Fuchs E & Green H (1980) Changes in keratin gene expression during terminal 
differentiation of the keratinocyte. Cell 19(4):1033-1042. 
10. Fuchs E (1990) Epidermal differentiation. Current opinion in cell biology 
2(6):1028-1035. 
11. Moll R, Divo M, & Langbein L (2008) The human keratins: biology and 
pathology. Histochemistry and cell biology 129(6):705-733. 
12. Nelson WG & Sun TT (1983) The 50- and 58-kdalton keratin classes as 
molecular markers for stratified squamous epithelia: cell culture studies. The 
Journal of cell biology 97(1):244-251. 
13. Eichner R & Kahn M (1990) Differential extraction of keratin subunits and 
filaments from normal human epidermis. The Journal of cell biology 
110(4):1149-1168. 
14. Fuchs E (1993) Epidermal differentiation and keratin gene expression. Journal 
of cell science. Supplement 17:197-208. 
15. Eckhart L, Lippens S, Tschachler E, & Declercq W (2013) Cell death by 
cornification. Biochimica et biophysica acta 1833(12):3471-3480. 
16. Mehrel T, et al. (1990) Identification of a major keratinocyte cell envelope 
protein, loricrin. Cell 61(6):1103-1112. 
17. Rice RH & Green H (1979) Presence in human epidermal cells of a soluble 
protein precursor of the cross-linked envelope: activation of the cross-linking by 
calcium ions. Cell 18(3):681-694. 
18. Eckert RL & Green H (1986) Structure and evolution of the human involucrin 
gene. Cell 46(4):583-589. 
19. Resing KA, al-Alawi N, Blomquist C, Fleckman P, & Dale BA (1993) 
Independent regulation of two cytoplasmic processing stages of the 
intermediate filament-associated protein filaggrin and role of Ca2+ in the 
second stage. The Journal of biological chemistry 268(33):25139-25145. 
20. Manabe M, Sanchez M, Sun TT, & Dale BA (1991) Interaction of filaggrin with 
keratin filaments during advanced stages of normal human epidermal 
differentiation and in ichthyosis vulgaris. Differentiation; research in biological 
diversity 48(1):43-50. 
21. Presland RB, Haydock PV, Fleckman P, Nirunsuksiri W, & Dale BA (1992) 
Characterization of the human epidermal profilaggrin gene. Genomic 
organization and identification of an S-100-like calcium binding domain at the 
amino terminus. The Journal of biological chemistry 267(33):23772-23781. 
22. Blanpain C & Fuchs E (2009) Epidermal homeostasis: a balancing act of stem 
cells in the skin. Nat Rev Mol Cell Biol 10(3):207-217. 
207 
 
23. Fuchs E & Chen T (2013) A matter of life and death: self-renewal in stem cells. 
EMBO Rep 14(1):39-48. 
24. Hsu YC, Li L, & Fuchs E (2014) Emerging interactions between skin stem cells 
and their niches. Nature medicine 20(8):847-856. 
25. Mascre G, et al. (2012) Distinct contribution of stem and progenitor cells to 
epidermal maintenance. Nature 489(7415):257-262. 
26. Di Meglio P, Perera GK, & Nestle FO (2011) The multitasking organ: recent 
insights into skin immune function. Immunity 35(6):857-869. 
27. Chorro L, et al. (2009) Langerhans cell (LC) proliferation mediates neonatal 
development, homeostasis, and inflammation-associated expansion of the 
epidermal LC network. The Journal of experimental medicine 206(13):3089-
3100. 
28. Hoeffel G, et al. (2012) Adult Langerhans cells derive predominantly from 
embryonic fetal liver monocytes with a minor contribution of yolk sac-derived 
macrophages. The Journal of experimental medicine 209(6):1167-1181. 
29. Merad M, et al. (2002) Langerhans cells renew in the skin throughout life under 
steady-state conditions. Nature immunology 3(12):1135-1141. 
30. Kissenpfennig A, et al. (2005) Dynamics and function of Langerhans cells in 
vivo: dermal dendritic cells colonize lymph node areas distinct from slower 
migrating Langerhans cells. Immunity 22(5):643-654. 
31. Kupper TS & Fuhlbrigge RC (2004) Immune surveillance in the skin: 
mechanisms and clinical consequences. Nature reviews. Immunology 4(3):211-
222. 
32. Bobr A, et al. (2010) Acute ablation of Langerhans cells enhances skin immune 
responses. J Immunol 185(8):4724-4728. 
33. Gomez de Aguero M, et al. (2012) Langerhans cells protect from allergic 
contact dermatitis in mice by tolerizing CD8(+) T cells and activating Foxp3(+) 
regulatory T cells. The Journal of clinical investigation 122(5):1700-1711. 
34. Malissen B, Tamoutounour S, & Henri S (2014) The origins and functions of 
dendritic cells and macrophages in the skin. Nature reviews. Immunology 
14(6):417-428. 
35. Liu K, et al. (2009) In vivo analysis of dendritic cell development and 
homeostasis. Science 324(5925):392-397. 
36. Geissmann F, et al. (2010) Development of monocytes, macrophages, and 
dendritic cells. Science 327(5966):656-661. 
37. Tamoutounour S, et al. (2013) Origins and functional specialization of 
macrophages and of conventional and monocyte-derived dendritic cells in 
mouse skin. Immunity 39(5):925-938. 
38. Kobayashi M, et al. (2009) Expression of toll-like receptor 2, NOD2 and dectin-1 
and stimulatory effects of their ligands and histamine in normal human 
keratinocytes. The British journal of dermatology 160(2):297-304. 
39. Harder J & Nunez G (2009) Functional expression of the intracellular pattern 
recognition receptor NOD1 in human keratinocytes. The Journal of investigative 
dermatology 129(5):1299-1302. 
40. Kalali BN, et al. (2008) Double-stranded RNA induces an antiviral defense 
status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-
mediated differential signaling. J Immunol 181(4):2694-2704. 
41. Baker BS, Ovigne JM, Powles AV, Corcoran S, & Fry L (2003) Normal 
keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR 
expression in chronic plaque psoriasis. The British journal of dermatology 
148(4):670-679. 
42. Lebre MC, et al. (2007) Human keratinocytes express functional Toll-like 
receptor 3, 4, 5, and 9. The Journal of investigative dermatology 127(2):331-
341. 
208 
 
43. Gutowska-Owsiak D & Ogg GS (2012) The epidermis as an adjuvant. The 
Journal of investigative dermatology 132(3 Pt 2):940-948. 
44. Uchi H, Terao H, Koga T, & Furue M (2000) Cytokines and chemokines in the 
epidermis. Journal of dermatological science 24 Suppl 1:S29-38. 
45. Tokura Y, Kobayashi M, & Kabashima K (2008) Epidermal chemokines and 
modulation by antihistamines, antibiotics and antifungals. Experimental 
dermatology 17(2):81-90. 
46. Grone A (2002) Keratinocytes and cytokines. Veterinary immunology and 
immunopathology 88(1-2):1-12. 
47. Locksley RM, Killeen N, & Lenardo MJ (2001) The TNF and TNF receptor 
superfamilies: integrating mammalian biology. Cell 104(4):487-501. 
48. Schroder K, Hertzog PJ, Ravasi T, & Hume DA (2004) Interferon-gamma: an 
overview of signals, mechanisms and functions. Journal of leukocyte biology 
75(2):163-189. 
49. Francisco-Cruz A, et al. (2014) Granulocyte-macrophage colony-stimulating 
factor: not just another haematopoietic growth factor. Med Oncol 31(1):774. 
50. Basham TY, Nickoloff BJ, Merigan TC, & Morhenn VB (1984) Recombinant 
gamma interferon induces HLA-DR expression on cultured human 
keratinocytes. The Journal of investigative dermatology 83(2):88-90. 
51. Black AP, et al. (2007) Human keratinocyte induction of rapid effector function 
in antigen-specific memory CD4+ and CD8+ T cells. European journal of 
immunology 37(6):1485-1493. 
52. Wakem P, et al. (2000) Allergens and irritants transcriptionally upregulate CD80 
gene expression in human keratinocytes. The Journal of investigative 
dermatology 114(6):1085-1092. 
53. Symington FW & Santos EB (1991) Lysis of human keratinocytes by allogeneic 
HLA class I-specific cytotoxic T cells. Keratinocyte ICAM-1 (CD54) and T cell 
LFA-1 (CD11a/CD18) mediate enhanced lysis of IFN-gamma-treated 
keratinocytes. J Immunol 146(7):2169-2175. 
54. Kim BS, et al. (2009) Keratinocytes function as accessory cells for presentation 
of endogenous antigen expressed in the epidermis. The Journal of investigative 
dermatology 129(12):2805-2817. 
55. Doorbar J, et al. (2012) The biology and life-cycle of human papillomaviruses. 
Vaccine 30 Suppl 5:F55-70. 
56. Peretti A, FitzGerald PC, Bliskovsky V, Buck CB, & Pastrana DV (2015) 
Hamburger polyomaviruses. The Journal of general virology. 
57. Bravo IG, de Sanjose S, & Gottschling M (2010) The clinical importance of 
understanding the evolution of papillomaviruses. Trends in microbiology 
18(10):432-438. 
58. Bernard HU, et al. (2010) Classification of papillomaviruses (PVs) based on 189 
PV types and proposal of taxonomic amendments. Virology 401(1):70-79. 
59. de Villiers EM, Fauquet C, Broker TR, Bernard HU, & zur Hausen H (2004) 
Classification of papillomaviruses. Virology 324(1):17-27. 
60. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, & Wacholder S (2007) 
Human papillomavirus and cervical cancer. Lancet 370(9590):890-907. 
61. Smith JS, et al. (2007) Human papillomavirus type distribution in invasive 
cervical cancer and high-grade cervical lesions: a meta-analysis update. 
International journal of cancer. Journal international du cancer 121(3):621-632. 
62. Watson M, et al. (2008) Using population-based cancer registry data to assess 
the burden of human papillomavirus-associated cancers in the United States: 
overview of methods. Cancer 113(10 Suppl):2841-2854. 
63. Doorbar J (2005) The papillomavirus life cycle. Journal of clinical virology : the 
official publication of the Pan American Society for Clinical Virology 32 Suppl 
1:S7-15. 
209 
 
64. Harwood CA, et al. (2004) Increased risk of skin cancer associated with the 
presence of epidermodysplasia verruciformis human papillomavirus types in 
normal skin. The British journal of dermatology 150(5):949-957. 
65. Bouwes Bavinck JN, et al. (2010) Multicenter study of the association between 
betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer 
research 70(23):9777-9786. 
66. Heilman CA, Law MF, Israel MA, & Howley PM (1980) Cloning of human 
papilloma virus genomic DNAs and analysis of homologous polynucleotide 
sequences. Journal of virology 36(2):395-407. 
67. Ustav M, Ustav E, Szymanski P, & Stenlund A (1991) Identification of the origin 
of replication of bovine papillomavirus and characterization of the viral origin 
recognition factor E1. The EMBO journal 10(13):4321-4329. 
68. McBride AA (2008) Replication and partitioning of papillomavirus genomes. 
Advances in virus research 72:155-205. 
69. Baker TS, et al. (1991) Structures of bovine and human papillomaviruses. 
Analysis by cryoelectron microscopy and three-dimensional image 
reconstruction. Biophysical journal 60(6):1445-1456. 
70. Buck CB, et al. (2008) Arrangement of L2 within the papillomavirus capsid. 
Journal of virology 82(11):5190-5197. 
71. Duensing S & Munger K (2004) Mechanisms of genomic instability in human 
cancer: insights from studies with human papillomavirus oncoproteins. 
International journal of cancer. Journal international du cancer 109(2):157-162. 
72. Dyson N, Howley PM, Munger K, & Harlow E (1989) The human papilloma 
virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. 
Science 243(4893):934-937. 
73. Lee JO, Russo AA, & Pavletich NP (1998) Structure of the retinoblastoma 
tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 
391(6670):859-865. 
74. Schulze A, et al. (1995) Cell cycle regulation of the cyclin A gene promoter is 
mediated by a variant E2F site. Proceedings of the National Academy of 
Sciences of the United States of America 92(24):11264-11268. 
75. Zerfass K, et al. (1995) Sequential activation of cyclin E and cyclin A gene 
expression by human papillomavirus type 16 E7 through sequences necessary 
for transformation. Journal of virology 69(10):6389-6399. 
76. Funk JO, et al. (1997) Inhibition of CDK activity and PCNA-dependent DNA 
replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. 
Genes & development 11(16):2090-2100. 
77. Zerfass-Thome K, et al. (1996) Inactivation of the cdk inhibitor p27KIP1 by the 
human papillomavirus type 16 E7 oncoprotein. Oncogene 13(11):2323-2330. 
78. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, & Howley PM (1990) The 
E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes 
the degradation of p53. Cell 63(6):1129-1136. 
79. Scheffner M, Huibregtse JM, Vierstra RD, & Howley PM (1993) The HPV-16 E6 
and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination 
of p53. Cell 75(3):495-505. 
80. Stanley MA & Sterling JC (2014) Host responses to infection with human 
papillomavirus. Current problems in dermatology 45:58-74. 
81. Egawa N, Egawa K, Griffin H, & Doorbar J (2015) Human Papillomaviruses; 
Epithelial Tropisms, and the Development of Neoplasia. Viruses 7(7):3863-
3890. 
82. Schiller JT, Day PM, & Kines RC (2010) Current understanding of the 
mechanism of HPV infection. Gynecologic oncology 118(1 Suppl):S12-17. 
83. Roberts JN, et al. (2007) Genital transmission of HPV in a mouse model is 
potentiated by nonoxynol-9 and inhibited by carrageenan. Nature medicine 
13(7):857-861. 
210 
 
84. Boxman IL, et al. (1997) Detection of human papillomavirus DNA in plucked 
hairs from renal transplant recipients and healthy volunteers. The Journal of 
investigative dermatology 108(5):712-715. 
85. Combita AL, et al. (2001) Gene transfer using human papillomavirus 
pseudovirions varies according to virus genotype and requires cell surface 
heparan sulfate. FEMS microbiology letters 204(1):183-188. 
86. Johnson KM, et al. (2009) Role of heparan sulfate in attachment to and 
infection of the murine female genital tract by human papillomavirus. Journal of 
virology 83(5):2067-2074. 
87. Richards KF, Mukherjee S, Bienkowska-Haba M, Pang J, & Sapp M (2014) 
Human papillomavirus species-specific interaction with the basement 
membrane-resident non-heparan sulfate receptor. Viruses 6(12):4856-4879. 
88. Giroglou T, Florin L, Schafer F, Streeck RE, & Sapp M (2001) Human 
papillomavirus infection requires cell surface heparan sulfate. Journal of 
virology 75(3):1565-1570. 
89. Richards RM, Lowy DR, Schiller JT, & Day PM (2006) Cleavage of the 
papillomavirus minor capsid protein, L2, at a furin consensus site is necessary 
for infection. Proceedings of the National Academy of Sciences of the United 
States of America 103(5):1522-1527. 
90. Day PM & Schelhaas M (2014) Concepts of papillomavirus entry into host cells. 
Current opinion in virology 4:24-31. 
91. Schelhaas M, et al. (2012) Entry of human papillomavirus type 16 by actin-
dependent, clathrin- and lipid raft-independent endocytosis. PLoS pathogens 
8(4):e1002657. 
92. Spoden G, et al. (2008) Clathrin- and caveolin-independent entry of human 
papillomavirus type 16--involvement of tetraspanin-enriched microdomains 
(TEMs). PloS one 3(10):e3313. 
93. Bergant Marusic M, Ozbun MA, Campos SK, Myers MP, & Banks L (2012) 
Human papillomavirus L2 facilitates viral escape from late endosomes via 
sorting nexin 17. Traffic 13(3):455-467. 
94. Ustav M & Stenlund A (1991) Transient replication of BPV-1 requires two viral 
polypeptides encoded by the E1 and E2 open reading frames. The EMBO 
journal 10(2):449-457. 
95. Chiang CM, et al. (1992) Viral E1 and E2 proteins support replication of 
homologous and heterologous papillomaviral origins. Proceedings of the 
National Academy of Sciences of the United States of America 89(13):5799-
5803. 
96. Ilves I, Kivi S, & Ustav M (1999) Long-term episomal maintenance of bovine 
papillomavirus type 1 plasmids is determined by attachment to host 
chromosomes, which Is mediated by the viral E2 protein and its binding sites. 
Journal of virology 73(5):4404-4412. 
97. Lorenz LD, Rivera Cardona J, & Lambert PF (2013) Inactivation of p53 rescues 
the maintenance of high risk HPV DNA genomes deficient in expression of E6. 
PLoS pathogens 9(10):e1003717. 
98. Bedell MA, et al. (1991) Amplification of human papillomavirus genomes in vitro 
is dependent on epithelial differentiation. Journal of virology 65(5):2254-2260. 
99. Buck CB, Thompson CD, Pang YY, Lowy DR, & Schiller JT (2005) Maturation 
of papillomavirus capsids. Journal of virology 79(5):2839-2846. 
100. Day PM, Roden RB, Lowy DR, & Schiller JT (1998) The papillomavirus minor 
capsid protein, L2, induces localization of the major capsid protein, L1, and the 
viral transcription/replication protein, E2, to PML oncogenic domains. Journal of 
virology 72(1):142-150. 
101. Griffin H, et al. (2012) E4 antibodies facilitate detection and type-assignment of 
active HPV infection in cervical disease. PloS one 7(12):e49974. 
211 
 
102. Kanodia S, Fahey LM, & Kast WM (2007) Mechanisms used by human 
papillomaviruses to escape the host immune response. Current cancer drug 
targets 7(1):79-89. 
103. Rudolf MP, et al. (1999) Induction of HPV16 capsid protein-specific human T 
cell responses by virus-like particles. Biological chemistry 380(3):335-340. 
104. Le Bon A & Tough DF (2002) Links between innate and adaptive immunity via 
type I interferon. Current opinion in immunology 14(4):432-436. 
105. Diamond MS & Farzan M (2013) The broad-spectrum antiviral functions of IFIT 
and IFITM proteins. Nature reviews. Immunology 13(1):46-57. 
106. Nees M, et al. (2001) Papillomavirus type 16 oncogenes downregulate 
expression of interferon-responsive genes and upregulate proliferation-
associated and NF-kappaB-responsive genes in cervical keratinocytes. Journal 
of virology 75(9):4283-4296. 
107. Tummers B & Burg SH (2015) High-risk human papillomavirus targets 
crossroads in immune signaling. Viruses 7(5):2485-2506. 
108. Hasan UA, et al. (2007) TLR9 expression and function is abolished by the 
cervical cancer-associated human papillomavirus type 16. J Immunol 
178(5):3186-3197. 
109. Reiser J, et al. (2011) High-risk human papillomaviruses repress constitutive 
kappa interferon transcription via E6 to prevent pathogen recognition receptor 
and antiviral-gene expression. Journal of virology 85(21):11372-11380. 
110. Um SJ, et al. (2002) Abrogation of IRF-1 response by high-risk HPV E7 protein 
in vivo. Cancer letters 179(2):205-212. 
111. Park JS, et al. (2000) Inactivation of interferon regulatory factor-1 tumor 
suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated 
immune evasion mechanism in cervical carcinogenesis. The Journal of 
biological chemistry 275(10):6764-6769. 
112. Li S, et al. (1999) The human papilloma virus (HPV)-18 E6 oncoprotein 
physically associates with Tyk2 and impairs Jak-STAT activation by interferon-
alpha. Oncogene 18(42):5727-5737. 
113. Sunthamala N, et al. (2014) E2 proteins of high risk human papillomaviruses 
down-modulate STING and IFN-kappa transcription in keratinocytes. PloS one 
9(3):e91473. 
114. Rincon-Orozco B, et al. (2009) Epigenetic silencing of interferon-kappa in 
human papillomavirus type 16-positive cells. Cancer research 69(22):8718-
8725. 
115. Stanley MA (2012) Epithelial cell responses to infection with human 
papillomavirus. Clinical microbiology reviews 25(2):215-222. 
116. Barnard P & McMillan NA (1999) The human papillomavirus E7 oncoprotein 
abrogates signaling mediated by interferon-alpha. Virology 259(2):305-313. 
117. Perea SE, Massimi P, & Banks L (2000) Human papillomavirus type 16 E7 
impairs the activation of the interferon regulatory factor-1. Int J Mol Med 
5(6):661-666. 
118. Havard L, Rahmouni S, Boniver J, & Delvenne P (2005) High levels of p105 
(NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: role 
of E6 and E7 oncoproteins. Virology 331(2):357-366. 
119. Spitkovsky D, Hehner SP, Hofmann TG, Moller A, & Schmitz ML (2002) The 
human papillomavirus oncoprotein E7 attenuates NF-kappa B activation by 
targeting the Ikappa B kinase complex. The Journal of biological chemistry 
277(28):25576-25582. 
120. Tummers B, et al. (2015) The interferon-related developmental regulator 1 is 
used by human papillomavirus to suppress NFkappaB activation. Nat Commun 
6:6537. 
212 
 
121. Franchi L, Warner N, Viani K, & Nunez G (2009) Function of Nod-like receptors 
in microbial recognition and host defense. Immunological reviews 227(1):106-
128. 
122. Karim R, et al. (2011) Human papillomavirus deregulates the response of a 
cellular network comprising of chemotactic and proinflammatory genes. PloS 
one 6(3):e17848. 
123. Niebler M, et al. (2013) Post-translational control of IL-1beta via the human 
papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune 
escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS pathogens 
9(8):e1003536. 
124. Huang SM & McCance DJ (2002) Down regulation of the interleukin-8 promoter 
by human papillomavirus type 16 E6 and E7 through effects on CREB binding 
protein/p300 and P/CAF. Journal of virology 76(17):8710-8721. 
125. Sperling T, et al. (2012) Human papillomavirus type 8 interferes with a novel 
C/EBPbeta-mediated mechanism of keratinocyte CCL20 chemokine expression 
and Langerhans cell migration. PLoS pathogens 8(7):e1002833. 
126. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, & Matsushima K (1989) 
The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. 
Science 243(4897):1464-1466. 
127. Leong CM, Doorbar J, Nindl I, Yoon HS, & Hibma MH (2010) Loss of epidermal 
Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but 
not beta genus infections. The Journal of investigative dermatology 130(2):472-
480. 
128. Georgopoulos NT, Proffitt JL, & Blair GE (2000) Transcriptional regulation of the 
major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 
genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. 
Oncogene 19(42):4930-4935. 
129. Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, & Campo MS (2005) E5 
protein of human papillomavirus type 16 selectively downregulates surface HLA 
class I. International journal of cancer. Journal international du cancer 
113(2):276-283. 
130. Zhou F, Chen J, & Zhao KN (2013) Human papillomavirus 16-encoded E7 
protein inhibits IFN-gamma-mediated MHC class I antigen presentation and 
CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. The 
Journal of general virology 94(Pt 11):2504-2514. 
131. Zhang B, et al. (2003) The E5 protein of human papillomavirus type 16 perturbs 
MHC class II antigen maturation in human foreskin keratinocytes treated with 
interferon-gamma. Virology 310(1):100-108. 
132. Maglennon GA & Doorbar J (2012) The biology of papillomavirus latency. The 
open virology journal 6:190-197. 
133. Nicholls PK, et al. (2001) Regression of canine oral papillomas is associated 
with infiltration of CD4+ and CD8+ lymphocytes. Virology 283(1):31-39. 
134. Wilgenburg BJ, Budgeon LR, Lang CM, Griffith JW, & Christensen ND (2005) 
Characterization of immune responses during regression of rabbit oral 
papillomavirus infections. Comparative medicine 55(5):431-439. 
135. Knowles G, O'Neil BW, & Campo MS (1996) Phenotypical characterization of 
lymphocytes infiltrating regressing papillomas. Journal of virology 70(12):8451-
8458. 
136. Coleman N, et al. (1994) Immunological events in regressing genital warts. 
American journal of clinical pathology 102(6):768-774. 
137. Selvakumar R, Schmitt A, Iftner T, Ahmed R, & Wettstein FO (1997) 
Regression of papillomas induced by cottontail rabbit papillomavirus is 
associated with infiltration of CD8+ cells and persistence of viral DNA after 
regression. Journal of virology 71(7):5540-5548. 
213 
 
138. Savani BN, et al. (2008) Increased risk of cervical dysplasia in long-term 
survivors of allogeneic stem cell transplantation--implications for screening and 
HPV vaccination. Biology of blood and marrow transplantation : journal of the 
American Society for Blood and Marrow Transplantation 14(9):1072-1075. 
139. Moscicki AB, et al. (2000) Prevalence of and risks for cervical human 
papillomavirus infection and squamous intraepithelial lesions in adolescent girls: 
impact of infection with human immunodeficiency virus. Archives of pediatrics & 
adolescent medicine 154(2):127-134. 
140. Torres M, et al. (2015) Prevalence of beta and gamma human papillomaviruses 
in the anal canal of men who have sex with men is influenced by HIV status. 
Journal of clinical virology : the official publication of the Pan American Society 
for Clinical Virology 67:47-51. 
141. Maglennon GA, McIntosh P, & Doorbar J (2011) Persistence of viral DNA in the 
epithelial basal layer suggests a model for papillomavirus latency following 
immune regression. Virology 414(2):153-163. 
142. Amella CA, et al. (1994) Latent infection induced with cottontail rabbit 
papillomavirus. A model for human papillomavirus latency. The American 
journal of pathology 144(6):1167-1171. 
143. Hibma MH (2012) The immune response to papillomavirus during infection 
persistence and regression. The open virology journal 6:241-248. 
144. Okabayashi M, Angell MG, Christensen ND, & Kreider JW (1991) Morphometric 
analysis and identification of infiltrating leucocytes in regressing and 
progressing Shope rabbit papillomas. International journal of cancer. Journal 
international du cancer 49(6):919-923. 
145. Nasir L & Campo MS (2008) Bovine papillomaviruses: their role in the aetiology 
of cutaneous tumours of bovids and equids. Veterinary dermatology 19(5):243-
254. 
146. Ingle A, et al. (2011) Novel laboratory mouse papillomavirus (MusPV) infection. 
Veterinary pathology 48(2):500-505. 
147. Schulz E, et al. (2012) Isolation of three novel rat and mouse papillomaviruses 
and their genomic characterization. PloS one 7(10):e47164. 
148. Joh J, et al. (2011) Genomic analysis of the first laboratory-mouse 
papillomavirus. The Journal of general virology 92(Pt 3):692-698. 
149. Joh J, et al. (2012) Molecular diagnosis of a laboratory mouse papillomavirus 
(MusPV). Experimental and molecular pathology 93(3):416-421. 
150. Handisurya A, et al. (2013) Characterization of Mus musculus papillomavirus 1 
infection in situ reveals an unusual pattern of late gene expression and capsid 
protein localization. Journal of virology 87(24):13214-13225. 
151. Handisurya A, et al. (2014) Strain-specific properties and T cells regulate the 
susceptibility to papilloma induction by Mus musculus papillomavirus 1. PLoS 
pathogens 10(8):e1004314. 
152. Cladel NM, et al. (2013) Secondary infections, expanded tissue tropism, and 
evidence for malignant potential in immunocompromised mice infected with 
Mus musculus papillomavirus 1 DNA and virus. Journal of virology 87(16):9391-
9395. 
153. Sundberg JP, et al. (2014) Immune status, strain background, and anatomic 
site of inoculation affect mouse papillomavirus (MmuPV1) induction of exophytic 
papillomas or endophytic trichoblastomas. PloS one 9(12):e113582. 
154. Cladel NM, et al. (2015) A novel pre-clinical murine model to study the life cycle 
and progression of cervical and anal papillomavirus infections. PloS one 
10(3):e0120128. 
155. Noguchi M, Adelstein S, Cao X, & Leonard WJ (1993) Characterization of the 
human interleukin-2 receptor gamma chain gene. The Journal of biological 
chemistry 268(18):13601-13608. 
214 
 
156. Takeshita T, Asao H, Suzuki J, & Sugamura K (1990) An associated molecule, 
p64, with high-affinity interleukin 2 receptor. International immunology 2(5):477-
480. 
157. Takeshita T, et al. (1992) An associated molecule, p64, with IL-2 receptor beta 
chain. Its possible involvement in the formation of the functional intermediate-
affinity IL-2 receptor complex. J Immunol 148(7):2154-2158. 
158. Takeshita T, et al. (1992) Cloning of the gamma chain of the human IL-2 
receptor. Science 257(5068):379-382. 
159. Wang X, Rickert M, & Garcia KC (2005) Structure of the quaternary complex of 
interleukin-2 with its alpha, beta, and gammac receptors. Science 
310(5751):1159-1163. 
160. Rickert M, Boulanger MJ, Goriatcheva N, & Garcia KC (2004) Compensatory 
energetic mechanisms mediating the assembly of signaling complexes between 
interleukin-2 and its alpha, beta, and gamma(c) receptors. Journal of molecular 
biology 339(5):1115-1128. 
161. Noguchi M, et al. (1993) Interleukin-2 receptor gamma chain: a functional 
component of the interleukin-7 receptor. Science 262(5141):1877-1880. 
162. Russell SM, et al. (1993) Interleukin-2 receptor gamma chain: a functional 
component of the interleukin-4 receptor. Science 262(5141):1880-1883. 
163. Giri JG, et al. (1994) Utilization of the beta and gamma chains of the IL-2 
receptor by the novel cytokine IL-15. The EMBO journal 13(12):2822-2830. 
164. Kimura Y, et al. (1995) Sharing of the IL-2 receptor gamma chain with the 
functional IL-9 receptor complex. International immunology 7(1):115-120. 
165. Asao H, et al. (2001) Cutting edge: the common gamma-chain is an 
indispensable subunit of the IL-21 receptor complex. J Immunol 167(1):1-5. 
166. Habib T, Senadheera S, Weinberg K, & Kaushansky K (2002) The common 
gamma chain (gamma c) is a required signaling component of the IL-21 
receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 
41(27):8725-8731. 
167. Giri JG, et al. (1995) Identification and cloning of a novel IL-15 binding protein 
that is structurally related to the alpha chain of the IL-2 receptor. The EMBO 
journal 14(15):3654-3663. 
168. Rochman Y, Spolski R, & Leonard WJ (2009) New insights into the regulation of 
T cells by gamma(c) family cytokines. Nature reviews. Immunology 9(7):480-
490. 
169. Miyazaki T, et al. (1994) Functional activation of Jak1 and Jak3 by selective 
association with IL-2 receptor subunits. Science 266(5187):1045-1047. 
170. Chen M, et al. (1997) The amino terminus of JAK3 is necessary and sufficient 
for binding to the common gamma chain and confers the ability to transmit 
interleukin 2-mediated signals. Proceedings of the National Academy of 
Sciences of the United States of America 94(13):6910-6915. 
171. Rodig SJ, et al. (1998) Disruption of the Jak1 gene demonstrates obligatory and 
nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 
93(3):373-383. 
172. Leonard WJ (2001) Cytokines and immunodeficiency diseases. Nature reviews. 
Immunology 1(3):200-208. 
173. Leonard WJ & O'Shea JJ (1998) Jaks and STATs: biological implications. 
Annual review of immunology 16:293-322. 
174. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, & Tsichlis PN (1997) 
Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt 
protein kinase. Proceedings of the National Academy of Sciences of the United 
States of America 94(8):3627-3632. 
175. Migone TS, et al. (1998) Functional cooperation of the interleukin-2 receptor 
beta chain and Jak1 in phosphatidylinositol 3-kinase recruitment and 
phosphorylation. Molecular and cellular biology 18(11):6416-6422. 
215 
 
176. Song G, Ouyang G, & Bao S (2005) The activation of Akt/PKB signaling 
pathway and cell survival. Journal of cellular and molecular medicine 9(1):59-
71. 
177. Ravichandran KS & Burakoff SJ (1994) The adapter protein Shc interacts with 
the interleukin-2 (IL-2) receptor upon IL-2 stimulation. The Journal of biological 
chemistry 269(3):1599-1602. 
178. Murata T, Noguchi PD, & Puri RK (1996) IL-13 induces phosphorylation and 
activation of JAK2 Janus kinase in human colon carcinoma cell lines: 
similarities between IL-4 and IL-13 signaling. J Immunol 156(8):2972-2978. 
179. Murata T, Noguchi PD, & Puri RK (1995) Receptors for interleukin (IL)-4 do not 
associate with the common gamma chain, and IL-4 induces the phosphorylation 
of JAK2 tyrosine kinase in human colon carcinoma cells. The Journal of 
biological chemistry 270(51):30829-30836. 
180. Dubois S, Mariner J, Waldmann TA, & Tagaya Y (2002) IL-15Ralpha recycles 
and presents IL-15 In trans to neighboring cells. Immunity 17(5):537-547. 
181. Olsen SK, et al. (2007) Crystal Structure of the interleukin-15.interleukin-15 
receptor alpha complex: insights into trans and cis presentation. The Journal of 
biological chemistry 282(51):37191-37204. 
182. Morgan DA, Ruscetti FW, & Gallo R (1976) Selective in vitro growth of T 
lymphocytes from normal human bone marrows. Science 193(4257):1007-
1008. 
183. Taniguchi T, et al. (1983) Structure and expression of a cloned cDNA for human 
interleukin-2. Nature 302(5906):305-310. 
184. Trinchieri G, et al. (1984) Response of resting human peripheral blood natural 
killer cells to interleukin 2. The Journal of experimental medicine 160(4):1147-
1169. 
185. Zubler RH, et al. (1984) Activated B cells express receptors for, and proliferate 
in response to, pure interleukin 2. The Journal of experimental medicine 
160(4):1170-1183. 
186. Liao W, Lin JX, & Leonard WJ (2011) IL-2 family cytokines: new insights into 
the complex roles of IL-2 as a broad regulator of T helper cell differentiation. 
Current opinion in immunology 23(5):598-604. 
187. Liao W, et al. (2008) Priming for T helper type 2 differentiation by interleukin 2-
mediated induction of interleukin 4 receptor alpha-chain expression. Nature 
immunology 9(11):1288-1296. 
188. Sakaguchi S, Yamaguchi T, Nomura T, & Ono M (2008) Regulatory T cells and 
immune tolerance. Cell 133(5):775-787. 
189. Ahmadzadeh M & Rosenberg SA (2006) IL-2 administration increases CD4+ 
CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107(6):2409-2414. 
190. Antony PA, et al. (2006) Interleukin-2-dependent mechanisms of tolerance and 
immunity in vivo. J Immunol 176(9):5255-5266. 
191. Sadlack B, et al. (1995) Generalized autoimmune disease in interleukin-2-
deficient mice is triggered by an uncontrolled activation and proliferation of 
CD4+ T cells. European journal of immunology 25(11):3053-3059. 
192. Horak I (1995) Immunodeficiency in IL-2-knockout mice. Clinical immunology 
and immunopathology 76(3 Pt 2):S172-173. 
193. Paul WE (1991) Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 
77(9):1859-1870. 
194. Thurner B, et al. (1999) Generation of large numbers of fully mature and stable 
dendritic cells from leukapheresis products for clinical application. Journal of 
immunological methods 223(1):1-15. 
195. Kuhn R, Rajewsky K, & Muller W (1991) Generation and analysis of interleukin-
4 deficient mice. Science 254(5032):707-710. 
216 
 
196. Metwali A, et al. (1996) The granulomatous response in murine Schistosomiasis 
mansoni does not switch to Th1 in IL-4-deficient C57BL/6 mice. J Immunol 
157(10):4546-4553. 
197. Jankovic D, et al. (1999) Schistosome-infected IL-4 receptor knockout (KO) 
mice, in contrast to IL-4 KO mice, fail to develop granulomatous pathology while 
maintaining the same lymphokine expression profile. J Immunol 163(1):337-
342. 
198. Namen AE, et al. (1988) Stimulation of B-cell progenitors by cloned murine 
interleukin-7. Nature 333(6173):571-573. 
199. Chazen GD, Pereira GM, LeGros G, Gillis S, & Shevach EM (1989) Interleukin 
7 is a T-cell growth factor. Proceedings of the National Academy of Sciences of 
the United States of America 86(15):5923-5927. 
200. Mazzucchelli R & Durum SK (2007) Interleukin-7 receptor expression: intelligent 
design. Nature reviews. Immunology 7(2):144-154. 
201. Link A, et al. (2007) Fibroblastic reticular cells in lymph nodes regulate the 
homeostasis of naive T cells. Nature immunology 8(11):1255-1265. 
202. Alves NL, van Leeuwen EM, Derks IA, & van Lier RA (2008) Differential 
regulation of human IL-7 receptor alpha expression by IL-7 and TCR signaling. 
J Immunol 180(8):5201-5210. 
203. von Freeden-Jeffry U, et al. (1995) Lymphopenia in interleukin (IL)-7 gene-
deleted mice identifies IL-7 as a nonredundant cytokine. The Journal of 
experimental medicine 181(4):1519-1526. 
204. Peschon JJ, et al. (1994) Early lymphocyte expansion is severely impaired in 
interleukin 7 receptor-deficient mice. The Journal of experimental medicine 
180(5):1955-1960. 
205. Van Snick J, et al. (1989) Cloning and characterization of a cDNA for a new 
mouse T cell growth factor (P40). The Journal of experimental medicine 
169(1):363-368. 
206. Uyttenhove C, Simpson RJ, & Van Snick J (1988) Functional and structural 
characterization of P40, a mouse glycoprotein with T-cell growth factor activity. 
Proceedings of the National Academy of Sciences of the United States of 
America 85(18):6934-6938. 
207. Renauld JC, Goethals A, Houssiau F, Van Roost E, & Van Snick J (1990) 
Cloning and expression of a cDNA for the human homolog of mouse T cell and 
mast cell growth factor P40. Cytokine 2(1):9-12. 
208. Hauber HP, Bergeron C, & Hamid Q (2004) IL-9 in allergic inflammation. 
International archives of allergy and immunology 134(1):79-87. 
209. Dugas B, et al. (1993) Interleukin-9 potentiates the interleukin-4-induced 
immunoglobulin (IgG, IgM and IgE) production by normal human B 
lymphocytes. European journal of immunology 23(7):1687-1692. 
210. Townsend JM, et al. (2000) IL-9-deficient mice establish fundamental roles for 
IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell 
development. Immunity 13(4):573-583. 
211. Grabstein KH, et al. (1994) Cloning of a T cell growth factor that interacts with 
the beta chain of the interleukin-2 receptor. Science 264(5161):965-968. 
212. Carson WE, et al. (1997) A potential role for interleukin-15 in the regulation of 
human natural killer cell survival. The Journal of clinical investigation 99(5):937-
943. 
213. Sato N, Patel HJ, Waldmann TA, & Tagaya Y (2007) The IL-15/IL-15Ralpha on 
cell surfaces enables sustained IL-15 activity and contributes to the long 
survival of CD8 memory T cells. Proceedings of the National Academy of 
Sciences of the United States of America 104(2):588-593. 
214. Lodolce JP, et al. (1998) IL-15 receptor maintains lymphoid homeostasis by 
supporting lymphocyte homing and proliferation. Immunity 9(5):669-676. 
217 
 
215. Kennedy MK, et al. (2000) Reversible defects in natural killer and memory CD8 
T cell lineages in interleukin 15-deficient mice. The Journal of experimental 
medicine 191(5):771-780. 
216. Parrish-Novak J, et al. (2000) Interleukin 21 and its receptor are involved in NK 
cell expansion and regulation of lymphocyte function. Nature 408(6808):57-63. 
217. Recher M, et al. (2011) IL-21 is the primary common gamma chain-binding 
cytokine required for human B-cell differentiation in vivo. Blood 118(26):6824-
6835. 
218. Yi JS, Du M, & Zajac AJ (2009) A vital role for interleukin-21 in the control of a 
chronic viral infection. Science 324(5934):1572-1576. 
219. Elsaesser H, Sauer K, & Brooks DG (2009) IL-21 is required to control chronic 
viral infection. Science 324(5934):1569-1572. 
220. Yano S, Komine M, Fujimoto M, Okochi H, & Tamaki K (2003) Interleukin 15 
induces the signals of epidermal proliferation through ERK and PI 3-kinase in a 
human epidermal keratinocyte cell line, HaCaT. Biochem Biophys Res 
Commun 301(4):841-847. 
221. Caruso R, et al. (2009) Involvement of interleukin-21 in the epidermal 
hyperplasia of psoriasis. Nature medicine 15(9):1013-1015. 
222. Heufler C, et al. (1993) Interleukin 7 is produced by murine and human 
keratinocytes. The Journal of experimental medicine 178(3):1109-1114. 
223. Hong CH, Chang KL, Wang HJ, Yu HS, & Lee CH (2015) IL-9 induces IL-8 
production via STIM1 activation and ERK phosphorylation in epidermal 
keratinocytes: A plausible mechanism of IL-9R in atopic dermatitis. Journal of 
dermatological science 78(3):206-214. 
224. Kovanen PE & Leonard WJ (2004) Cytokines and immunodeficiency diseases: 
critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, 
and 21, and their signaling pathways. Immunological reviews 202:67-83. 
225. Buckley RH (2004) Molecular defects in human severe combined 
immunodeficiency and approaches to immune reconstitution. Annual review of 
immunology 22:625-655. 
226. Gaspar HB, et al. (2013) How I treat severe combined immunodeficiency. Blood 
122(23):3749-3758. 
227. Antoine C, et al. (2003) Long-term survival and transplantation of haemopoietic 
stem cells for immunodeficiencies: report of the European experience 1968-99. 
Lancet 361(9357):553-560. 
228. Gaspar HB, et al. (2004) Gene therapy of X-linked severe combined 
immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 
364(9452):2181-2187. 
229. Hacein-Bey-Abina S, et al. (2008) Insertional oncogenesis in 4 patients after 
retrovirus-mediated gene therapy of SCID-X1. The Journal of clinical 
investigation 118(9):3132-3142. 
230. Hacein-Bey-Abina S, et al. (2014) A modified gamma-retrovirus vector for X-
linked severe combined immunodeficiency. The New England journal of 
medicine 371(15):1407-1417. 
231. Roifman CM (2000) Human IL-2 receptor alpha chain deficiency. Pediatric 
research 48(1):6-11. 
232. Caudy AA, Reddy ST, Chatila T, Atkinson JP, & Verbsky JW (2007) CD25 
deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. 
The Journal of allergy and clinical immunology 119(2):482-487. 
233. Kotlarz D, et al. (2013) Loss-of-function mutations in the IL-21 receptor gene 
cause a primary immunodeficiency syndrome. The Journal of experimental 
medicine 210(3):433-443. 
234. Horev L, et al. (2015) Generalized verrucosis and HPV-3 susceptibility 
associated with CD4 T-cell lymphopenia caused by inherited human interleukin-
218 
 
7 deficiency. Journal of the American Academy of Dermatology 72(6):1082-
1084. 
235. Neven B, et al. (2009) Long-term outcome after hematopoietic stem cell 
transplantation of a single-center cohort of 90 patients with severe combined 
immunodeficiency. Blood 113(17):4114-4124. 
236. Laffort C, et al. (2004) Severe cutaneous papillomavirus disease after 
haemopoietic stem-cell transplantation in patients with severe combined 
immune deficiency caused by common gammac cytokine receptor subunit or 
JAK-3 deficiency. Lancet 363(9426):2051-2054. 
237. Gaspar HB, Harwood C, Leigh I, & Thrasher AJ (2004) Severe cutaneous 
papillomavirus disease after haematopoietic stem-cell transplantation in 
patients with severe combined immunodeficiency. British journal of 
haematology 127(2):232-233. 
238. Kamili QU, et al. (2014) Severe cutaneous human papillomavirus infection 
associated with natural killer cell deficiency following stem cell transplantation 
for severe combined immunodeficiency. The Journal of allergy and clinical 
immunology 134(6):1451-1453 e1451. 
239. Schmalstieg FC & Goldman AS (2002) Immune consequences of mutations in 
the human common gamma-chain gene. Molecular genetics and metabolism 
76(3):163-171. 
240. Frucht DM, et al. (2001) Unexpected and variable phenotypes in a family with 
JAK3 deficiency. Genes and immunity 2(8):422-432. 
241. Pullen RP, Somberg RL, Felsburg PJ, & Henthorn PS (1997) X-linked severe 
combined immunodeficiency in a family of Cardigan Welsh corgis. Journal of 
the American Animal Hospital Association 33(6):494-499. 
242. Jezyk PF, Felsburg PJ, Haskins ME, & Patterson DF (1989) X-linked severe 
combined immunodeficiency in the dog. Clinical immunology and 
immunopathology 52(2):173-189. 
243. Henthorn PS, et al. (1994) IL-2R gamma gene microdeletion demonstrates that 
canine X-linked severe combined immunodeficiency is a homologue of the 
human disease. Genomics 23(1):69-74. 
244. Felsburg PJ, Somberg RL, Hartnett BJ, Henthorn PS, & Carding SR (1998) 
Canine X-linked severe combined immunodeficiency. A model for investigating 
the requirement for the common gamma chain (gamma c) in human lymphocyte 
development and function. Immunologic research 17(1-2):63-73. 
245. Felsburg PJ, et al. (1999) Canine X-linked severe combined immunodeficiency. 
Veterinary immunology and immunopathology 69(2-4):127-135. 
246. Hartnett BJ, et al. (1999) Bone marrow transplantation for canine X-linked 
severe combined immunodeficiency. Veterinary immunology and 
immunopathology 69(2-4):137-144. 
247. Goldschmidt MH, et al. (2006) Severe papillomavirus infection progressing to 
metastatic squamous cell carcinoma in bone marrow-transplanted X-linked 
SCID dogs. Journal of virology 80(13):6621-6628. 
248. Bogunovic M, et al. (2006) Identification of a radio-resistant and cycling dermal 
dendritic cell population in mice and men. The Journal of experimental medicine 
203(12):2627-2638. 
249. Merad M, Collin M, & Bromberg J (2007) Dendritic cell homeostasis and 
trafficking in transplantation. Trends in immunology 28(8):353-359. 
250. Kanitakis J, Petruzzo P, & Dubernard JM (2004) Turnover of epidermal 
Langerhans' cells. The New England journal of medicine 351(25):2661-2662. 
251. Beilin C, et al. (2013) Dendritic cell-expressed common cytokine receptor g-
chain is essential for effective IL-15 transpresentation to CD4+T cells at the 
immunological synapse. Immunology 140:156-156. 
219 
 
252. Choudhuri K, et al. (2013) Dendritic cell-expressed common gamma-chain 
recruits IL-15 for trans-presentation at the immunological synapse. Journal of 
Immunology 190. 
253. Arima N, et al. (1992) Pseudo-high affinity interleukin 2 (IL-2) receptor lacks the 
third component that is essential for functional IL-2 binding and signaling. The 
Journal of experimental medicine 176(5):1265-1272. 
254. Ishii N, et al. (1994) Impairment of ligand binding and growth signaling of 
mutant IL-2 receptor gamma-chains in patients with X-linked severe combined 
immunodeficiency. J Immunol 153(3):1310-1317. 
255. Allen-Hoffmann BL, et al. (2000) Normal growth and differentiation in a 
spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. 
The Journal of investigative dermatology 114(3):444-455. 
256. Todaro GJ & Green H (1963) Quantitative studies of the growth of mouse 
embryo cells in culture and their development into established lines. The 
Journal of cell biology 17:299-313. 
257. de Chaumont F, et al. (2012) Icy: an open bioimage informatics platform for 
extended reproducible research. Nature methods 9(7):690-696. 
258. Record J, et al. (2015) Immunodeficiency and severe susceptibility to bacterial 
infection associated with a loss-of-function homozygous mutation of MKL1. 
Blood. 
259. Yano S, Komine M, Fujimoto M, Okochi H, & Tamaki K (2003) Interleukin 15 
induces the signals of epidermal proliferation through ERK and PI 3-kinase in a 
human epidermal keratinocyte cell line, HaCaT. Biochemical and Biophysical 
Research Communications 301(4):841-847. 
260. Raingeaud J & Pierre J (2005) Interleukin-4 downregulates TNFalpha-induced 
IL-8 production in keratinocytes. FEBS Lett 579(18):3953-3959. 
261. Nishio H, Matsui K, Tsuji H, Tamura A, & Suzuki K (2001) Immunolocalisation 
of the janus kinases (JAK)--signal transducers and activators of transcription 
(STAT) pathway in human epidermis. Journal of anatomy 198(Pt 5):581-589. 
262. Kagami S, et al. (2005) Interleukin-4 and interleukin-13 enhance CCL26 
production in a human keratinocyte cell line, HaCaT cells. Clinical and 
experimental immunology 141(3):459-466. 
263. Zhang SQ, et al. (2008) Autoinhibition of IL-15 expression in KC cells is ERK1/2 
and PI3K dependent. Scandinavian journal of immunology 68(4):397-404. 
264. Distler JH, et al. (2005) Expression of interleukin-21 receptor in epidermis from 
patients with systemic sclerosis. Arthritis and rheumatism 52(3):856-864. 
265. Luff JA, et al. (2014) Keratinocyte antiviral response to Poly(dA:dT) stimulation 
and papillomavirus infection in a canine model of X-linked severe combined 
immunodeficiency. PloS one 9(7):e102033. 
266. Lindemann MJ, Benczik M, & Gaffen SL (2003) Anti-apoptotic signaling by the 
interleukin-2 receptor reveals a function for cytoplasmic tyrosine residues within 
the common gamma (gamma c) receptor subunit. The Journal of biological 
chemistry 278(12):10239-10249. 
267. Johnson SE, Shah N, Panoskaltsis-Mortari A, & LeBien TW (2005) Murine and 
human IL-7 activate STAT5 and induce proliferation of normal human pro-B 
cells. J Immunol 175(11):7325-7331. 
268. Lin JX, et al. (1995) The role of shared receptor motifs and common Stat 
proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, 
IL-7, IL-13, and IL-15. Immunity 2(4):331-339. 
269. Barrera-Oro JG, Smith KO, & Melnick JL (1962) Quantitation of papova virus 
particles in human warts. Journal of the National Cancer Institute 29:583-595. 
270. Boyle WF, Riggs JL, Oshiro LS, & Lennette EH (1973) Electron microscopic 
identification of papova virus in laryngeal papilloma. The Laryngoscope 
83(7):1102-1108. 
220 
 
271. Stauffer Y, Raj K, Masternak K, & Beard P (1998) Infectious human 
papillomavirus type 18 pseudovirions. Journal of molecular biology 283(3):529-
536. 
272. Unckell F, Streeck RE, & Sapp M (1997) Generation and neutralization of 
pseudovirions of human papillomavirus type 33. Journal of virology 71(4):2934-
2939. 
273. Zhao KN, Sun XY, Frazer IH, & Zhou J (1998) DNA packaging by L1 and L2 
capsid proteins of bovine papillomavirus type 1. Virology 243(2):482-491. 
274. Meyers C, Frattini MG, Hudson JB, & Laimins LA (1992) Biosynthesis of human 
papillomavirus from a continuous cell line upon epithelial differentiation. Science 
257(5072):971-973. 
275. Meyers C, Mayer TJ, & Ozbun MA (1997) Synthesis of infectious human 
papillomavirus type 18 in differentiating epithelium transfected with viral DNA. 
Journal of virology 71(10):7381-7386. 
276. Ozbun MA (2002) Infectious human papillomavirus type 31b: purification and 
infection of an immortalized human keratinocyte cell line. The Journal of general 
virology 83(Pt 11):2753-2763. 
277. Buck CB, Pastrana DV, Lowy DR, & Schiller JT (2004) Efficient intracellular 
assembly of papillomaviral vectors. Journal of virology 78(2):751-757. 
278. Buck CB & Thompson CD (2007) Production of papillomavirus-based gene 
transfer vectors. Current protocols in cell biology / editorial board, Juan S. 
Bonifacino ... [et al.] Chapter 26:Unit 26 21. 
279. Kwak K, et al. (2014) Impact of inhibitors and L2 antibodies upon the infectivity 
of diverse alpha and beta human papillomavirus types. PloS one 9(5):e97232. 
280. Warren CJ, et al. (2014) The antiviral restriction factors IFITM1, 2 and 3 do not 
inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PloS 
one 9(5):e96579. 
281. Pyeon D, Pearce SM, Lank SM, Ahlquist P, & Lambert PF (2009) Establishment 
of human papillomavirus infection requires cell cycle progression. PLoS 
pathogens 5(2):e1000318. 
282. Griffin LM, Cicchini L, & Pyeon D (2013) Human papillomavirus infection is 
inhibited by host autophagy in primary human keratinocytes. Virology 
437(1):12-19. 
283. Ruckert R, et al. (2000) Inhibition of keratinocyte apoptosis by IL-15: a new 
parameter in the pathogenesis of psoriasis? J Immunol 165(4):2240-2250. 
284. Boukamp P, et al. (1988) Normal keratinization in a spontaneously immortalized 
aneuploid human keratinocyte cell line. The Journal of cell biology 106(3):761-
771. 
285. Schelhaas M, et al. (2008) Human papillomavirus type 16 entry: retrograde cell 
surface transport along actin-rich protrusions. PLoS pathogens 4(9):e1000148. 
286. Flores ER, Allen-Hoffmann BL, Lee D, Sattler CA, & Lambert PF (1999) 
Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an 
immortalized human foreskin keratinocyte cell line. Virology 262(2):344-354. 
287. Lambert PF, et al. (2005) Using an immortalized cell line to study the HPV life 
cycle in organotypic "raft" cultures. Methods in molecular medicine 119:141-
155. 
288. Peh WL, et al. (2002) Life cycle heterogeneity in animal models of human 
papillomavirus-associated disease. Journal of virology 76(20):10401-10416. 
289. Middleton K, et al. (2003) Organization of human papillomavirus productive 
cycle during neoplastic progression provides a basis for selection of diagnostic 
markers. Journal of virology 77(19):10186-10201. 
290. Flores ER, Allen-Hoffmann BL, Lee D, & Lambert PF (2000) The human 
papillomavirus type 16 E7 oncogene is required for the productive stage of the 
viral life cycle. Journal of virology 74(14):6622-6631. 
221 
 
291. Merrick DT, Blanton RA, Gown AM, & McDougall JK (1992) Altered expression 
of proliferation and differentiation markers in human papillomavirus 16 and 18 
immortalized epithelial cells grown in organotypic culture. The American journal 
of pathology 140(1):167-177. 
292. Jones DL, Alani RM, & Munger K (1997) The human papillomavirus E7 
oncoprotein can uncouple cellular differentiation and proliferation in human 
keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes & 
development 11(16):2101-2111. 
293. Westphal K, Akgul B, Storey A, & Nindl I (2009) Cutaneous human 
papillomavirus E7 type-specific effects on differentiation and proliferation of 
organotypic skin cultures. Cellular oncology : the official journal of the 
International Society for Cellular Oncology 31(3):213-226. 
294. Chenoweth MJ, et al. (2012) IL-15 can signal via IL-15Ralpha, JNK, and NF-
kappaB to drive RANTES production by myeloid cells. J Immunol 188(9):4149-
4157. 
295. Tong WW, et al. (2015) Human papillomavirus 16-specific T-cell responses and 
spontaneous regression of anal high-grade squamous intraepithelial lesions. 
The Journal of infectious diseases 211(3):405-415. 
296. Hopfl R, et al. (2000) Spontaneous regression of CIN and delayed-type 
hypersensitivity to HPV-16 oncoprotein E7. Lancet 356(9246):1985-1986. 
297. Peng S, et al. (2007) HLA-DQB1*02-restricted HPV-16 E7 peptide-specific 
CD4+ T-cell immune responses correlate with regression of HPV-16-associated 
high-grade squamous intraepithelial lesions. Clinical cancer research : an 
official journal of the American Association for Cancer Research 13(8):2479-
2487. 
298. Kennedy-Crispin M, et al. (2012) Human keratinocytes' response to injury 
upregulates CCL20 and other genes linking innate and adaptive immunity. The 
Journal of investigative dermatology 132(1):105-113. 
299. McDermott DH, et al. (2015) Chromothriptic cure of WHIM syndrome. Cell 
160(4):686-699. 
300. Luff JA, et al. (2013) Canine keratinocytes upregulate type I interferons and 
proinflammatory cytokines in response to poly(dA:dT) but not to canine 
papillomavirus. Veterinary immunology and immunopathology 153(3-4):177-
186. 
301. Chuntharapai A, Lee J, Hebert CA, & Kim KJ (1994) Monoclonal antibodies 
detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on 
human peripheral blood leukocytes. J Immunol 153(12):5682-5688. 
302. Lippert U, Zachmann K, Henz BM, & Neumann C (2004) Human T lymphocytes 
and mast cells differentially express and regulate extra- and intracellular 
CXCR1 and CXCR2. Experimental dermatology 13(8):520-525. 
303. Sozzani S, et al. (1997) Receptor expression and responsiveness of human 
dendritic cells to a defined set of CC and CXC chemokines. J Immunol 
159(4):1993-2000. 
304. Wang JM, Xu L, Murphy WJ, Taub DD, & Chertov O (1996) IL-8-Induced T-
Lymphocyte Migration: Direct as Well as Indirect Mechanisms. Methods 
10(1):135-144. 
305. Oppenheim JJ, Zachariae CO, Mukaida N, & Matsushima K (1991) Properties 
of the novel proinflammatory supergene "intercrine" cytokine family. Annual 
review of immunology 9:617-648. 
306. Inngjerdingen M, Damaj B, & Maghazachi AA (2001) Expression and regulation 
of chemokine receptors in human natural killer cells. Blood 97(2):367-375. 
307. Kershaw MH, et al. (2002) Redirecting migration of T cells to chemokine 
secreted from tumors by genetic modification with CXCR2. Human gene 
therapy 13(16):1971-1980. 
222 
 
308. Scimone ML, et al. (2005) Migration of polymorphonuclear leucocytes is 
influenced by dendritic cells. Immunology 114(3):375-385. 
309. Hieshima K, et al. (1997) Molecular cloning of a novel human CC chemokine 
liver and activation-regulated chemokine (LARC) expressed in liver. 
Chemotactic activity for lymphocytes and gene localization on chromosome 2. 
The Journal of biological chemistry 272(9):5846-5853. 
310. Liao F, et al. (1999) CC-chemokine receptor 6 is expressed on diverse memory 
subsets of T cells and determines responsiveness to macrophage inflammatory 
protein 3 alpha. J Immunol 162(1):186-194. 
311. Greaves DR, et al. (1997) CCR6, a CC chemokine receptor that interacts with 
macrophage inflammatory protein 3alpha and is highly expressed in human 
dendritic cells. The Journal of experimental medicine 186(6):837-844. 
312. Yang HT, Cohen P, & Rousseau S (2008) IL-1beta-stimulated activation of 
ERK1/2 and p38alpha MAPK mediates the transcriptional up-regulation of IL-6, 
IL-8 and GRO-alpha in HeLa cells. Cellular signalling 20(2):375-380. 
313. Ovestad IT, et al. (2011) The impact of epithelial biomarkers, local immune 
response and human papillomavirus genotype in the regression of cervical 
intraepithelial neoplasia grades 2-3. Journal of clinical pathology 64(4):303-307. 
314. Kollipara R, et al. (2015) Advancements in Pharmacotherapy for Noncancerous 
Manifestations of HPV. Journal of clinical medicine 4(5):832-846. 
315. Hislop AD (2015) Early virological and immunological events in Epstein-Barr 
virus infection. Current opinion in virology 15:75-79. 
316. Bilu D & Sauder DN (2003) Imiquimod: modes of action. The British journal of 
dermatology 149 Suppl 66:5-8. 
317. Schon MP & Schon M (2007) Imiquimod: mode of action. The British journal of 
dermatology 157 Suppl 2:8-13. 
318. Nambudiri VE, et al. (2013) Successful treatment of perianal giant condyloma 
acuminatum in an immunocompromised host with systemic interleukin 2 and 
topical cidofovir. JAMA dermatology 149(9):1068-1070. 
319. Hamblin TJ (2007) Long-lasting response of therapy-resistant viral warts to 
treatment with interleukin-2 in a patient with chronic lymphocytic leukemia (CLL) 
and profound immunodeficiency. Leukemia research 31(3):413-414. 
320. Lichti U, Anders J, & Yuspa SH (2008) Isolation and short-term culture of 
primary keratinocytes, hair follicle populations and dermal cells from newborn 
mice and keratinocytes from adult mice for in vitro analysis and for grafting to 
immunodeficient mice. Nature protocols 3(5):799-810. 
321. Handisurya A, et al. (2012) Murine skin and vaginal mucosa are similarly 
susceptible to infection by pseudovirions of different papillomavirus 
classifications and species. Virology 433(2):385-394. 
322. Cao X, et al. (1995) Defective lymphoid development in mice lacking expression 
of the common cytokine receptor gamma chain. Immunity 2(3):223-238. 
 
